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 ABSTRACT 
Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a tissue–specific protein that 
promotes α4β7+ lymphocyte recruitment on gut mucosal endothelium, playing an important 
role in the development of inflammatory bowel disease (IBD). Recent studies have reported its 
expression in liver diseases such as primary sclerosing cholangitis (PSC) and autoimmune 
hepatitis (AIH) that complicate IBD, therefore understanding the factors that drive hepatic 
expression of MAdCAM-1 might elucidate the pathogenesis of these diseases. In vitro 
stimulation of HSEC with tumor necrosis factor-α (TNFα) and methylamine, the physiological 
substrate of vascular adhesion protein-1 (VAP-1), as well as with the end products of 
methylamine deamination by VAP-1, resulted in increased levels of secreted and cell surface 
MAdCAM-1 protein that was able to support binding of α4β7+ lymphocytes under flow 
conditions. In vivo stimulation of mice that expressed hVAP-1 as a transgene, with 
methylamine, induced expression of MAdCAM-1 in Peyer’s patches and mesenteric lymph 
nodes, validating the effect of VAP-1 enzyme activity. In conclusion, we report for the first time 
that MAdCAM-1 is normally present in human liver and is further induced upon TNFα and 
methylamine stimulation resulting in the recruitment of mucosal cells to the liver, thus 
sustaining a destructive inflammatoty influx responsible for the establishment of chronic 
inflammation. 
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Laistrygonians, Cyclops, 
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you ‘ ll never find things like that on your way 
as long as you keep your thoughts raised high, 
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stirs your spirit and your body. 
Laistrygonians, Cyclops, 
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unless you bring them along inside your soul, 
unless your soul sets them up in front of you. 
Hope your road is a long one. 
…. 
Arriving there is what you’re destined for. 
But don’t hurry the journey at all. 
Better if it lasts for years,  
so you’re old by the time you reach the island 
wealthy with all you’ve gained on the way, 
not expecting Ithaca to make you rich. 
Ithaca gave you the marvelous journey. 
Without her you wouldn’t have set out. 
She has nothing left to give you now. 
And if you find her poor, Ithaca won’t have fooled you. 
Wise as you will have become, so full of experience,  
You’ll have understood by then what those Ithacas mean.” 
I thaca of  C.P Cavafy 
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1.1  OVERVIEW 
The immune system is one of nature’s most fascinating developments. It protects against the 
billions of infectious viruses, bacteria and other parasites that humans are exposed to daily. 
However, although for the most part the immune system is beneficial, it can also have 
detrimental effects. During inflammation in response to an invading pathogen, healthy tissue 
can be damaged by the immune system itself in what is called collateral or bystander damage. 
Additionally, in some cases the immune system can be directed toward self–antigens resulting 
in autoimmune diseases. Autoimmune and chronic inflammatory liver disease is characterised 
by continuous and uncontrolled leukocyte infiltration of the liver. The molecular basis of 
leukocyte recruitment has gained much attention over recent years because it has been 
recognised as a critical process in the development of inflammation. MAdCAM-1 is an 
endothelial cell addressin that was initially recognised to be key player in gut inflammation and 
especially in inflammatory bowel disease (IBD). The importance of MAdCAM-1 in IBD has 
been validated by the efficacy of antibodies directed against either MAdCAM-1 or its 
counterligand α4β7 integrin to ameliorate disease effects in animal models, as well as from the 
positive clinical outcomes of pharmaceutical inhibitors (MLN02, humanised anti–α4β7 
antibody for the treatment of IBD). Thereafter, its expression in different tissues under 
inflammatory conditions has been documented and there is evidence that it has a role in the 
recruitment of lymphocytes to extra–intestinal tissues under certain conditions. A few years ago 
MAdCAM-1 was detected in the liver in inflammatory liver diseases (PSC, AIH), which often 
occur as extra–intestinal complications of IBD. My thesis aims to identify the factors that are 
responsible for the hepatic expression of MAdCAM-1, thereby elucidating the molecular 
pathogenesis of extra–intestinal hepatic inflammation.  
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1.2  IMMUNE SYSTEM 
The immune system is made up of a network of cells, tissues and organs, coordinated in order 
to recognise and destroy invading organisms, tumour and substances that may cause tissue 
damage. The immune system is classified as central and peripheral lymphoid tissues, and the 
different components of the immune system produced from the above tissues are then able to 
respond to pathogens in two ways, either natural (innate immunity) or more specific (adaptive 
immunity) (Goldsby, 2002). 
 
1.2.1 Central and Peripheral Lymphoid Tissues 
The bone marrow and thymus constitute the central or primary lymphoid organs. The 
peripheral lymphoid tissues are composed of secondary organs at or near possible portals of 
entry for pathogens. These are exemplified by the lymph nodes, spleen and mucosa–associated 
lymphoid tissues (e.g. Peyer’s patches). Bone marrow is located in the hollow centre of the bones 
and is the site where erythroid (erythrocytes, platelets), myeloid [neutrophils, 
monocytes/macrophages, basophils, eosinophils, dendritic cells (DCs)] and lymphoid cells 
[natural killer (NK) cells, B– and T–lymphocytes and lymphoid dendritic cells] are produced in 
a process named haematopoiesis. Of note, during foetal development, haematopoiesis takes 
place initially in the yolk sac, which is then shifted to the fetal liver and finally to the bone 
marrow and spleen.  
 
The thymus, is located above the heart behind the breastbone, and is the location where 
education and maturation of T lymphoid cells, prior to release into the circulation, occurs. 
Precursor T cells migrate to the thymus where they differentiate into two distinct types: the 
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CD4+ T helper and the CD8+ pre–cytotoxic T cells. In addition, in the thymus, T cells become 
educated and undergo two selection processes, an initial positive selection, in which the T cells 
that are capable of responding to MHC proteins complexed with foreign peptides are selected 
for survival, and a negative selection, in which T cells whose receptors bind strongly to the 
complex of self–peptides and self–MHC proteins are eliminated by apoptosis (Alberts, 2002). 
 
1.2.2 Innate and Adaptive Immunity 
Innate immunity (or natural immunity) is the first line of defence during the first critical hours 
and days of exposure to a new invading organism. Through anatomical barriers (skin and 
internal epithelial surfaces), secretory substances (lysozyme and phospholipase in tears, saliva 
and nasal secretions, defensins in gastrointestinal tract and lungs, acidic pH secretions) and 
cellular components, the natural immune system provides physical barriers between the inside 
of the body and the outside world. The innate immune response depends upon a group of 
proteins (complement system, coagulation system, lactoferins and transferins, interferons, 
lysozyme and interleukin-1) and phagocytic cells [neutrophils, macrophages, eosinophils, natural 
killer (NK) and lymphokine activated killer (LAK) cells] that possess specific receptors [pattern 
recognition receptors (PRRs)] in order to recognise conserved molecular patterns common to 
many pathogens [the pathogen associated molecular patterns (PAMPs)] but absent from the 
host (Gao et al., 2008). 
 
The innate immune response thus recognises molecular motifs associated with pathogens, 
whereas the adaptive immune response can develop more sophisticated responses that are 
highly specific and which can be magnified on second or subsequent exposure, so–called 
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immune memory. The primary function of the adaptive immune system is to eliminate 
invading pathogens and any toxic substances that they produce and to develop a memory of the 
pathogens so that subsequent immune responses are rapid and protective. This is achieved in 
two ways: a humoral and a cellular immune response, carried out by divergent classes of 
lymphocytes, B– and T– cells, respectively. Humoral immunity is mediated by antibodies, which 
are secreted by activated B cells and are specific for the antigen that caused the B cell to become 
activated. Secreted antibodies are responsible for eliminating extracellular pathogens (e.g. 
viruses and microbial toxins) by blocking their ability to bind receptors on host cells, and also 
by “marking” invading pathogens for destruction, thus facilitating their recognition, destruction 
and ingestion by the phagocytic cells (granulocytes, macrophages, dendritic cells) of the innate 
immune system.  
 
Cellular immunity is mediated by T cells, precisely by activated cytotoxic T cells (CD8+), which 
can kill infected target cells by several mechanisms and by helper T (CD4+) cells that secrete a 
variety of cytokines that can stimulate the cytotoxic T and B cells to mature and proliferate, 
attract neutrophils and enhance the ability of macrophages to engulf and destroy microbes 
(Alberts, 2002). In addition, cellular immunity involves suppressor T cells, named T regulatory 
cells, which are responsible for suppressing any further immune responses after the foreign 
pathogen is eliminated and also for maintaining immune tolerance to self (Di Nunzio et al., 
2009). 
 
In general, the hallmarks of the adaptive immune system are memory and specificity, which 
reside in the antigen receptors on B and T cells, the BCRs and TCRs, respectively. Moreover, 
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notably, the adaptive immune system “remembers” each encounter with a foreign antigen so 
that subsequent encounters will stimulate increasingly effective defence mechanisms.  
 
1.2.3 Lymphocytes 
There are three main types of lymphocytes, B– and T– lymphocytes (see below) and natural 
killer (NK) cells. NK cells are also known as large granular lymphocytes (LGL). They resemble 
lymphocytes in their morphology, but they are larger with numerous granules. NK cells are 
capable of killing virus–infected and malignant target cells, after exposure to IL-2 and IFNγ and 
can be identified by the presence of CD56 and CD16 cell surface markers (Trotta et al., 2005). 
 
1.2.3.1 B and T lymphocytes 
Both B and T cells originate in the bone marrow. B cells mature in the bone marrow whereas 
progenitor T cells migrate to the thymus to differentiate. Naïve B and T (helper and cytotoxic) 
lymphocytes are cells that have not encountered an antigen, and these naïve cells are small, 
motile and non–phagocytic with similar morphological characteristics with a lifespan of several 
months (von Boehmer and Hafen, 1993). Upon interaction with an antigen, lymphocytes 
enlarge into lymphoblasts, which then proliferate and eventually differentiate into effector or 
memory cells. These populations are distinguishable from naïve precursors since they express 
additional and different membrane molecules (Goldsby, 2002). 
 
Apart from CD4 T helper (Th1 and Th2) cells, a few more CD4 T cell populations have been 
described: the T regulatory cells (Tregs), the Th17 cells, the follicular helper T cells (Tfh), the 
Th9 cells and the natural killer T (NKT) cells. The Tregs are currently divided into two major 
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subpopulations, the naturally arising thymic CD4+CD25+ Tregs, and the peripherally induced 
Tr1 and Th3 cells (Bluestone and Abbas, 2003)(Jonuleit and Schmitt, 2003). The natural Tregs 
express high levels of IL-2Rα chain (CD25) on their cell surface and the transcription factor 
forkhead box p3 (Foxp3). They are specific for self–antigens and can act via contact–dependent 
mechanisms, whereas the adaptive Tr1 and Th3 cells can act against both self and non–self 
antigens via cell–contact–independent inhibition by generation of IL-10 and TGF-β cytokines, 
respectively. Both natural and adaptive Tregs require IL-2 for their activation and function and 
can actively suppress the activation and expansion of self–reactive T cells (Miyara and 
Sakaguchi, 2007). Expression of Foxp3 has also been demonstrated in CD8+ Tregs, which also 
contribute to immunoregulation (Andersen et al., 2009).  
 
Another recently identified CD4+ T helper subset, is the population of IL-17 producing Th17 
cells that play critical role in autoimmunity. Th17 cells produce additional cytokines IL-21, IL-
22, TNFα and IL-6, and their development is driven by TGF-β and IL-6. Of note, Th1 and Th2 
related cytokines inhibit Th17 cell differentiation, but on the contrary, IL-17 cannot suppress 
Th1 and Th2 cells or can do so but very weakly (Bettelli et al., 2008)(Gocke et al., 2007)(X. O. 
Yang et al., 2008). 
 
An effector T cell population, initially described as Th1 and/or Th2, was found to be resident 
at the edge of the B cell zones and follicular regions and germinal centres, thus named the 
follicular helper T cells (Tfh). Since these cells expressed the B–cell promoting cytokines IL-10 
and IL-21, not associated with Th1 or Th2 cells, this led to the suggestion that this T cell 
population represents a separate effector T cell subset (Nurieva et al., 2008). Tfh cells express 
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high levels of CXCR5, which is the receptor for CXCL13, which is abundant in the B cell zones 
(Vermi et al., 2008). 
 
A new type of helper T cell, the Th9 cell has been reported that appears to develop from Th2 
cells upon stimulation with TGF-β or by antigenic stimulation of naïve T cells in the presence 
of TGF-β and IL-4. Th9 cells are characterised by the secretion of IL-9, they lack expression of 
specific transcription factors, and thus they are not recognised by any lineage specific 
characteristics (Dardalhon et al., 2008)(Veldhoen et al., 2008). 
 
Finally, another subpopulation of T cells has been recognised, named natural killer T (NKT) 
cells, defined by co–expression of T–cell receptor (TCR) and NK1.1 expression [CD161 in 
humans (marker of NK cells)]. Two major subtypes of NKT cells have been identified, termed 
type I or iNKT (invariant) cells and type II NKT (non–invariant) cells. In general, NKT cells can 
be CD4+, CD8+ or double negative for these molecules, and recognise antigens presented by 
the MHC class I related antigen CD1, adapted for presentation of lipid antigens. Upon 
activation NKT cells are able to rapidly produce both Th1–type (IFNγ and TNFα) and Th2–
type (IL-4, IL-10 and IL-13) cytokines and IL-17. Moreover, activated NKT cells are able to 
release cytotoxic molecules and kill other cells through FASL–mediated and perforin–
dependent pathways, hence contributing to the protection of hosts from infections and 
tumours by regulating immunity (Godfrey et al., 2004)(Swain, 2008)(Tupin et al., 2007). 
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1.2.3.2 The Career of B– and T– lymphocytes 
Once mature, lymphocytes leave the bone marrow or thymus and start circulating through the 
secondary lymphoid organs. This continuous recirculation of lymphocytes significantly 
enhances the chance of a successful encounter with specific antigen. Naïve antigen 
inexperienced cells pass directly from the blood to secondary lymphoid tissues through 
specialised high endothelial venules (HEVs) into the surrounding T (–rich) zones (Mackay et al., 
1990). Naïve B cells follow the same route but after they have entered the T cell zone, they 
move further to the adjacent B (–rich) cell follicles that also contain follicular dendritic cells 
(Picker and Butcher, 1992). If lymphocytes do not encounter an antigen in the lymph nodes, 
they return back to the blood circulation via the main lymphatic vessel (the thoracic duct). This 
continuous circulation between the blood and lymph ends only when the lymphocyte 
encounters its specific antigen, along with a co–stimulatory molecule on the surface of an 
antigen–presenting cell (APC) in peripheral lymphoid organs.  
 
Upon activation, lymphocytes proliferate and differentiate into effector cells. Precisely, activated 
B cells within the lymphoid follicles, known as follicle centre cells, undergo clonal expansion; 
with the most of the family clones becoming antibody–producing plasma cells. The other B 
cells become long–lived memory cells. Activated T cells, differentiate in either CD4 T helper 
cells (Th1 and Th2) or T cytotoxic cells (CD8). After several days, some of the effector cells 
leave the peripheral lymphoid organs via the lymph and migrate through the blood to the site 
of infection. This change in migration is a consequence of activation, differentiation and 
functional maturation of lymphocytes re–programming their expression profiles of adhesion 
molecules and chemokine receptors promoting their migration towards the tissue in which they 
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were activated (Butcher et al., 1999)(Sallusto et al., 2000)(Yoshie et al., 2001). Thus, T cells that 
have encountered their antigen in Peyer’s patches, express the leukocyte integrin α4β7, which 
preferentially binds to MAdCAM-1 on gut endothelium and thereby promotes recruitment to 
the gut (Mackay, 1993)(Schweighoffer et al., 1993). Similar principles have been demonstrated 
for other anatomical sites such as the skin, where skin homing lymphocytes express high levels 
of cutaneous lymphocyte antigen (CLA) that binds E–selectin, and CCR4 that responds to the 
chemokines CCL17 and CCL22 (Eksteen et al., 2004b)(Picker and Butcher, 1992). Therefore, 
T cells are primed in this way in order to migrate into sites where is more likely that they will 
re–encounter the same activating antigen. Interestingly, the memory cells, in a second 
encounter with antigen, follow different recirculation pathways than naïve cells, in the sense 
that they can enter draining lymph nodes directly from blood by afferent lymphatics without 
the need to migrate through HEVs (Mackay, 1993). 
 
1.3  LEUKOCYTE RECRUITMENT CASCADE 
Leukocytes circulate continuously from blood into tissues and secondary lymphoid organs, and 
then return back to the blood to patrol the body in search for antigens, thus providing an 
effective immune surveillance (Girard and Springer, 1995)(Warnock et al., 1998). Activation by 
an antigen confers the T cell with the ability to home to non–lymphoid tissues, preferentially to 
those that are connected to the secondary lymphoid organs where antigen was first encountered 
(D. J. Campbell and Butcher, 2002)(Masopust et al., 2001). Therefore, in order to complete all 
these tasks, leukocytes must be capable of crossing multiple vascular barriers and in all cases the 
key interaction is between leukocyte and endothelial cells lining the vessels (Springer, 1995). 
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Leukocytes leave the bloodstream through the specialised postcapillary vascular sites, named 
high endothelial venules (HEV), which are present in all secondary lymphoid organs (with 
exception of spleen, where lymphocyte migration occurs via the blood sinusoids in the marginal 
zone), and through microvascular endothelium within tissue. HEV–like vessels are also 
observed in chronically inflamed non–lymphoid tissues thus supporting unremitting leukocyte 
recruitment to these sites (Girard and Springer, 1995)(Grant et al., 2002a). The initial 
interactions between endothelium and leukocytes induce tethering or rolling of the latter on 
the endothelial surface (Lalor et al., 1997)(Tedder et al., 1995a). Because blood flow generates 
shear forces, leukocytes have to resist these significant forces whilst interacting with the 
endothelium (Sackstein, 2005). This first contact allows leukocytes to sample the endothelial 
microenvironment for chemokines, which are immobilised by glycosaminoglycans on the 
endothelial luminal surface (Adams and Lloyd, 1997)(Tanaka et al., 1993). The appropriate 
pairing of chemokine/chemokine receptor induces intracellular signals that trigger activation of 
the leukocyte integrins, which in turn are able to bind to their ligands, members of the 
immunoglobulin superfamily expressed on the endothelial surface, hence becoming firmly 
arrested on the endothelium. In the final step, leukocytes pass through the endothelial 
monolayer in a process named transendothelial migration or diapedesis, mediated by poorly 
understood mechanisms, and then follow directional cues to the site of infection or tissue 
injury (Figure 1.1) (Muller, 2003).  
 
Different classes of adhesion and activation molecules mediate each step of the recruitment 
cascade, all of which are critical for an efficient extravasation process, since the presence of the 
appropriate pair in one step is needed for the next step to occur. Adhesion molecules and 
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chemokines are induced with inflammation allowing peripheral tissues to readily recruit 
effector cells. In addition, effector cells generated in the different lymphoid organs undergo a 
re–programming process to express tissue specific adhesion molecules resulting in tissue 
selective homing. This latter process controls the extent and scope of immune responses, and 
accounts for the regional compartmentalisation of immune system (Butcher and Picker, 1996). 
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Figure 1.1 The leukocyte recruitment cascade. The initial capture of leukocyte is followed by 
rolling on the endothelial surface, mediated by members of the selectin family and some integrins. The 
cell starts moving along the endothelial lining at reduced velocity, sampling the endothelial 
microenvironment for appropriate chemotactic signals (chemokines), either soluble or immobilised by 
glycosaminoglycans on the endothelial surface. Binding of chemokines to their cognate chemokine 
receptors on the leukocyte surface, leads to rapid G-protein coupled signalling pathways, which finally 
trigger cytoskeletal rearrangement and integrin activation. Then, activated integrins are able to bind with 
high affinity and avidity to their ligands, members of the immunoglobulin superfamily (CAMs), promote 
firm adhesion and allow the leukocyte to crawl on the endothelial surface towards the endothelial 
borders searching for signals in order to transmigrate. Thereafter, the leukocyte can pass to the basement 
membrane following either the “legal” way through the endothelial junctions (paracellular) or the 
peculiar way through the endothelial body (transcellular). The latter route is accepted, although it is still 
unknown what makes leukocyte decide which route to follow. Some of the molecules taking part in the 
leukocyte process are demonstrated in boxes. PSGL-1, P-selectin glycoprotein ligand-1; ICAM-1, 
intracellular cell adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; MAdCAM-1, 
mucosal addressin cell adhesion molecule-1; LFA-1, lymphocyte function-associated antigen 1 (also 
known as αLβ2- integrin); JAM, junctional adhesion molecule; PECAM-1, platelet endothelial cell 
adhesion molecule -1; ESAM-1, endothelial cell selective adhesion molecule (Ley et al., 2007). 
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1.3.1 Rolling 
The rolling step has been described as an inherently unstable transition state, poised between 
firm adhesion and lack of adhesion (Hammer and Apte, 1992). The adhesion molecules that 
classically mediate this rolling step are members of the selectin family and their carbohydrate 
ligands on the vascular endothelium surface (Tedder et al., 1995a). The driving force for rolling 
is the hydrodynamic force of the bloodstream (Alon et al., 1995a). Although the wall shear 
stress in postcapillary venules varies widely within tissues as well as under inflammation or 
exercise, the velocity of rolling cells both in vitro and in vivo appears more stable, suggesting the 
importance of the rolling step as a checkpoint in the leukocyte recruitment process, especially 
in inflammation (Lawrence and Springer, 1991). 
 
During rolling, selectin–ligand bonds are clustered and thus can resist to force collectively 
rather than individually (Chen and Springer, 1999). Furthermore, as shear stress increases, the 
number of selectin–ligand bonds between the flowing cell and the substrate increases at the 
front edge of the cell, hence counterbalancing the elevated rate of pre–existing bond 
dissociation at the rear edge (Yago et al., 2007). In addition, the increased shear stress, prolongs 
the selectin–ligand bond lifetimes, meaning that each bond is strengthened and the molecules 
lock more tightly, in a phenomenon named “catch–bond” (Marshall et al., 2003). Of note, the 
velocity of a rolling cell will determine the time duration of exposure of the leukocyte to 
activating stimuli on the vessel wall, and thus is important in determining whether activation 
will occur or not.  In the absence of appropriate stimuli, leukocytes might roll through a 
postcapillary venule without undergoing firm adhesion or transmigration (Chen and Springer, 
1999). 
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Of note, although integrins are critical players in the following firm adhesion step of the 
extravasation cascade, it has been reported that α4 and β2 integrins can also support rolling. 
The α4β1 integrin can support rolling on VCAM-1 that lacks a mucin domain (Alon et al., 
1995b), however the α4β7 integrin can support more efficient rolling when binding to its 
ligand MAdCAM-1 that contains a mucin–domain (Berlin et al., 1995). The β2 integrins, αLβ2 
(LFA-1) and αMβ2 (Mac-1; macrophage antigen-1) have also been suggested to mediate rolling 
when binding to ICAM-1 and ICAM-2 (Dunne et al., 2002).  
 
1.3.1.1 Selectins 
The selectin family consists of three closely related cell–surface molecules: L–selectin (CD62L), 
E–selectin (CD62E) and P–selectin (CD62P), which are named after the cells in which they are 
expressed (Bevilacqua and Nelson, 1993)(McEver, 2001)(Vestweber and Blanks, 1999). 
 
L–selectin is expressed on hematopoietic cells, with most classes of leukocytes constitutively 
expressing this molecule. The majority of B and naïve T cells, as well as circulating neutrophils, 
monocytes and eosinophils express L–selectin, whereas only a subpopulation of memory T cells 
and NK cells are L–selectin positive. Moreover, early myeloid progenitor cells express L–
selectin, although mature erythrocytes are L–selectin negative. The broad expression of L–
selectin explains its critical role in the trafficking of all leukocyte lineages into secondary 
lymphoid tissues and peripheral sites of injury and inflammation (Gallatin et al., 1983)(Tedder 
et al., 1990). 
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 P–selectin is produced and stored in the α granules of platelets and in the Weibel–Palade 
bodies of endothelial cells. After stimulation with pro–inflammatory factors (oxygen–derived 
free radicals, complement fragments and cytokines) and thrombogenic mediators (thrombin, 
histamine), P–selectin is rapidly released and immobilised to the cell surface (Hsu-Lin et al., 
1984)(McEver et al., 1989). Moreover, P–selectin is constitutively expressed on the endothelium 
of lung and choroid plexus microvessels (Kivisakk et al., 2003) and is induced on endothelial 
cells under several inflammatory diseases, including atherosclerosis (Kansas, 1996)(Ley, 2003).  
 
E–selectin is de novo expressed on endothelial cells upon cytokine stimulation (e.g. by TNFα, 
LPS and IL-1) in most organs. E–selectin is only constitutively expressed in skin microvessels 
allowing it to recruit skin homing memory T cells that express the E–selectin ligand cutaneous 
lymphocyte antigen (CLA) (Vestweber and Blanks, 1999). 
 
All selectins are type I membrane proteins (transmembrane proteins having their N–terminus 
exposed to the extracellular or luminal space), composed of five domains, which are starting 
from the N–terminal end: a calcium (Ca2+) dependent lectin domain, an epidermal growth 
factor (EGF)–like domain, two to nine short consensus repeat (SCR) units, a transmembrane 
domain and a cytoplasmic tail (Kansas, 1996)(Vestweber and Blanks, 1999). The long 
extracellular molecular structure of E– and P– selectin renders them the most suitable for the 
rolling step, since the well extended structure above the surrounding glycocalyx allows them to 
capture flowing leukocytes that express the appropriate receptors (Lasky, 1992). L–selectin, 
possesses only two SCRs, but since it is localised to leukocyte microvilli extending from the 
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leukocyte body, is able to support optimal leukocyte–endothelial cell interactions (Erlandsen et 
al., 1993). 
 
Selectins recognise sialyl Lewis X and related carbohydrate ligands, presented on specialised 
glycoprotein scaffolds (Ley and Kansas, 2004)(McEver, 2002). The ligands for selectins are 
various glycoproteins, including P–selectin glycoprotein–1 (PSGL-1), E–selectin ligand–1 (ESL-
1) (Steegmaier et al., 1995) and CD44 (Hidalgo et al., 2007), both ligands for E–selectin, 
glycoslylation–dependent cell adhesion molecule–1 (GlyCAM-1) and CD34, both members of 
the peripheral node addressin family (PNAd) that serve as ligands for L–selectin (Puri et al., 
1995)(Rosen, 2004). Another adhesion molecule, mucosal addressin cell adhesion molecule–1 
(MAdCAM-1), a member of the immunoglobulin superfamily, can also serve as ligand for L–
selectin, when it is properly glycosylated (M. J. Briskin et al., 1993)(Streeter et al., 1988). PSGL-
1 can bind to all three selectins when properly glycosylated (Moore, 1998). Very interestingly, 
the binding of PSGL-1 to L–selectin (both expressed on leukocytes) can mediate a secondary 
tethering process, so that leukocytes expressing PSGL-1 can adhere to leukocytes already rolling 
on L–selectin. Moreover, through this secondary tethering process, leukocytes that do not 
express ligands for E–selectin or P–selectin can still reach sites of inflammation (Ley et al., 
2007). 
 
1.3.2 Activation and Arrest 
During leukocyte rolling, the cells bind endothelium via fast acting molecular bonds, which are 
unable to arrest the leukocytes firmly. The movement in the vicinity of endothelial cells enables 
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the leukocytes to sample the endothelial microenvironment for chemoattractant cytokines, 
named chemokines, which are needed for integrin activation and subsequent firm arrest.  
 
1.3.2.1 Chemokines 
Chemokines are a group of small, closely–related chemotactic cytokine proteins that play 
important roles in both innate and adaptive immunity (Baggiolini et al., 1997). The chemokine 
family is rapidly increasing and to date there are more than 50 human members identified 
(Cyster, 1999)(Kim and Broxmeyer, 1999), which have been classified into four major families 
on the basis of the number and spacing of conserved cysteines in the NH2–terminus (Rossi and 
Zlotnik, 2000). These are termed the CXC, CC, C and CX3C chemokine families. The CXC 
chemokines are further subdivided into two subclasses based on the presence or absence of the 
ELR amino acid motif (glutamic acid [E]–leucine [L]–arginine [R]) at the N–terminus. The ELR 
chemokines include CXCL1/GROα, CXCL5/ENA-78, CXCL6/GCP-2, CXCL7/NAP-2 and 
CXCL8/IL-8, which are strong neutrophil chemoattractants and exert angiogenic effects. The 
non–ELR chemokines consist of CXCL9/MIG, CXCL10/IP-10, CXCL11/-TAC, 
CXCL12/SDF-1a and CXCL13/BLC, which recruit mainly lymphocytes and exert angiostatic 
effects (Koch et al., 1992). 
 
The CC group includes the chemokines CCL5/RANTES, CCL3/MIP-1α and CCL4/MIP-1β, 
CCL2/MCP-1, CCL11/eotaxin, CCL21/6ckine, CCL20/MIP-3α and CCL19/MIP-3β, which 
exert their effects on monocytes, lymphocytes, eosinophils and basophils but not neutrophils 
(Baggiolini et al., 1997)(Luster, 1998)(Rollins, 1997). In the C chemokine group, lymphotactin 
attracts lymphocytes and natural killer (NK) cells but not monocytes (Kelner et al., 1994) 
 19 
(Kennedy et al., 1995). The chemokine fractalkine defines the CX3C group. CX3CL1 
(fractalkine) along with CXCL16 of the CXC group are expressed as transmembrane molecules, 
which possess an N–terminal chemokine domain, a mucin–like stalk, a transmembrane domain 
and a short cytoplasmic tail. Both CX3CL1 and CXCL16 also exist in soluble forms after 
proteolysis at the cell surface (Bazan et al., 1997)(Schulte et al., 2007). The current chemokine 
nomenclature is based on the chemokine receptor nomenclature, which uses CXC, CC, C or 
CX3C followed by R (receptor) and then a number. The new nomenclature replaces R with L 
(ligand) to designate the ligands (Table 1.3) (Zlotnik and Yoshie, 2000).  
 
Chemokines can be divided into homeostatic and inflammatory types based on their functional 
properties. Homeostatic chemokines are constitutively expressed at high levels in lymphoid 
organs as well as in non–lymphoid tissues such as skin and mucosa (Oo and Adams, 2009) 
where they mediate the naïve and memory lymphocyte trafficking to lymphoid and effector 
tissues, as well as their guidance to the correct microenvironment within the tissue (Olson and 
Ley, 2002). Among this group CCL19 (Yoshida et al., 1997) and CCL21 (SLC; secondary 
lymphoid organ chemokine) (Nagira et al., 1997) are ligands for CCR7, and their importance is 
highlighted in mice deficient in CCR7 or CCL21, which show defective recruitment of naïve T 
cells to secondary lymphoid organs (Forster et al., 1999)(Gunn et al., 1999). On the other hand, 
inflammatory chemokines are up–regulated by inflammatory stimuli in inflamed tissues by 
resident and infiltrating immune cells, and mainly regulate the recruitment of neutrophils, 
monocytes, NK cells and effector lymphocytes into effector sites (Olson and Ley, 2002)(Oo and 
Adams, 2009). 
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Activated endothelial cells, epithelial cells and leukocytes produce chemokines, but virtually any 
cell is capable of chemokine generation upon stimulation with lipopolysaccharides or 
inflammatory cytokines (Kim and Broxmeyer, 1999). After secretion chemokines can bind to 
heparin–like glycosaminoglycans on the cell surface and in the extracellular matrix, which helps 
leukocytes to track down these immobilised chemokines in a process named haptotaxis (Cyster, 
1999)(S. Jung and Littman, 1999). The binding of chemokines to glycosaminoglycans not only 
prevents them from being washed away, but also maintains them in mono/dimeric forms, 
which increases their affinity for their chemokine receptors (Baltus et al., 2003). Additionally, 
the immobilised chemokines can persist at high concentrations in tissues for longer than freely 
diffusible chemokines (von Andrian and Mackay, 2000). Thereafter, chemokines can elicit their 
effects during leukocyte recruitment through interactions with their receptors, members of the 
seven–transmembrane, rhodopsin–like G protein–coupled receptors (Yoshie et al., 2001). Some 
chemokines recognise multiple receptors whereas others only have one receptor and similarly 
some receptors bind only one chemokine whereas others are highly promiscuous and bind 
multiple chemokines (Zlotnik and Yoshie, 2000). 
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Table 1.1 Chemokines and chemokine receptors. The chemokine and chemokine receptor family 
have been classified into four groups dependent on the number and spacing of conserved 
cysteines in the NH2-terminus. The two largest groups are the CC chemokines, where 
conserved cysteines lie adjacent to each other, and the CXC chemokines where the first two 
cysteines are separated by a non–conserved amino acid. The two minor groups include the 
XC chemokines, which lack two out of four canonical cysteines and the CX3C chemokines 
in which three amino acids separate both cysteines. 
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1.3.2.2 Integrins 
Integrins are a family of over 20 heterodimeric membrane–bound glycoproteins composed of 
one α and one β chain. In addition to their role in mediating cell adhesion and migration, they 
can also regulate cell growth and survival (Kummer and Ginsberg, 2006). Integrin subunits have 
large, structurally complex extracellular domains, which contain three to four divalent cation–
binding sites that are involved in ligand binding, a single–pass transmembrane helix and 
cytoplasmic tails that regulate integrin function (Hynes, 2002). The two subunits are non–
covalently associated; therefore α chains can associate with more than one β chains, and vice 
versa, thus creating a large molecular variety.  
 
Integrins can be broadly grouped into further subfamilies based on the β subunit. The most 
essential integrin subfamilies for the leukocytes are the β1, β2 and β7 integrins. The β1 
integrins (also known as VLA proteins) share a common β chain (CD29) paired with different α 
subunits (CD49a- CD49f), and mainly bind with the extracellular matrix components such as 
fibronectin, laminin and collagen. The β2 integrins have a common β chain CD18 paired with 
the α chains CD11a (LFA-1), CD11b (Mac-1) or CD11c (p150, 95), and they are expressed on 
lymphocytes (CD11a), neutrophils and monocytes (CD11a and CD11b) and dendritic cells 
(CD11a and CD11c), and bind to ICAM-1 and ICAM-2 on other cells including endothelial 
cells (Adams and Shaw, 1994)(Diamond et al., 1990)(Makgoba et al., 1988)(Sadhu et al., 2007). 
The α4β7 integrin belongs in the β7 integrin group and is expressed on leukocytes where it 
mediates binding to fibronectin, VCAM-1 (Postigo et al., 1993) and more efficiently to 
MAdCAM-1. The αEβ7 integrin, which is constitutively expressed by intestinal intraepithelial 
lymphocytes, mediates binding to E–cadherin (Berlin et al., 1993)(Cepek et al., 1994). The 
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most important integrins on leukocytes responsible for mediating adhesion to endothelial 
targets are members of the β2 integrins, LFA-1 (CD11a/CD18 or αLβ2) and Mac-1 
(CD11b/CD18 or αMβ2), the β1 integrin α4β1 (VLA-4) and the β7 integrin α4β7 (Hynes, 
2002). 
  
Integrins function as bi–directional signalling molecules and their ability to bind to their 
ligands is dynamically regulated by conformational changes (Schwartz et al., 1995). In 
particular, in resting cells, integrins exist predominantly in a non–adhesive state and change 
into an adhesive state only upon cellular stimulation (Carman and Springer, 2003). The 
binding of chemokines to their receptors is one signal that results in integrin activation via 
phosphorylation of carboxyl–terminal serine/threonine residues, dissociation of heterotrimeric 
G proteins, generation of inositol triphosphate, intracellular calcium release and activation of 
protein kinase C (PKC) (Luster, 1998). With additional activation of the Ras and Rho families 
of guanosine triphosphate (GTP)–binding proteins, chemokine receptors mediate multiple 
signalling pathways that regulate integrin activation. The activation of the G–protein coupled 
receptor leads to the binding of intracellular proteins (such as talin–1, an actin–binding 
protein) to the integrin cytoplasmic domains, thereby triggering conformational signal 
transmission to the extracellular domains (Kinashi, 2005). Thereafter, the integrin extracellular 
domains undergo structural changes that result in conformations competent for ligand binding. 
Interestingly, this dynamic regulation of integrin adhesiveness, termed “inside–out” signalling 
(Carman and Springer, 2003), induces integrins to undergo a dramatic transition from a bent 
low–affinity conformation to an extended intermediate and high–affinity conformation, which 
in turn leads to an opening of the ligand–binding “pocket” (Arnaout et al., 2005). Divalent 
 24 
cations such as Mg2+ and Mn2+ are also able to modulate integrin affinity (Stewart and Hogg, 
1996). This “inside–out” signalling along with the shear forces exerted on the arrested 
leukocyte, are thought to play a critical role in the process of leukocyte recruitment, in which 
the appropriate balance between up–regulation of ligand binding at the leading edge and 
down–regulation at the trailing edge maintains the forward locomotion of leukocytes (Alon and 
Ley, 2008)(Kinashi, 2005)(Sanchez-Madrid and del Pozo, 1999). 
 
Moreover, binding of integrins to their ligands, induces signalling pathways from the 
extracellular domain to the cytoplasm in the classical outside–in direction (“outside–in” 
signalling), regulating various cellular functions, including cell motility, proliferation and 
apoptosis (Giagulli et al., 2006)(Shattil, 2005). During the leukocyte recruitment process, the 
overall strength of cellular adhesiveness, named avidity, is governed by two parameters; the 
intrinsic affinity of the individual receptor–ligand bonds and the number of the bonds formed, 
which is dependent on the ability of integrins to move in the plasma membrane and cluster 
together into the zone of cell adhesion (Carman and Springer, 2003).  
 
1.3.3  Transmigration 
After adhesion and crawling, leukocytes move towards the endothelial cell borders looking for 
signals in order to complete transendothelial migration, or diapedesis. Of note, while the 
preceding steps of tethering, rolling and firm adhesion are reversible, diapedesis is arguably the 
“point of no return” for the leukocyte (Gunn et al., 1998). In depth investigations of this 
process however have revealed that after diapedesis leukocytes might reverse transmigrate, 
although this has phenotypic and functional consequences (Buckley et al., 2006)(Muller, 2009).  
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Slow progress has been made in understanding leukocyte transmigration due to the complex 
nature of the vessel wall, which is difficult to accurately model and study in vitro (Voisin et al., 
2009). Particularly, venular walls have two cellular components, the endothelial cells, which are 
the primary barrier for emigrating leukocytes, and the pericytes that are long cells forming a 
discontinuous, subendothelial layer. Both appear to contribute to the generation of the non–
cellular specialised matrix or basement membrane (BM) that surrounds blood vessels (Hirschi 
and D'Amore, 1996). The vascular BM consists of two independent protein networks formed 
by laminin-8 and laminin-10, and collagen type IV, all largely interconnected with other 
components of the BM such as nidogen-2 and perlecan (Timpl, 1996). 
 
The well–accepted dogma is that leukocytes transmigrate through endothelial cell junctions (the 
paracellular route) although studies have reported an additional route, through the body of an 
endothelial cell (transcellular route) which has been observed in the central nervous system and 
in various inflammatory scenarios (Engelhardt and Wolburg, 2004)(D. Feng et al., 1998). 
Although contradictory opinions have been presented over the years, it has become clear that 
lymphocytes can migrate both in a “paracellular” and “transcellular” way although the precise 
contribution of each mechanism is poorly understood in most circumstances (Phillipson et al., 
2006). 
 
In general, luminal chemoattractants in combination with hydrodynamic shear forces can 
induce transendothelial cell migration (Cinamon et al., 2001b)(Cinamon et al., 2004). Initially, 
the interaction of an already firmly arrested leukocyte integrin, αLβ2 (LFA-1) with its counter–
receptor on endothelial cells, ICAM-1, induces the clustering of ICAM-1 as the leukocyte 
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approaches the endothelial cell border (Barreiro et al., 2002), which in turn stimulates the 
phosphorylation of contractin that leads in actin polymerization and recruitment of more 
ICAM-1 around the tightly adherent leukocytes (Durieu-Trautmann et al., 1994). If endothelial 
cells express VCAM-1 and leukocytes α4β1, their interaction also induces VCAM-1 clustering 
around the leukocytes, into endothelial projections termed “transmigratory cups” (Carman and 
Springer, 2004).  
 
The multimerisation of ICAM-1 and VCAM-1 on the endothelial cell surface transmits a variety 
of signals to the cell. The most important of those is the increased intracellular Ca2+ which 
leads to endothelial cell contraction and loosening of endothelial cell junctions, therefore 
facilitating the movement of leukocyte through the endothelial barrier (Huang et al., 1993). 
Additionally, the loosening of the endothelial junctions by ICAM-1 and VCAM-1 signalling 
pathways is mediated by their effects on VE–cadherin phosphorylation, a molecule that is a 
prerequisite for adherens junction disassembly (Turowski et al., 2008). While the leukocyte is 
transmigrating there is a continuous recycling of membrane from the later border recycling 
compartment (LBRC) to the position where the leukocyte is migrating, providing increased 
surface area and un–ligated molecules for leukocytes to interact with before passing through the 
endothelial layer (Muller, 2009). In the intracellular pathway of migration, ligation of ICAM-1 
by leukocyte integrin leads to translocation of ICAM-1 to actin and caveolae–rich regions. The 
caveolae (typical recycling endosomes) that contain ICAM-1 are linked together forming vesico–
vacuolar organelles (VVOs) that create an intracellular channel through which the leukocyte 
can migrate (Ley et al., 2007). 
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After leukocytes have migrated through the endothelial cell barrier, they need to migrate 
through the endothelial basement membrane as well. The existence of regions of low matrix 
protein deposition, named “low expression regions” or LERs, has been previously reported in 
the vascular basement membrane (BM) of the postcapillary venules. Interestingly, these LERs 
seem to be aligned with the gaps between adjacent pericytes, thus acting as “gates” for 
infiltrating neutrophils and monocytes (Voisin et al., 2009). Additionally, it has been proposed 
that leukocytes possess a variety of proteases that they use in order to degrade matrix 
components, thus facilitating their transmigration through the BM (S. Wang et al., 2006).  
 
1.3.3.1 Junctional Adhesion Molecules 
Several junctional adhesion molecules have been implicated in transendothelial migration of 
leukocytes (Muller, 2003). These molecules include immunoglobulin superfamily members such 
as PECAM-1, ICAM-1, ICAM-2, VCAM-1, JAM-A, JAM-B, JAM-C (Barreiro et al., 
2002)(Woodfin et al., 2007), the endothelial cell selective adhesion molecule (ESAM) and the 
non–immunoglobulin molecule CD99 (Vestweber, 2002). Of note, apart from ICAM-1 and 
VCAM-1, a characteristic of all the molecules involved in transmigration is that they are 
concentrated at cell junctions where they appear to play an important role in the steps just 
before diapedesis. Notably, during transmigration both ICAM-1 and VCAM-1 are also 
translocated to cell borders (Muller, 2009). 
 
Although all the preceding steps of the cascade (tethering, rolling, adhesion) are based on 
heterophilic interactions between one class of molecule on the leukocyte surface and another 
class of molecule on the endothelial cell, transmigration proceeds by both heterophilic 
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(LFA1/JAM-A, Mac-1/JAM-C and α4β1/JAM-B) and homophilic interactions between 
lymphocyte and endothelial PECAM-1, CD99, JAM-A and JAM-C (Muller, 2003). In addition, 
these adhesion molecules appear to mediate leukocyte transmigration in either leukocyte–
specific or stimulus–specific manner. For example, PECAM-1, ICAM-2 and JAM-A mediate 
leukocyte transmigration in response to IL-1β but not TNFα (Nourshargh et al., 2006) whereas, 
ESAM appears to mediate the migration of neutrophils rather than T cells, without showing 
any stimulus–specific role (Wegmann et al., 2006). 
 
1.4  MADCAM-1: AN ENDOTHELIAL CELL ADHESION MOLECULE 
MAdCAM-1 or “mucosal addressin cell adhesion molecule–1” is an endothelial cell adhesion 
molecule significant for directing leukocytes into mucosal and inflamed tissues, via interactions 
with the leukocyte alpha4 beta7 integrin (LPAM-1), L–selectin and alpha4 beta1 integrin (VLA-
4) (Girard and Springer, 1995). MAdCAM-1 belongs to the immunoglobulin (Ig) superfamily 
and shows many common characteristics with the other two members of the family, ICAM-1 
(intercellular cell adhesion molecule–1) and VCAM-1 (vascular cell adhesion molecule–1). 
Additional members of the immunoglobulin superfamily are ICAM-2 and ICAM-3. 
 
1.4.1  Genomic Organisation of MAdCAM-1 
MAdCAM-1 protein is encoded by a gene, located at p13.3 on chromosome 19, in close 
proximity to the ICAM-1 and ICAM-3 genes (19p13.2–p13.3), raising the possibility that these 
molecules are clustered together in the short arm of chromosome 19. The coding sequence of 
human MAdCAM-1 is contained in 5 exons, under the control of a 717bp 5’ flanking 
promoter region. The signal peptide, the two Ig domains and the mucin domain (major and 
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minor) are each encoded by separate exons, whereas the transmembrane domain, the 
cytoplasmic tail and the 3’ untranslated region are encoded on exon 5. Several potential 
transcriptional regulatory elements, including NF-κB, SP1, AP2, PEA3, NF-E1, Adh1, MyoD, 
E2A, ENKCRE, IRS sites and a GC box, have been indentified in the promoter region of the 
gene. Notably, only two NF-κB sites, one SP1 and a potential TATA box are also present in the 
mouse MAdCAM-1 gene promoter region and are conserved in position (Leung et al., 1997). 
 
1.4.2 MAdCAM-1 Protein Structure 
The encoded MAdCAM-1 protein is a 40kDa (406aa) protein that is extensively post–
translationally modified in vivo, through O–linked glycosylation leading to the formation of a 
60kDa mature glycoprotein. Structurally MAdCAM-1 comprises two N–terminal Ig domains of 
52 and 71 amino acids (aa) respectively, each possessing the invariant cysteine residue 
responsible for stabilisation of the Ig loop, with the first domain having doublet cysteines 
(Leung et al., 1996), and both Ig domains being separated from the cell surface by a 117aa 
mucin like region. Human MAdCAM-1 also comprises a transmembrane domain of 20 
hydrophobic residues and a 43aa cytoplasmic tail, which is longer than the murine homologue 
(Shyjan et al., 1996). The extracellular domain of murine MAdCAM-1 contains an additional Ig 
domain, adjacent to the transmembrane segment that displays high homology to the Ca2 
domain of IgA1 (33%) (M. J. Briskin et al., 1993) and is separated from the second Ig domain 
by a mucin–like region. An additional Ig domain has also been observed in rodents, dogs, pig 
and ruminant homologues (Tachedjian et al., 2006). In rats, the last immunoglobulin–like 
domain shows homology to the a3 domain of the rat MHC class I molecule, but not to the Ca2 
region of IgA1 (Rada et al., 1990). Studies have shown that the two N–terminal Ig domains of 
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MAdCAM-1 are sufficient for activation–independent adhesion to α4β7 (M. J. Briskin et al., 
1996) and a number of structural elements such as the cysteine residues that stabilise the Ig 
loops are conserved in those two Ig domains across many species (rodents, dogs, ruminants, 
pigs) (Tachedjian et al., 2006), supporting their role in α4β7 integrin binding. 
 
The human MAdCAM-1 mucin domain is rich in proline/serine/threonine (P/S/T) residues 
(58%) and this motif is repeated 8 times, whereas in mice this mucin–like region is also rich in 
P/S/T (51%), but only found once probably because this region is shorter (37aa). The suggested 
primary function of the MAdCAM-1 mucin–like region is to provide a framework for 
decoration with carbohydrate moieties allowing MAdCAM-1 to serve as a vascular ligand for 
the L–selectin (Berg et al., 1993). Indeed, human MAdCAM-1 has 19 potential sites for O–
linked glycosylation, and one N–linked glycosylation site within the first Ig domain, which is 
conserved in all MAdCAM-1 homologues except those from the mouse and rat. Of note, site–
directed mutagenesis to remove the N–linked glycosylation site in human MAdCAM-1 has 
revealed that it is not essential for activity (Tan et al., 1998). Intriguingly, human MAdCAM-1 
has compensated for a lack of the third Ig domain (present in the murine and other species 
homologues) by extending its mucin domain as two separate regions (major and minor domain) 
in order to hold the two N–terminal ligand–binding domains above the glycocalyx for 
presentation to α4β7 integrin. The fact that the repeats apparent in the mucin domain are 
highly similar to one another (75–100%) suggests that they arose by duplication. Another 
possibility is that the repeats in the major domain may have been inserted possibly by a gene 
conversion event that involves a mucin gene, resulting in enrichment of Ser–Thr–Pro residues 
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(40% in the major domain) and thus enabling better presentation to L–selectin (Leung et al., 
1996). 
 
Two general functions have been proposed for the mucin–like domains. The primary general 
function, based on the extended structure of the mucins would be to hold the distal Ig domains 
further above the glycocalyx, thus allowing more efficient interactions between the N–terminal 
domains and ligand. Secondly, the mucin domain could facilitate the physical presentation in 
vivo of the N–terminal domains under flow conditions, where the hemodynamic parameters do 
not favour close physical contact between cells (Jentoft, 1990). Hence, similar functions might 
apply for MAdCAM-1 mucin domain for α4β7 integrin recognition.  
 
Of note, the overall nucleotide and protein identity between human and murine MAdCAM-1 
is poor (42% and 39% respectively), although the two first Ig domains are highly conserved 
(59% and 65% respectively). Additional phylogenetic analysis of domains I and II have shown 
that there is a relatively close evolutionary relationship amongst ruminant, pig, dog and primate 
MAdCAM-1 whereas the rodent counterparts seem to be more distantly related (Tachedjian et 
al., 2006). The transmembrane domain is 55% identical between human and murine 
MAdCAM-1, and the short cytoplasmic regions share only 35% identity (Leung et al., 1996). 
Homology searches of multiple databases have shown that human MAdCAM-1 only has 
significant homology to ICAM-1 and VCAM-1, as has been reported for murine MAdCAM-1. 
Specifically, the first Ig domain of murine MAdCAM-1 displays homology to the first domain of 
ICAM-1 (32%) and VCAM-1 (28%), and the second MAdCAM-1 Ig domain shows homology 
with the fifth domain of VCAM-1 (30%) (Sampaio et al., 1995). 
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1.4.3 Alternative Splice Variants of MAdCAM-1 
At least seven alternatively spliced transcripts encoding different human MAdCAM-1 protein 
isoforms have been identified, but the full–length nature of some variants has not been 
determined. In particular, the splice variants identified include: one that lacks three mucin 
repeats, several other that lack almost all of the second Ig domain and the major mucin 
domain, and two others that have lost half of Ig domain II and 2–3 mucin repeats. An 
additional isoform of human MAdCAM-1 has been recognised that lacks exon 4, which 
encodes for the whole mucin domain, therefore this shorter MAdCAM-1 would be unable to 
accept and present specialised carbohydrate modifications and as a result would have a reduced 
capacity to support lymphocyte adhesion through binding to L–selectin (Figure 1.2) (Leung et 
al., 1996). In mouse too, an alternative splicing that results in deletion of exon 4, which in this 
case encodes for the mucin–like and IgA domains has been also recognised (Sampaio et al., 
1995). Different MAdCAM-1 protein isoforms have been also detected in the pig. 
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Figure 1.2 Proposed structures of MAdCAM-1 splice variants. Several alternatively spliced 
variants of human MAdCAM-1 gene have been identified that encode different protein isoforms. (a) 
The full–length MAdCAM-1 protein consisted of two Ig domains (domain I and II), a major and minor 
mucin domain, a transmembrane region and a cytoplasmic tail. Splice variant (b) lacking the second Ig 
domain (domain II) and some of the major mucin repeats, (c) lacking the domain II and the entire 
major mucin domain and (d) lacking both major and minor mucin domains (Leung et al., 1996). 
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1.4.4 MAdCAM-1 Motifs for α4β7 Integrin Recognition and Binding 
The study of the crystal structure of the N–terminal fragment of human MAdCAM-1, which 
contains the two Ig domains, has revealed unique characteristics among the Ig integrin ligands 
regarding specificity for the α4β7 integrin interaction. The presence of an aspartate residue, 
Asp42, located in the CD loop of the N–terminal domain (domain I) of MAdCAM-1 has been 
shown to be of key importance for integrin binding (M. J. Briskin et al., 1996)(Shyjan et al., 
1996)(Viney et al., 1996). The C and D strands form an “edge” of the domain, and as a result 
the side chain of Asp42 points up allowing it to be free for integrin recognition. The critical 
nature of the Asp42 has been substantiated by its conservation amongst mammalian 
MAdCAM-1 species (Tachedjian et al., 2006). In the case of VCAM-1, the critical integrin–
binding residue is also an aspartate (Asp40), located in the CD loop of domain I (Jones et al., 
1995). However, there is a key distinction between these two integrin recognition motifs in 
MAdCAM-1 and VCAM-1. In the overall superposition of domain I of MAdCAM-1 and 
VCAM-1, Asp42 in MAdCAM-1 and Asp40 in VCAM-1 lie 8Å apart (Tan et al., 1998), 
although in a new overlaying model for hMAdCAM-1 and hVCAM-1, the positions of the two 
aspartate residues are found to be only 2Å apart, probably accounting for the differences in 
binding α4β7 and α4β1 integrins, respectively (Dando et al., 2002). 
 
Interestingly, in previous studies involving domain–swapping experiments, it was found that the 
first domain alone is not sufficient to support efficient integrin binding and sequences from the 
second domain are also required. Thus a construct containing Ig domain I of MAdCAM-1 in 
place of domain I of ICAM-1, resulted in a poor α4β7 interaction (M. J. Briskin et al., 1996). In 
addition, a fragment containing a single Ig domain of VCAM-1 was inefficient at supporting 
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adhesion to α4β1 (Pepinsky et al., 1992) and even when domain II of VCAM-1 was replaced 
with the corresponding domain of ICAM-1, a diminished binding to α4β1 was detected, 
implying that stabilisation of the N–terminal domain by a similar structure (domain II) is not 
sufficient to support integrin interaction (Osborn et al., 1992).  
 
In MAdCAM-1, the most striking structural feature identified in domain II, is a negatively 
charged β ribbon that extends from the D and E strands. This region contains a very high 
proportion of negatively charged residues, with seven of the eleven residues being glutamate or 
aspartate (149–159). The importance of these residues has been highlighted by the substitution 
of six of the nine acidic residues with alanine, which resulted in a significant loss of α4β7 
binding (Green et al., 1999). Moreover, the residues in this loop have very high temperature 
factors, indicating high motility, a fact that led Tan and coworkers to suggest that this negatively 
charged loop might function as an antenna, electrostatically orientating the MAdCAM-1 
integrin binding face above the cell membrane (Tan et al., 1998). Interestingly, both the CD 
loop in domain I and the DE loop in domain II occupy the same face of the hMAdCAM-1 
molecule, providing further evidence that these loops are involved in ligand binding (Figure 
1.3) (Green et al., 1999). In domain II of hVCAM-1 an equivalent negatively charged loop, the 
C’E loop, which is shorter and less negatively charged than hMAdCAM-1, but is still important 
for integrin binding, has also been identified (Jones et al., 1995). Another essential 
characteristic of domain II of hMAdCAM-1 is its unusually high proline content (12.3% 
compared to 5.1% for average proteins) (McCaldon and Argos, 1988), concentrated on the 
bottom of domain II near to the boundary with the mucin–like domain, and this is suggested to 
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add rigidity and support the bottom of domain II against the forces exerted during adhesion to 
integrins (Tan et al., 1998). 
 
Mutational studies have revealed another critical arginine residue for ligand binding (Arg70) 
(Green et al., 1999) fully buried in the domain I surrounded by seven hydrophobic residues 
with no negatively charged residues in the vicinity to neutralise the strong positive charge (Tan 
et al, 1998). Of note, although buried un–neutralised arginines are rare, they have structural 
roles by forming multiple hydrogen bonds to backbone carbonyl oxygens (Borders et al., 1994). 
In the new model presented by Dando et al., however, the guanidium group Arg70 rather than 
being buried and supporting the structure of the loop through hydrogen bonds, was found 
located at the base of a surface cleft. In the monomeric form of MAdCAM-1, this leaves the 
arginine surface accessible and potentially free to interact with ligand (Dando et al., 2002). 
 
Overall, the critical elements for α4β7 integrin recognition and binding by hMAdCAM-1 are: 
an aspartate residue (Asp42) in the CD loop of domain I, a negatively charged β ribbon on the 
DE loop of domain II that stretches out far from the body of domain II, and thus optimally 
orienting domains I and II for recognition of integrin, and an arginine (Arg)70 in domain II, 
important for formation of a MAdCAM-1 dimeric form (see section 1.4.5). 
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Figure 1.3 Structure of the N-terminal domains of human MAdCAM-1. (a) Ribbon drawing 
showing the N–terminal two–domain structure of human MAdCAM-1 as described by Tan et al. and (b) 
as described by Dando et al. Residues, amongst which the Asp42, in the C/D (a) or C/C’ (b) loop of 
domain I are shown in red. (Figure was taken from the publication of Dando et al., 2002). 
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1.4.5 MAdCAM-1 Oligomerisation: Dimeric Form 
In the study of Dando et al., a dimeric form of MAdCAM-1 was observed created by two 
symmetry–related full–length molecules within the crystal lattice, through an extensive interface 
formed by residues from the edge of a β–sandwich in domain I (Dando et al., 2002). Such 
edge–to–edge dimerisation of Ig domains has also been reported for human ICAM-1 
(Casasnovas et al., 1998)(Reilly et al., 1995). In addition, the fact that the two Ig domains of 
MAdCAM-1 project approximately 22nm away from the cell surface by an extended mucin 
domain (Shyjan et al., 1996), indicates that there are no steric restrictions for the formation of a 
dimer. Moreover, the previously identified arginine (Arg)70 residue important for integrin 
recognition also contributes to the formation of the MAdCAM-1 dimer, via formation of 
bifurcated charged hydrogen bonds across the dimer interface. The previous mutational analysis 
experiments that identified the significance of Arg70 in integrin binding (Green et al., 1999) 
might suggest that the diminished integrin binding of the mutants could be a consequence of 
dimeric structure disruption, thus suggesting that the arrangement of MAdCAM-1 in a dimeric 
form is essential for activity. Interestingly, in the dimer form, the two loops that are important 
for integrin binding are brought closer together than in the monomer, with the CD loop in 
domain I and the DE loop in domain II being 15Å apart on the dimer surface (Figure 1.4) 
(Dando et al., 2002). 
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Figure 1.4 MAdCAM-1 dimer structure. Ribbon diagrams showing the crystal packing of 
MAdCAM-1 monomers described by (a) Dando et al. (2002) and (b) Tan et al. (1998). Individual 
monomers within each dimer are represented by dark and light shading (of blue and green respectively). 
Residues in the C/C’ (a) or C/D (b) loop of domain I are shown in red and yellow and residues in the 
D/E loop of domain II are shown in cyan and grey. (Figure was taken from the publication of Dando et 
al., 2002). 
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1.4.6 Soluble MAdCAM-1 
Elevated levels of circulating soluble adhesion molecules have been suggested to be essential for 
understanding the prognosis and pathology of certain diseases. In support of this, reports have 
shown that soluble forms of ICAM-1 and VCAM-1 are elevated in inflammatory, infectious and 
malignant diseases (Gearing and Newman, 1993) and are correlated with disease activity. Leung 
et al. revealed for the first time that human MAdCAM-1 can be secreted as a soluble molecule 
into serum, urine and probably other biological fluids. In particular, the average levels of 
MAdCAM-1 detected in the serum were 237ng/ml (range 180–315ng/ml), levels most similar 
to those of ICAM-1 in serum and the levels of sMAdCAM-1 in urine ranged from 20–
123ng/ml. Therefore, increased levels of circulating MAdCAM-1 could be a marker for the 
presence or progression of a chronic inflammatory disease (Leung et al., 2004). 
 
1.4.7 Sites of MAdCAM-1 Expression 
MAdCAM-1 is expressed on the high endothelial venules of the organised lymphoid tissues of 
Peyer’s patches (PPs) and mesenteric lymph nodes (MLN) as well as in the flat–walled vessels of 
the non–lymphoid tissues of lamina propria in both human and mice (M. J. Briskin et al., 
1993)(Shyjan et al., 1996). To a lesser extent, MAdCAM-1 is expressed in the spleen, pancreas 
and colon and expression at these sites increases under inflammation. In normal colon, human 
MAdCAM-1 is constitutively expressed on venular endothelium of the lamina propria and 
submucosa (M. Briskin et al., 1997), whereas in murine experimental colitis models MAdCAM-
1 expression is induced on colonic vascular endothelium and on the vessels within the 
muscularis propria and serosa when compared to control animals (Viney et al., 1996). In the 
inflamed pancreas of non–obese diabetic mice, elevated levels of MAdCAM-1 in HEV–like 
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vessels of Langerhans islets is also observed (Hanninen et al., 1993). In addition, murine 
MAdCAM-1 has been detected in the lactating mammary glands (Nishimura, 2003) and there 
are rare reports of human MAdCAM-1 on the venular endothelium of tonsils (M. Briskin et al., 
1997). MAdCAM-1 has been reported to be absent in the thymus, heart, lung, placenta, brain, 
liver, skeletal muscle, kidney, prostate, ovaries, testis and peripheral blood leukocytes, as well as 
on arterial endothelium (Viney et al., 1996). 
 
In foetal and neonatal mice, MAdCAM-1 is expressed both in peripheral lymph nodes (PLN) 
and mesenteric lymph nodes (MLN) at high levels. After the fourth week of postnatal life, 
MAdCAM-1 expression on PLN HEV declines until it is almost absent, and remains expressed 
only in MLN HEV (Mebius et al., 1996)(Salmi et al., 2001a). In murine adult PLN rare high 
endothelial venule cells expressing MAdCAM-1 have also been observed (Mebius et al., 1996). 
In addition to vascular and lymphatic endothelium, MAdCAM-1 has been also detected on 
follicular dendritic cells throughout B cell follicles, as well as in dendritic cells in the Peyer’s 
dome of normal and inflamed mice, in DCs of chronically inflamed spleen (M. Briskin et al., 
1997)(Szabo et al., 1997), and in lymphoid aggregates of several human liver diseases (Grant et 
al., 2001). In addition, fibroblasts with an unusual phenotype located in the perifollicular zone, 
the outer marginal zone, and the T cell zone of the splenic white pulp, as well as fibroblasts 
from murine tails, are also MAdCAM-1 positive (Steiniger et al., 2001). In addition, MAdCAM-
1 expression has been reported in astrocytes surrounding blood vessels in lesions from animals 
displaying chronic relapsing experimental autoimmune encephalomyelitis (Cannella et al., 
1991). 
 42 
Interestingly, although for many years MAdCAM-1 was thought to belong to the few truly 
tissue–specific adhesion molecules (M. Briskin et al., 1997), in 1999 Hillan et al. demonstrated 
MAdCAM-1 expression in adult liver in association with portal tract inflammation in chronic 
diseases (Hillan et al., 1999). In agreement Grant et al., subsequently demonstrated expression 
of MAdCAM-1 on portal tract vessels and sinusoidal endothelium during liver inflammation 
(Grant et al., 2001). 
 
1.4.8 The Role of MAdCAM-1 in Leukocyte Recruitment  
1.4.8.1 MAdCAM-1 during homeostasis 
Lymphocytes continuously circulate through the blood and lymphoid tissues as part of a process 
of immune surveillance that allows the immune system to respond appropriately to antigen 
wherever it enters the body. MAdCAM-1 plays an essential role in lymphocyte contact and 
rolling (L–selectin and α4β7–dependent rolling) as well as in strengthening adhesion and arrest 
(α4β7–mediated activation–dependent adhesion) (Berlin et al., 1995) as part of the multistep 
process that regulates lymphocyte homing into mucosal tissues associated with the 
gastrointestinal tract (Nakache et al., 1989)(Schweighoffer et al., 1993). The important role of 
the MAdCAM-1/α4β7 interaction has been highlighted by studies using monoclonal antibodies 
directed against either MAdCAM-1 or α4β7 integrin, which show diminished lymphocyte 
recruitment to the intestine (Hamann et al., 1994). Moreover, the essential role of the 
α4β7/MAdCAM-1 interaction for formation of gut–associated lymphoid tissue has been 
revealed in β7–integrin deficient mice, which show hypocellular Peyer’s patches as well as loss 
of lymphocytes in the lamina propria (Wagner et al., 1996). In contrast, in L–selectin–deficient 
mice, the cellularity of Peyer’s patches is unaffected but they show reduced numbers of 
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lymphocytes within peripheral lymph nodes (PLN) (Tedder et al., 1995b). Of note, 
simultaneous loss of both β7 and L–selectin (both ligands of MAdCAM-1) results in a 
significant decrease in the size and cellularity of Peyer’s patches (Wagner et al., 1998).  
 
Moreover, the interaction of MAdCAM-1 with α4β7 is a prerequisite for B cell localisation to 
Peyer’s patches, a process that cannot be compensated for by the interaction of L–selectin with 
MAdCAM-1 or of α4β7 with VCAM-1 (Schippers et al., 2009). Studies in MAdCAM-1 
deficient mice have also revealed that MAdCAM-1 is important for migration of IgA–secreting 
plasma cells to the intestinal lamina propria. This is a very important role since secretoty IgA 
protects the host from invading pathogens, facilitating antigen capture by M cells within the 
follicle associated epithelium (see section 1.6.3) and is needed for preserving the homeostasis of 
the gut with the commensal microflora (Macpherson et al., 2008). 
 
MAdCAM-1 has been reported to serve functions additional to those in leukocyte recruitment. 
Specifically, in spleen MAdCAM-1 plays a role in the organisation of the marginal sinus around 
the splenic white pulp nodules. Moreover, it has been demonstrated that recombinant 
MAdCAM-1 can enhance MLN T lymphocyte activation (Viney et al., 1996), similar to VCAM-
1 (Lukacs et al., 1994). In addition, human peripheral blood T cells can be co–stimulated with 
antibodies to the α4β7 integrin (Teague et al., 1994). 
 
1.4.8.2  MAdCAM-1 under inflammation 
Although the expression of MAdCAM-1 has been tightly linked with a physiological role in 
normal immune surveillance in the gut, in conditions of chronic gastrointestinal tract 
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inflammation, MAdCAM-1 facilitates increased lymphocyte extravasation thereby contributing 
to mucosal damage. During mucosa–associated inflammatory events, constitutively expressed 
MAdCAM-1 in gut associated lymphoid tissue, is greatly amplified (Connor et al., 1999). Most 
notably, such over–expression has been linked with inflammatory bowel disease (IBD), an 
idiopathic disorder of chronic inflammation of the gastrointestinal tract, which has been 
traditionally classified into two subtypes, Crohn’s disease (CrD) and ulcerative colitis (UC), 
based on histological appearance and anatomical distribution. In particular, UC is 
characterised by mucosal inflammation and extensive formation of ulcers, usually confined to 
the submucosa, whereas CrD is characterised by non–caseating granulomas, lymphoid 
aggregates and extension of inflammation through all layers of bowel wall (Arihiro et al., 2002). 
Interestingly, divergent distribution of MAdCAM-1 is observed in these two diseases. Precisely, 
more prominent expression of MAdCAM-1 is detected in the ulcer base and lymphoid 
aggregates, formed in the deeper layer of the intestinal wall in CrD. In addition, the occurrence 
of MAdCAM-1+ venules is higher in the submucosal lymphoid aggregates than in subserosa, 
suggesting that MAdCAM-1 expression is induced by enhanced entry of dietary antigens or 
various bacteria into the intestinal tissue (Arihiro et al., 2002). 
 
Up–regulation of MAdCAM-1 during gut inflammation has been suggested to be responsible 
for the sustained recruitment of α4β7 expressing lymphocytes and the establishment of chronic 
inflammation (Eksteen et al., 2004b). The functional significance of MAdCAM-1 in IBD has 
been highlighted by several studies where immunoneutralisation of either MAdCAM-1 or α4β7 
integrin, attenuate inflammation in animal models as well as in patients with colitis (Feagan et 
al., 2005)(Hamann et al., 1994) and Crohn’s disease (Feagan et al., 2008)(Guagnozzi and 
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Caprilli, 2008). Notably, several studies have also reported the efficacy of monoclonal 
antibodies directed against other endothelial cell adhesion molecules (CAMs), especially 
VCAM-1, to abolish recruitment and reduce disease severity in colitis models (Burns et al., 
2001), suggesting that a combination of adhesion molecule/ligand interactions take part in the 
destructive inflammatory influx that characterises IBD. 
 
Numerous animal models of colitis have been used in order to study the hidden mechanisms 
responsible for the development of chronic bowel inflammation. In the SAMP1/Yit mouse 
strain, which develops spontaneous ileal inflammation and shares histological features with 
human ileal Crohn’s disease, MAdCAM-1 was found to be significantly increased with 
worsening of disease from 4 to 40 weeks of age (Burns et al., 2001). Interestingly, the inhibition 
of MAdCAM-1 alone during established inflammation was less effective than the combined 
blockade of MAdCAM-1 and VCAM-1, which is also strongly expressed in the SAMP1/Yit 
mice with spontaneous ileitis. Therefore, since the simultaneous blockade of both CAMs 
significantly attenuated T–lymphocyte binding to microvessels in the ileal mucosa, it is 
suggested that pathways independent of the α4β7/MAdCAM-1 can also mediate trafficking to 
inflamed intestine (Kosiewicz et al., 2001)(Matsuzaki et al., 2005). Furthermore, the 
prophylactic Ab blockade of MAdCAM-1 prevented the development of ileitis, whereas the 
early administration of VCAM-1 Ab had no effect, indicating that the contribution of 
MAdCAM-1 is probably most pronounced during the early phases of the disease. Therefore, it 
is likely that MAdCAM-1 affects ileal inflammation locally not only in the mucosa but also in 
the MLN, as significant amelioration of acute and chronic inflammatory infiltrates has been 
observed when both MAdCAM-1 and L–selectin were blocked (Rivera-Nieves et al., 2005). 
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Additional studies have shown that administration of anti–β7 integrin and anti–MAdCAM-1 
Abs to SCID mice significantly reduced the number of leukocytes infiltrating the lamina 
propria and mesenteric lymph nodes of inflamed colons (Picarella et al., 1997). Moreover, using 
antisense MAdCAM-1 oligonucleotides in mice suffering from trinitrobenzene sulfonate–
induced colitis, significant suppression of the disease was reported (Goto et al., 2006). The 
interaction of α4β7 integrin with MAdCAM-1 in the intestine is mainly dependent on the 
CCL25/CCR9 interaction. Interestingly, therapeutic studies in the SAMP/Yit mice, where 
targeting CCL25 or CCR9, have shown that this receptor/ligand pair is important during the 
early stages of induction of spontaneous chronic murine ileitis, but not in late disease, 
suggesting that in the late stages the recruitment process is less dependent on this 
chemokine/receptor pair (Rivera-Nieves et al., 2006). To that effect, TRAFICET–EN, an orally 
active pharmaceutical CCR9 inhibitor is currently being assessed for the treatment of CrD and 
might be more effective early in disease. 
 
Increased expression of MAdCAM-1 has been observed in other animal models such as the 
dextran sulphate sodium (DSS)–induced colitis, SCID mice with CD45RAhigh CD4+ T cells, IL-
10 deficient mice, and in the granulomatous colitis induced by peptidoglycan–polysaccharide 
(PG–PS), where expression of MAdCAM-1 was elevated on the vessels in the lamina propria 
and the submucosal layer, thus providing further evidence for the role of MAdCAM-1 in the 
development of ileitis (Matsuzaki et al., 2005). Moreover, elevated levels of MAdCAM-1 have 
been observed in animal models that are not associated with inflammatory bowel disease, such 
as in the non–obese diabetic (NOD) mice (Faveeuw et al., 1994)(Hanninen et al., 1993) and in 
the central nervous system in chronic relapsing experimental encephalomyelitis (Kanwar et al., 
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2000). In NOD mice, which spontaneously develop an autoimmune syndrome similar to 
human insulin dependent diabetes mellitus (IDDM) (Atkinson and Maclaren, 1994), 
MAdCAM-1 has been reported to be strongly induced on islet vessels playing a major role in 
the recruitment of lymphocytes from blood into the inflamed pancreas (Faveeuw et al., 
1994)(Hanninen et al., 1993)(X. D. Yang et al., 1994). This role of MAdCAM-1 has been 
further validated by function blocking antibodies specific for L–selectin and α4 integrins, which 
resulted in inhibition of insulitis and prevention of autoimmune diabetes. MAdCAM-1 is also 
induced on brain endothelial cells during chronic relapsing experimental allergic 
encephalomyelitis (EAE), where functional blockade of MAdCAM-1 has been shown to 
effectively prevent the development of a progressive, non–remitting form of EAE. Of note, 
combinational treatment with anti–MAdCAM-1, anti–VCAM-1 and anti–ICAM-1 antibodies 
induced a more rapid remission than the anti–MAdCAM-1 treatment alone (Kanwar et al., 
2000). 
 
In humans, enhanced expression of MAdCAM-1 has also been reported in the gastric mucosa 
of patients with nodular gastritis (Ohara et al., 2003), and in malignant pancreatic tissues where 
MAdCAM-1 protein levels were significantly elevated and were able to recruit CD62L+ β7+ 
Tregs both in vitro and in vivo. Interestingly, blocking antibodies directed against MAdCAM-1 or 
its ligands CD62L and β7–integrin, strongly reduced the Treg transmigration, with the anti–β7 
integrin blockade having the highest effect in abolishment of Treg transmigration through the 
tumour endothelium (approximately 50%) (Nummer et al., 2007). Furthermore, aberrant 
expression of MAdCAM-1 has been detected on inflamed portal vein and sinusoidal 
endothelium of patients with autoimmune liver diseases, PSC and AIH, where it supports the 
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adhesion of α4β7+ lymphocytes from patients with IBD and PSC, an effect that could be 
abolished by anti–MAdCAM-1 and anti–α4β7 antibodies (Grant et al., 2001). 
 
1.4.8.3 Therapies directed against the MAdCAM-1/α4β7interaction 
The important role of the MAdCAM-1/α4β7 interaction in leukocyte recruitment under 
inflammatory conditions and its consequent role in establishment of chronic inflammation in 
both gut (IBD) and liver (PSC, AIH) has led pharmaceutical companies to develop humanised 
blocking monoclonal antibody–based therapies aimed at selectively inhibiting the pathways 
associated with these two molecules. For example MLN02, from Millenium Pharmaceuticals, is 
a humanised monoclonal antibody that inhibits adhesion and migration of leukocytes into the 
gastrointestinal tract by binding to the α4β7 integrin, and thus reducing inflammation. 
Currently, MLN02 has shown promising results in patients with active ulcerative colitis (Behm 
and Bickston, 2009). Another humanised monoclonal antibody, vedolizumab, which represents 
an enhanced form of MLN02, has been developed that targets α4β7 integrin exclusively, but 
not α4β1 or αEβ7, therefore inhibiting only the adhesion of α4β7 expressing cells to 
MAdCAM-1, without inducing the systemic immunosuppression that characterises anti–α4 
chain monoclonal antibodies (Soler et al., 2009). 
 
Natalizumab (Biogen Idec), is another humanised (95% human–derived) monoclonal antibody, 
directed against human α4 integrins, which inhibits leukocyte adhesion by blocking both 
VCAM-1/α4β1 and MAdCAM-1/α4β7 pathways (Stefanelli et al., 2008). It was initially 
approved in 2004, for induction and maintenance of moderate to severe Crohn’s disease, but 
later on it was withdrawn from the market after 3 patients developed progressive multifocal 
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leukoencephalopathy (Targan et al., 2007)(Van Assche et al., 2005). This is a consequence of 
defective immune surveillance of the central nervous system (CNS) because α4β1 is required for 
T cell trafficking to the CNS. Natalizumab is back on the market in US where it is used for the 
treatment of patients with Crohn’s disease.  
 
Very recently, the first human blocking anti–MAdCAM-1 mAb from Pfizer, PF00547659 has 
been described, which selectively binds to MAdCAM-1 and reduces homing of specific lineages 
of leukocytes to the gastrointestinal tract without impairing normal CNS immune surveillance. 
Thus this reagent is suggested to represent a better therapeutic approach for treatment of IBD 
than other available antibodies (Pullen et al., 2009). 
 
1.5  HUMAN LIVER 
The adult human liver is the largest internal organ in the human body, normally weighing 1.2–
1.5kg. It is located below the diaphragm in the thoracic region of the abdomen, to the right of 
the stomach overlying the gallbladder and possesses a unique location between the 
gastrointestinal tract and peripheral lymphoid organs. One of the most interesting 
characteristics of the liver is its capacity for natural regeneration, a feature recognised since the 
earliest times, which features in ancient Greek mythology. Prometheus, a Titan who stole fire 
from Zeus and gave it to mortals, was punished by Zeus, by being bound to a rock and his liver 
was eaten by a great eagle every day only to “regenerate” in the night and be eaten again the 
next day. Of note, as little as 25% remaining liver can generate into a whole liver again, which 
has the ability to adjust in size in order to match its host in cases of transplantation. 
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1.5.1 Architecture of The Liver 
The liver has been subdivided on the basis of both its external aspect and its internal 
architecture. Based on external appearance, traditional gross anatomy has divided the liver into 
four anatomical lobes. Observing the liver from the anterior side, a left and a larger right lobe 
are distinguished, being divided by the falciform ligament, whereas from behind, two additional 
minor lobes exist between the right and the left lobes, the caudate lobe (the more superior) and 
the quadrate lobe (the lower one) (Figure 1.5).  
 
 
 
Figure 1.5 Structure and morphology of human liver. The liver is divided into four anatomical 
lobes. In the figure are shown the bigger right and the smaller left lobe, whereas two more minor lobes 
exist in the posterior side (not shown). The liver is supplied with blood from the portal vein that 
transfers deoxygenated but nutrient–rich blood from the intestines, and with blood from the hepatic 
artery that supplies liver with oxygenated blood from the heart. Hepatocytes secrete bile, which is stored 
in the gall bladder and is transferred through the common bile duct into the duodenum (upper part of 
the intestine) to facilitate digestion (Liver Cirrhosis Case Study, 2008).  
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Investigation of the liver’s internal anatomy has revealed that its structural unit is the lobule. 
The lobule is a polyhedral prism (0.7 x 2mm), the boundaries of which are limited by four to 
five portal triads prolonged by connective tissue septa. One portal triad contains three 
structures, one bile duct and two blood vessels, which are branches of the hepatic artery and the 
hepatic portal vein. Within each lobule, epithelial cells called hepatocytes are arranged in layers 
that radiate out from a central vein, and between the group of hepatocyte layers lay the hepatic 
sinusoids (Figure 1.6) (Malarkey et al., 2005).  
 
 
 
Figure 1.6 The hepatic triad. A hepatic triad consists of three vessels, one branch of the hepatic 
portal vein, one branch of the hepatic artery and one bile duct. Hepatic triads are located at the corners 
of the polyhedral (usually hexagonal) lobules. Arterial and portal venous blood percolate through the 
hepatic sinusoids into the central veins that coalesce into hepatic veins and finally drain into the inferior 
vena cava (The Internet Encyclopedia of science, Anatomy & Physiology, Liver). 
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1.5.1.1 Liver blood supply 
The liver has a dual blood supply. In particular, the hepatic artery supplies the liver with 
oxygenated blood from the heart (20%), and the hepatic portal vein with deoxygenated but 
nutrient–rich blood from the gastrointestinal tract (80%). Arterial and portal–venous blood 
percolate through the hepatic sinusoids generating a mixed arterial–venous perfusion collected 
in the central vein (Figure 1.6). Finally, the central veins of all the lobules coalesce into hepatic 
veins, draining into the inferior vena cava, therefore sending de–oxygenated blood from the 
lower half of the body into the right atrium of the heart (Lalor and Adams, 2002). 
 
1.5.1.2 Liver cell populations 
The liver is composed from many different cell types. Up to 80% of the liver cell population 
consists of hepatocytes, large polyhedral epithelial cells that are highly metabolically active. 
Hepatocytes are arranged into cell plates separated by hepatic sinusoids lined with endothelial 
cells. The lumen of the sinusoids is narrow and is penetrated by Kupffer cells and Pit cells 
(Enomoto et al., 2004). Kupffer cells are the resident macrophages that “guard” the entrance of 
sinusoids and they are predominantly located in the peripheral region of the liver lobule and to 
a lesser extent in the midzonal and central areas (Nemeth et al., 2009). Their strategic position 
allows them to phagocytose and eliminate antigens or pathogens that enter the liver with portal 
venous blood (Knolle and Gerken, 2000). Pit cells are large granular lymphocytes resident in 
the sinusoids providing protection against viral infections and tumour cells (Lalor et al., 2002b). 
 
Between hepatocytes and sinusoidal endothelial cells lies the space of Disse, which is 
characterised by extracellular matrix, including different types of collagen (mainly type III but 
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also type I and IV), proteoglycans and fibronectin. The role of the extracellular matrix is 
complex as it serves to anchor cells, allowing intercellular communication and affecting cellular 
differentiation. Hepatic stellate cells (HSC) are located in the space of Disse. These 
perisinusoidal mesenchymal cells belong to the myofibroblast family. Under normal conditions 
they store vitamin A, which they lose on activation when they produce collagen, and assume 
features of fibrogenic, contractile myofibroblasts (Senoo et al., 1998). In addition HSC can 
mediate the inflammatory response by the production of several cytokines and chemokines 
(Pinzani and Marra, 2001). Of note, activated HSC have been reported to control sinusoidal 
blood flow by contraction, thus leading to reduction of the sinusoidal diameter (Figure 1.7) 
(Reynaert et al., 2002).  
 
Another type of cell, the cholangiocyte resides in the biliary tract and represents the first line of 
defence against pathogens that invade the bile ducts, through their ability to express pattern 
recognition receptors (PRRs), and to produce adhesion molecules, cytokines, chemokines and 
antimicrobial peptides (Nemeth et al., 2009). 
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Figure 1.7 Hepatic sinusoids. The hepatocyte population of the liver is separated by the hepatic 
sinusoids lined by specialised endothelial cells, that lack underlying basement membrane thus forming a 
discontinuous cell lining with fenestrae. The lumen of the sinusoids is narrow and penetrated by 
Kupffer cells, mainly located in the peripheral region. Between hepatocytes and endothelial cells lies the 
space of Disse in which stellate cells are located. 
 
 
1.5.1.3 Liver hepatic sinusoidal endothelial cells 
Hepatic sinusoidal endothelial cells (HSEC) form a highly specialised layer of cells that line the 
sinusoids (Enomoto et al., 2004), physically separating leukocytes passing through liver within 
the bloodstream from hepatocytes. It is estimated that 20% of the cells in liver are HSEC, 
making the second most frequent cell type after hepatocytes. HSEC have some characteristics, 
which distinguish them from the endothelial cells of the microvasculature of most other organs 
and from large liver blood vessels. Liver sinusoidal endothelia are very thin, lack an underlying 
basement membrane and tight junctions and form a discontinuous cell lining, thus creating a 
vascular bed with fenestrae (pores), with a mean diameter of 100 to 150nm (Braet and Wisse, 
2002). This characteristic morphology of HSEC makes them act as a “sieve” allowing the 
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passage of molecules of smaller diameters and excluding the passage of macromolecules to the 
space of Disse and thereafter to hepatocytes (Wisse et al., 1985). Of note, upon contact with 
substances like alcohol or nicotine, the diameter of these fenestrae can dynamically change 
(Braet and Wisse, 2002). 
 
Moreover, HSEC are scavenger cells equipped with surface C–type lectins and mannose 
receptors that allow them to scavenge the sinusoidal blood for pathogens and macromolecules. 
HSEC take up such macromolecules, internalise and efficiently endocytose them through their 
numerous specialised pinocytic vesicles. After endocytosis they deliver the degradation products 
to the space of Disse, where hepatic microvilli take them up either for destruction and 
elimination via the bile or for further metabolism (Knolle and Limmer, 2003)(Smedsrod, 2004). 
HSEC also express molecules that are relevant to antigen presentation, MHC class I and class II 
molecules, CD40, CD80, CD86 and CD54 allowing them to act as antigen–presenting cells 
(Knolle et al., 1999)(Limmer et al., 2000). Interestingly, HSEC can perform all the functions of 
an APC (uptake, processing and presentation of an antigen), however, without the requirement 
for maturation, thus ensuring that antigen presentation of blood–borne antigens by HSEC 
occurs within a short time (Knolle and Gerken, 2000). It is believed that activation of 
lymphocytes in the liver by resident APCs, HSEC and hepatocytes, usually results in tolerance 
rather than immunity (Adams et al., 2008). 
 
Finally, HSEC play an important role in immunity and inflammation since they can facilitate 
leukocyte extravasation (Knolle and Limmer, 2003). The strategic position of HSEC in the 
hepatic sinusoid as well as the small diameter of the hepatic sinusoid (7–12µm) and the slow 
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and peculiar blood flow supports the establishment of interactions with leukocytes in the blood 
flowing through the liver. 
 
1.5.1.4 Liver leukocyte populations 
The uninfected normal liver contains about 109 to 1010 resident lymphocytes, and this 
lymphocyte population in the liver differs considerably from that of the blood and other 
organs. It includes liver–resident subpopulations of the innate (NK and NKT cells) and 
adaptive (T– and B– lymphocytes) immune response (Doherty and O'Farrelly, 2000).  
 
NK cells are present at a high frequency (about 30%) among liver–resident lymphocytes and 
this percentage is further enhanced under inflammatory conditions (Doherty and O'Farrelly, 
2000)(Emoto et al., 2000). NK cells mediate antiviral and cytotoxic effector functions and can 
regulate innate and adaptive immune responses by secreting IFNγ and chemokines including 
CCL3 (MIP-1α) and CCL4 (MIP-1β), that subsequently lead to T cell recruitment to the liver 
(Itoh et al., 2001). 
 
NKT cells constitute a divergent population of T cells that express MHC class I, CD3 and the 
NK cell markers CD56, CD161 and CD94 on their surface (Kronenberg and Gapin, 
2002)(MacDonald, 1995). In the liver, both classical (CD4+ or CD4/CD8 double negative) and 
non–classical NKT cells (TCRαβ and TCRγδ T cells) are present and constitute up to 30% of 
the intrahepatic lymphocyte pool. Intrahepatic NKT cells are more activated than peripheral 
blood NKT cells. Upon TCR induced activation, NKT cells release substantial amounts of Th1 
(IFNγ and TNFα) and Th2 (IL-1, IL-10 and IL-13) cytokines (Swain, 2008), which in turn 
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contribute to activation of other innate (NK cells, monocytes) and adaptive (CD4+ and CD8+ 
T cell) immune cells or to suppression of tissue destruction/allograft tolerance respectively 
(Godfrey and Kronenberg, 2004). In liver diseases, NKT cells are implicated in immune 
responses to bacterial, viral and parasitic infections and to tumours (Notas et al., 2009).  
 
The intrahepatic T cell population includes the conventional CD8+ and CD4+ T cells that 
display a diverse TCRαβ repertoire and recognise antigens in the context of MHC class I and II 
molecules, respectively. In peripheral blood, the ratio of CD4:CD8 T cells is about 2:1, whereas 
this ratio is reversed in normal liver (1:2.5). Apart from the conventional lymphocyte 
populations in the liver a large population of unconventional lymphocytes such as CD4/CD8 
“double negative” T cells, CD4/CD8 “double positive” T cells and γδ T cells is also present 
(Doherty and O'Farrelly, 2000)(Adams et al., 2008).  
 
Intrahepatic B cells comprise less than 10% of the total intrahepatic population. They are 
characterised by the expression of CD5 and they can be activated in a T–cell independent way 
producing low affinity autoreactive IgM antibodies. Of note, they have been suggested to be 
equivalent of γδTCR+ cells, thus bridging the innate and adaptive immune system (Nemeth et 
al., 2009). 
 
The liver contains natural CD4+CD25+Foxp3+ Tregs at much lower frequencies than lymph 
nodes but with increased numbers when peripherally activated CD8+ T cells are present. The 
total number of liver Tregs seems to be negatively correlated with disease activity (Nemeth et al., 
2009).  
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Several types of hepatic DCs have been identified in mice: lymphoid (CD8α+ B220–CD11b–), 
myeloid (CD8α– B220– CD11b+), plasmacytoid (CD8α– B220+), a mixture of myeloid and 
lymphoid DCs (B220– CD11b–) and natural killer DCs (B220– CD11cint CD69+ 2B4+ DC5+) 
(Nemeth et al., 2009). In humans, plasmacytoid and myeloid DCs have been described in the 
liver. DCs reside as “immature” APCs, expressing low levels of MHC and co–stimulatory 
molecules such as CD40, CD80 and CD86, all necessary for T cell activation. They are mainly 
located within portal tracts and around central veins, and together with Kupffer cells they 
scavenge pathogenic agents from portal venous blood (Thomson et al., 1999). Upon activation, 
DCs migrate from the parenchyma via the space of Disse to portal area carrying the ingested 
antigenic particles in order to interact with lymphocytes and initiate an effective immune 
response (Adams et al., 2008). Of note, hepatic DCs have been suggested to be the key players 
in maintaining the balance between liver tolerance and immunity (Nemeth et al., 2009). 
 
1.5.2  Function of The Human Liver 
The liver performs multiple vital functions. The hepatocyte cellular machinery is responsible for 
numerous metabolic functions, including synthesis of plasma proteins, complement 
components, growth factors, cytokines and blood clotting factors, synthesis of lipids and bile. 
Bile consists of bile salts, bilirubin, phospholipids (including lecithin), cholesterol and various 
ions. It is secreted into the duodenum where it is responsible for emulsification of fats. Another 
important function of the liver is the metabolism of amino acids and carbohydrates, plasma 
proteins and vitamins, as well as the regulation of glucose levels in the blood, by two processes: 
glycogenesis (conversion of glucose to glycogen and storage of the latter when the levels of 
glucose in blood are high) and glycogenolysis (break down of glycogen into glucose and release 
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into the blood). In addition, the liver acts as a storage site of vitamins (A, D and Β12) and 
minerals. The liver is also responsible for xenobiotic detoxification, by cytochrome P450 
enzymes that are involved in hepatic phase I drug metabolism (Pearson and Roberts, 1984). In 
order for all these functions to be efficiently served, hepatocytes must extract nutrients, as well 
as waste and toxic products from the blood circulating through the liver via the sinusoids 
(Knolle and Gerken, 2000). 
 
1.5.3 Lymphocyte Recruitment in Human Liver During Homeostasis and Inflammation 
The liver has a large population of resident leukocytes that provide ongoing immune 
surveillance. However, in response to an infection or injury, these cell populations are rapidly 
expanded and additional lymphocytes are recruited and infiltrate the liver, following the 
process of leukocyte recruitment described above (see section 1.3) (Lalor and Adams, 1999). 
Interestingly, the liver has a unique feature in the sense that it has several anatomical 
compartments for leukocyte recruitment including via endothelial cells lining hepatic sinusoids, 
as well as through those lining the portal and terminal hepatic veins (Edwards et al., 2005). 
 
1.5.3.1 Lymphocyte recruitment in hepatic sinusoids 
HSEC fail to express high levels of the selectin family of adhesion receptors. E–selectin and P–
selectin are absent from resting sinusoidal endothelium, and the non–expression of the latter is 
consistent with the lack of Weibel–Palade bodies in HSEC (G. Steinhoff et al., 1993). Further 
studies in animals deficient in both E–selectin and P–selectin demonstrate only minimal 
alteration in leukocyte adhesion, suggesting a negligible role of selectins in the capturing and 
tethering of leukocytes within the sinusoids (Adams et al., 1996)(Wong et al., 1997). However, 
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this could be explained by the narrow diameter (7–12µm) of the sinusoids in combination with 
the low velocity of blood flow (25µm/min to 250µM/min) which probably promote the contact 
of passaging leukocytes with the sinusoidal endothelial cells in the absence of selectins. 
 
In the absence of selectins, other tethering molecules might be responsible for the initial 
capture of flowing leukocytes on hepatic endothelium. Under basal conditions, VCAM-1 is 
expressed at low levels and favoured by the low shear stress forces in the sinusoids (Lalor et al., 
1997) it can directly capture lymphocytes by supporting rolling adhesion (Alon et al., 
1995b)(Lalor and Adams, 1999). Another candidate for mediating rolling in the absence of 
selectins has been VAP-1. In the absence of inflammation the endothelial expression of VAP-1 
is largely confined to hepatic vessels (McNab et al., 1996). The function of VAP-1 as a rolling 
receptor has been suggested by in vitro and in vivo studies. VAP-1 can support sialic acid 
dependent adhesion to hepatic endothelium both in tissue binding assays and in primary 
cultured HSEC under shear stress (Lalor et al., 2002a) and in vivo VAP-1 supports rolling on 
mesenteric vessels (McNab et al., 1996)(Tohka et al., 2001). Firm adhesion of arrested 
lymphocytes in the sinusoidal endothelium is mediated by ICAM-1 and ICAM-2, which are 
both expressed constitutively under normal conditions, and the low levels of VCAM-1 (Iigo et 
al., 1997). Functional studies have suggested the important role of ICAM-1 in recruitment via 
the sinusoids (Yoong et al., 1998) and additional blocking assays in in vitro studies have 
supported the role of both ICAM-1 and VCAM-1 in lymphocyte binding to primary cultured 
sinusoidal endothelium (Edwards et al., 2005). Stabilin-2 is another molecule constitutively 
expressed in hepatic sinusoidal endothelium where it supports αMβ2 mediated adhesion of 
lymphocytes, and its’ functional importance has been shown by blocking antibodies against 
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stabilin-2 that significantly abolish lymphocyte binding to hepatic sinusoidal endothelial cells 
under both static and flow conditions (M. Y. Jung et al., 2007). 
 
Thereafter, arrested lymphocytes undergo transendothelial migration. Interestingly, hepatic 
sinusoidal cells express low levels of the junctional adhesion molecules PECAM-1 and JAMs 
(Scoazec and Feldmann, 1994), which might be explained by the lack of tightly regulated cell 
junctions in HSEC, but other molecules such as ICAM-1 and VAP-1 have been reported to be 
important for diapedesis through hepatic sinusoids (Lalor et al., 2002a)(Yoong et al., 1998). 
CLEVER-1, a member of the scavenger receptor family, has also been reported as a potential 
molecule involved in lymphocyte transmigration since it is widely expressed in both vascular 
and lymphatic endothelium and has been demonstrated to mediate transmigration through 
both distinct types of endothelial cells both in vitro and in vivo (Salmi et al., 2004). 
 
Under normal conditions low levels of chemokines are detected in hepatic sinusoids. However, 
upon inflammation increased levels of both adhesion molecules and chemokines have been 
observed. Particularly, ICAM-1 and stabilin-2 expression are considerably increased, and 
VCAM-1 and PECAM-1 expression is induced (Adams et al., 1994)(Adams et al., 1991)(Lalor et 
al., 2002a)(Yachida et al., 1998). Moreover, upon inflammation the CXC chemokines, CXCL9, 
CXCL10, CXCL11 all of which bind to CXCR3 and CXCL16 that binds to CXCR6 are up–
regulated on sinusoidal endothelium (Figure 1.8) (Table 1.2) (Heydtmann and Adams, 2009). 
Further evidence supporting the preferential expression of these chemokines by sinusoidal 
endothelium comes by the high levels of the CXCR3 receptor detected on liver infiltrating 
lymphocytes in chronic inflammation (>80%) (Curbishley et al., 2005). 
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1.5.3.2 Lymphocyte recruitment in portal vessels 
Under normal conditions, portal vessel endothelium expresses VAP-1, ICAM-1 and ICAM-2 
and low levels of several chemokines including CCL3, CCL4 and CCL5, which lead to the 
recruitment of CCR5high T cells to portal cells in the normal liver during immune surveillance 
(Lalor and Adams, 1999). However, in inflammatory conditions, portal vessels induce the 
expression of P–selectin, E–selectin and VCAM-1 and up–regulate ICAM-1 levels (Ward et al., 
1998) as well as strongly express the chemokines CCL3, CCL4 and CCL5. Therefore, it seems 
that the inflamed portal vessels use the induced selectins to promote primary tethering and 
rolling with subsequent firm adhesion via LFA-1 and α4β1 integrins, which are elevated on liver 
infiltrating lymphocytes, and bind to their receptors ICAM-1 and VCAM-1, respectively (Yoong 
et al., 1998). The expression of VAP-1 is also maintained on inflamed portal endothelium 
where it supports lymphocyte binding (Figure 1.8) (Table 1.2). 
 
Interestingly, in certain inflammatory diseases that complicate IBD, such as PSC and AIH, 
elevated levels of the gut specific molecules MAdCAM-1 and CCL25, have been observed 
mainly in portal vessels promoting the recruitment of α4β7+CCR9+ gut derived lymphocytes to 
the liver (Eksteen et al., 2004a). Moreover, CCL28 has been detected in inflamed endothelium, 
in cholangiocytes and hepatocytes in a variety of liver diseases (Eksteen et al., 2006) (Figure 1.8). 
Finally, another chemokine CCL21, which is predominantly expressed in lymphoid tissues has 
been detected in small vessels and occasional cells with the morphology of CD11c+ dendritic 
cells in portal associated tertiary lymphoid follicles in chronic inflammatory liver diseases, 
mainly in PSC and PBC, two diseases associated with portal tract infiltration and formation of 
neolymphoid aggregates (Grant et al., 2002b) (Figure 1.8) (Table 1.2). 
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Figure 1.8 Lymphocyte recruitment to the liver. Adhesion molecules and chemokines being 
reported to mediate lymphocyte recruitment in the liver via (A) the portal tract endothelium and (B) the 
hepatic sinusoidal endothelium under normal and inflammatory conditions (Adams et al., 2006). 
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MOLECULES IMPLICATED IN LYMPHOCYTE RECRUITMENT WITHIN THE DIFFERENT HEPATIC 
ANATOMICAL COMPARTMENTS 
HEPATIC SINUSOIDS PORTAL VESSELS 
Normal Liver Inflamed Liver Normal Liver Inflamed Liver 
VAP-1 
VCAM-1 (low levels) 
ICAM-1, -2 
Stabilin-2 
CLEVER-1 
PECAM-1 (low levels) 
JAMs (low levels) 
CXCL9, -10,-11 
CXCL16 
 
VAP-1 
VCAM-1 
ICAM-1, -2 
Stabilin-2 
MAdCAM-1 
CLEVER-1 
PECAM-1 
CXCL9, -10, -11 
CXCL16 
CCL25 
VAP-1 
VCAM-1 (low 
levels) 
ICAM-1, -2 
PECAM-1 
JAMs 
CCL3, -4, -5 (low 
levels) 
VAP-1 
VCAM-1 
E-selectin 
P-selectin 
ICAM-1, -2 
MAdCAM-1 
PECAM-1 
JAMs 
CCL3, -4, -5 
CCL25, CCL28, 
CCL21 
 
Table 1.2 Molecules involved in recruitment of lymphocytes to the different hepatic 
anatomical compartments. Adhesion molecules and chemokines implicated in 
lymphocyte recruitment via hepatic sinusoids and portal vessels under normal and 
inflamed conditions. 
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1.6  ANATOMY & FUNCTION OF THE GUT 
1.6.1 Overview of The Digestive System 
The human digestive system consists of linked organs and glands responsible for food 
processing, digestion and absorption of nutrients. Two basic divisions of the digestive system 
have been recognised: the gastrointestinal (GI) tract (also known as the alimentary canal), a 
continuous tube consisting of the mouth, pharynx, esophagus, stomach, small and large 
intestine, through the walls of which the nutrients are absorbed prior to entering the blood or 
lymphatic vessels. The accessory organs are the second part of the digestive system and include 
the teeth and tongue, salivary glands, liver, gallbladder and pancreas, which are responsible for 
producing and storing digestive chemicals. 
 
1.6.2 Anatomy and Function of The Gut 
The digestive tract from mouth to anus is characterised by a wall of four layers: the mucosa, 
submucosa, the muscularis externa and the serosa (Figure 1.9).  
 
The mucosa is a mucous membrane lining the inside of the digestive tract, which protects the 
GI tract wall by secretion of substances and absorption of the end products of digestion. Three 
more layers define the mucosa: the epithelium, composed of columnar or stratified squamous 
epithelium, goblet cells that secrete mucus therefore protecting the epithelium from digestion, 
and endocrine cells that secrete hormones into the blood. The second layer, the lamina propria, 
lies outside the epithelium. Blood and lymphatic vessels are present in the lamina propria and 
provide nutrients for the epithelial layer, distribute the hormones that are produced in the 
epithelium and absorb the end products of digestion from the lumen. In addition, the lamina 
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propria contains the mucosa–associated lymphoid tissue (MALT) and the nodules of lymphatic 
tissue bearing lymphocytes and macrophages that protect the GI tract wall from bacteria and 
other pathogens that might be mixed with the food. The third layer, the muscularis mucosae, is 
the outer layer of the mucosa, consisting of a thin layer of smooth muscle responsible for the 
generation of local movements. In particular, in the stomach and small intestine, the smooth 
muscle generates folds that increase the absorptive surface area of the mucosa. The surface of 
the mucosa is covered by villi, fingerlike projections that increase the surface area over which 
absorption and digestion occurs and additional microscopic extensions, the microvilli, are also 
present in the outer surface of the absorptive cells present in each villus. 
 
The submucosa underlies the mucosa and contains blood vessels, lymphatic vessels and nerves. 
The small intestine submucosa has the following distinct characteristics: Brunner’s glands, 
which are found only in the submucosa of the duodenum and secrete an alkaline mucus that 
neutralises the gastric acid in the incoming chyme, and Peyer’s patches, aggregated lymphatic 
nodules, that provide a defensive barrier against bacteria.  
 
The muscularis externa is a layer of muscle that in the mouth and pharynx consists of skeletal 
muscle to aid swallowing, and in the rest of the GI tract consists of smooth muscle and 
associated nerve fibers. The smooth muscle is responsible for the movement of food by 
peristalsis and mechanical digestion by segmentation.  
 
Finally, the serosa is a serous membrane that lines outside the GI tract, and different serosae are 
associated with the different parts of the digestive tract.  
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Overall, the digestive system can serve the following main functions: mechanical and chemical 
digestion of food with the aid of secreted digestive enzymes, absorption of the digested end 
products and transfer into the blood and lymphatic vessels. 
 
 
 
 
Figure 1.9 Structure of the digestive tract. Representative image showing the four layers 
consisting the internal wall of the digestive tract: mucosa, submucosa, muscularis externa and 
serosa (Tortora and Grabowski, 1996). 
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1.6.3 Intestinal Immune System 
The gastrointestinal mucosal surfaces are the physical interfaces of the immune system with the 
outside world and, in addition to nutrient absorption the GI tract must also provide defence 
against exogenous pathogens. The gut harbors an abundant number of microbes, named 
commensal bacteria, which shape the normal functioning of the mucosal immune system 
(Hooper and Gordon, 2001). The gut is susceptible to inflammation and even under normal 
conditions there is a baseline degree of “physiological inflammation” in the mucosa, caused by 
tightly controlled immune responses directed against the wide array of local dietary and 
microbial antigens (Danese and Fiocchi, 2006). 
 
The intestinal immune system maintains immunologic homeostasis in response to self and 
foreign antigens through specific compartments that respond to invading pathogens and 
through a complex network of lymphoid and non–lymphoid cell populations and humoral 
factors. The first line of protection is provided by the intestinal epithelium, a polarised single 
layer covered by mucus that forms a primary cell barrier rich in antibacterial substances such as 
defensins and secreted IgA antibodies (Ayabe et al., 2000)(Macpherson et al., 2000) 
(McCracken and Lorenz, 2001). Each epithelial cell maintains tight contacts with its 
neighbours, thus creating tight junctions that prevent bacterial translocation (Madara, 1998) 
(Macdonald and Monteleone, 2005). Moreover, intestinal epithelium constitutively expresses 
evolutionary conserved and structurally related receptors, named pattern recognition receptors 
(PRRs), as well as Toll–like receptors  (TLRs) TLR1 and TLR9 and the nucleotide–binding 
oligomerisation domain (Nod) molecules Nod1 and Nod2 (also present in NK cells) (Strober et 
al., 2006)(Takeda and Akira, 2004) 
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In addition, gut epithelium contains abundant intraepithelial lymphocytes (IEL), mainly 
CD8α+ T cells, divided into two major groups and a low percentage of CD4+ T cells. The first 
group of CD8α+ cells consists of the conventional CD8αβ+TCRαβ+ IELs, the majority of 
which enter the epithelium after being activated in secondary lymphoid organs (SLOs). Of note, 
this group represents the predominant lymphocyte population in the human intestinal 
epithelium (Jabri and Ebert, 2007). The second group comprises CD8β– CD8αα+ IELs that 
express either TCRαβ+ or TCRγδ+ (Lambolez et al., 2007). IELs express CCR9 and are thus 
attracted by epithelial CCL25 to the intraepithelial compartment (Ericsson et al., 2004). 
 
The second immune compartment in the gut is the lamina propria, which is filled with 
numerous CD4+TCRαβ+ or CD8αβ+TCRαβ+ T cells displaying a previously activated or 
memory phenotype, that have entered the intestinal mucosa subsequent to their priming and 
activation in SLOs (Macdonald and Monteleone, 2005). IgA–producing plasma cells, 
macrophages, dendritic cells (DCs), and eosinophils are also present. Moreover, in the 
intestinal lamina propria and its associated lymphoid follicles, Foxp3+ regulatory T cells, IL-10 
expressing Tr1, TGFβ–producing Th3 cells and invariant NKT cells are resident, to help 
maintain tolerance to food antigens (Eksteen et al., 2008).  
  
Peyer’s patches present in the sub–epithelial compartment are lymphoid aggregates covered by a 
specialised follicle–associated epithelium (FAE). The FAE is composed of specialised epithelial 
cells, named M cells, which serve as a means to transport luminal antigens to antigen presenting 
cells (DCs) in the dome of the follicle (Neutra et al., 2001). M cells are able to sample the gut 
lumen for antigens and transport bacteria to professional antigen–presenting cells (DCs) on 
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their basolateral surface. Most of the bacteria are killed rapidly by macrophages, but those 
transferred by M cells to DCs can survive several days. Moreover, DCs can open the tight 
junctions between the epithelial cells and through their dendrites extend beyond the 
epithelium to directly sample luminal contents. DCs that take up antigens in the lamina 
propria migrate either to local mesenteric lymph nodes (MLN) or to Peyer’s patches, where they 
interact with naïve lymphocytes to generate primed, effector lymphocytes that leave the MLN 
through the efferent lymph, enter the bloodstream at the thoracic duct and home back to the 
intestinal mucosa (Macpherson and Harris, 2004)(Niess and Reinecker, 2006). After the 
antigen is cleared, most effector cells die, leaving a cohort of long–lived memory cells that can 
rapidly augment immunity on re–encounter with their cognate antigen (Hendriks et al., 2000). 
 
DCs in the gut are key players in controlling immunity against pathogens and tolerance towards 
commensals. They can distinguish between commensals and pathogens using pattern 
recognition receptors and co–stimulatory molecules (TLRs and Nods) and consequently can 
either activate or silence T cell responses (Iwasaki and Medzhitov, 2004)(Baumgart and 
Carding, 2007). In healthy individuals, an orchestrated system regulates intestinal T cells to 
sequester commensal microbiota within the intestinal lumen, in order to prevent their contact 
with innate and adaptive immune cells, thus restricting the production of pro–inflammatory 
cytokines and the induction of effector immune responses (Maynard and Weaver, 2009). 
Hence, even upon antigen encounter via DCs, balanced differentiation of naïve T cells to 
effector CD4+ T cells (Th1, Th2, Th17) and regulatory T cells (Tr1, Th3) is sufficient to 
maintain tolerance towards commensal organisms (Banchereau and Steinman, 1998). On the 
other hand, dysregulated effector T cell responses to commensal flora in genetically susceptible 
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individuals can cause spontaneous inflammation as happens with IBD (Maynard and Weaver, 
2009). 
  
1.6.4 Leukocyte Recruitment in Normal and Inflamed Gut 
1.6.4.1 Leukocyte recruitment during homeostasis 
P–selectin and its counter–receptor P–selectin glycoprotein ligand–1 (PSGL-1) mediate 
leukocyte tethering and rolling on mucosal vessels, a role supported by experimental evidence 
from mice that lack P–selectin and show aberrations in their intestinal T–cell numbers (U. 
Steinhoff et al., 1998). In order to firmly adhere to the mucosal vessels appropriate signals from 
chemokines are required.   
 
In the small bowel, the chemokine CCL25 is secreted by epithelial cells. In humans, CCL25 is 
localised in the crypts of Lieberkun in the small intestine, whereas in mice CCL25 is more 
widely expressed in villous epithelial cells and within the villi of the small intestine (Papadakis 
et al., 2000). In addition to epithelial cells, CCL25 has been detected on the venular 
endothelium, however since no message is present it seems that CCL25 expressed by epithelial 
cells is transported and presented by endothelial cells (Hieshima et al., 2004). This is a property 
of endothelial cells to take up, transcytose and finally present on their apical surface 
chemokines produced by surrounding cells (Schrage et al., 2008). Binding of CCL25 to its 
receptor CCR9, which is restricted to GALT lymphocytes (Kunkel et al., 2000), leads to 
activation of α4β7 integrin and subsequent binding to its ligand, MAdCAM-1, firmly arresting 
lymphocytes. Interaction between the leukocyte function–associated molecule-1 (LFA-1) and its 
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ligand ICAM-1 further promotes firm attachment and transmigration to mucosa associated 
lymphoid tissue (Schuermann et al., 1993). 
 
The homing of IgA–producing plasma B cells is also dependent on CCR9/CCL25 interactions 
(N. Feng et al., 2006). CCR9–deficient mice show reduced numbers of IgA+ plasma cells in the 
lamina propria of the small intestine and in addition CCR9–deficient IgA+ plasma cells show 
impaired migration into the small intestine when compared to wild–type controls (Pabst et al., 
2004). Moreover, compared to resting cells, activated B cells express different carbohydrate 
epitopes, which serve as ligands for selectins such as E– and P–selectin (Sinha et al., 2006).  
 
CCL28 is another epithelial chemokine highly expressed in the small intestine, and is 
responsible for attracting IgA–producing B cells, which bear its receptor CCR10 (Kunkel and 
Butcher, 2003). CCL28 is also expressed on epithelium in the colon, lung, liver and exocrine 
glands, suggesting that it acts as a common mucosal chemokine (Wilson and Butcher, 2004). In 
addition, the chemokine CXCL12 is found on high endothelial venules of Peyer’s patches 
(Okada et al., 2002) and promotes the homing of CXCR4 expressing cells to the small and large 
intestine. Functional studies using blocking antibodies against CXCL12 or its receptor CXCR4 
have shown significant inhibition of leukocyte adhesion to ileal and colonic microvessels under 
both normal and inflammatory conditions (Oyama et al., 2007). 
 
The chemokines CCL6, CXCL16 and CX3CL1 are expressed throughout the non–inflamed 
intestine. Other chemokines showing a more restricted expression profile are CCL5 being 
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predominantly expressed in the small intestine (as is CCL25) and CCL19, CCL21 and CXCL5 
being expressed in the large intestine (Shang et al., 2009). 
 
1.6.4.2 Leukocyte recruitment under inflammation 
Under inflammation, the mucosal vasculature undergoes changes, and the haemodynamics and 
permeability of the vessels are altered, leading to activation of the local microvascular 
endothelial cells (Nathan, 2002). The expression of the adhesion molecules, MAdCAM-1 (M. 
Briskin et al., 1997), ICAM-1 and P–selectin is enhanced whereas further adhesion molecules, 
E–selectin, VCAM-1 and VAP-1 are induced on the endothelium of mucosal vessels, thereby 
promoting continuous leukocyte adhesion and extravasation into tissue (Salmi et al., 
1993)(Butcher et al., 1999)(Mori et al., 1999)(Sans et al., 1999). Moreover, in addition to 
adhesion molecules, the chemokine expression pattern, along with chemokine receptor profiles, 
is also altered in inflammation. In IBD, elevated levels of CCL2 and CCL5 chemokines have 
been observed, and knockout animals lacking the receptors for these chemokines show 
resistance to IBD–like inflammation (Papadakis, 2004). In addition, increased levels of CCL25, 
CCL28 and CCL20 along with their receptors CCR9, CCR10 and CCR6, respectively, are 
involved in the pathogenesis of IBD. In inflamed colonic lamina propria of UC patients, 
increased levels of CXCL10 the ligand for CXCR3 have been also observed (Uguccioni et al., 
1999). Finally, CX3CL1 chemokine is increased in IBD patients, which is consistent with the 
increased expression of its receptor CX3CR1 on patient CD4+ T cells (Kobayashi et al., 2007).  
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1.7  LINKS BETWEEN THE LIVER AND THE GUT 
Inflammatory bowel disease (IBD) is an idiopathic disorder of the gastrointestinal tract, 
characterised by several intestinal inflammatory features, ranging from granulomatous, 
transmural inflammation (in Crohn’s disease) to crypt abscesses, restricted to the colon (in 
ulcerative colitis) (Adams and Eksteen, 2006). It is well known that patients with IBD are 
susceptible to develop inflammation at extra–intestinal sites, either in parallel with gut 
inflammation (such as pyoderma gangrenosum, erythema nodosum and anterior uveitis) or 
independently of the course of IBD [such as autoimmune hepatitis, primary sclerosing 
cholangitis (PSC) and ankylosing spondylitis]. In the latter case, the association of PSC and IBD 
is of particular interest, since patients can develop PSC de novo many years after total colectomy 
for fulminant colitis and, colonic inflammation can occur for the first time in patients after 
many years of liver transplantation for PSC (Adams and Eksteen, 2006). The association 
between IBD and liver diseases may be partly explained by observations that show ectopic 
expression in the liver of what were previously thought to be “gut–specific” addressins. Thus, in 
the extra–intestinal complications of IBD in the liver, PSC and AIH, aberrant expression of 
MAdCAM-1 has been detected (Hillan et al., 1999)(Grant et al., 2001), which supports α4β7–
integrin mediated lymphocyte adhesion to hepatic endothelium. Moreover, CCL25 which was 
thought to have a restricted expression in the gut and the thymus (Kunkel et al., 2000) was also 
detected in inflamed PSC tissues, where it could support recruitment of α4β7+CCR9+ 
lymphocytes to MAdCAM-1 expressing inflamed hepatic endothelium (Eksteen et al., 2004a). 
Furthermore, the ectopic expression of VAP-1, which is up–regulated on mucosal endothelium 
upon inflammation (Salmi et al., 1993), supports the existence of an “entero–hepatic” 
circulation where long–lived memory T cells are able to migrate to both gut and liver, thus 
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providing immune surveillance against gut–derived pathogens entering the liver via the hepatic 
portal tract circulation (Grant et al, 2001) (Figure 1.10). 
 
 
 
Figure 1.10 Overlapping expression of adhesion molecules in gut and liver. MAdCAM-1 is 
normally expressed in gut mucosa associated lymphoid tissues where it recruits α4β7+ lymphocytes 
initially activated in mesenteric lymph nodes (MLN). Similarly, the constitutively expressed in the liver 
VAP-1 attracts lymphocytes primarily activated in peripheral lymph nodes (PLN). However, during 
inflammation, MAdCAM-1 is induced in the liver and VAP-1 in the gut, leading both to aberrant 
recruitment of gut–and liver– derived lymphocytes to the liver and gut respectively.   
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1.8  AIMS OF THE THESIS 
The broad aim of this thesis was to investigate the mechanisms that regulate the expression of 
MAdCAM-1 in human liver under certain chronic inflammatory conditions, and to evaluate its 
function, in order to understand the pathogenesis of these disorders. More precisely the specific 
aims were: 
 
I. To investigate the presence of MAdCAM-1 and CCL25 in a variety of diseased human 
liver tissues. 
 
II. To use primary cultures of human hepatic and human umbilical vein endothelial cells 
to investigate the role of specific factors in the regulation of MAdCAM-1 expression. 
 
III. To study the role of VAP-1/SSAO enzyme activity in MAdCAM-1 expression both in 
vitro and in vivo using animal models. 
 
IV. To develop a flow–based adhesion using primary cell cultures in order to determine 
the function of MAdCAM-1 in the liver and the role of different chemokines in 
lymphocyte adhesion to MAdCAM-1.  
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2.1  HUMAN TISSUE 
Human liver tissue was obtained from explanted diseased livers that were removed after 
transplantation, or from normal tissue surplus to transplantation requirements or from excised 
tumour margin tissue collected after resection of tumours at the Queen Elizabeth Hospital, 
Birmingham, UK. Human umbilical cords were collected from the Women’s Hospital, 
Birmingham, UK. Whole blood was obtained from healthy volunteers, and for purposes of 
specific experiments, peripheral blood was obtained from patients with inflammatory bowel 
disease (IBD). All human tissue and blood samples were collected with local research ethics 
committee approval and patient consent. 
 
2.2  CELL CULTURE 
2.2.1 Solutions Used for Cell Culture 
Human AB serum purchased from HD Supplies, Bucks, UK and Fetal Calf Serum (FCS) 
purchased from Invitrogen were both heat inactivated at 56oC for 20min prior to use. 
Penicillin, Streptomycin and Glutamine (PSG) were purchased from Sigma-Aldrich. TrypLETM 
Express (1x) stable Trypsin-like enzyme with Phenol Red and Trypsin 0.5% (10x) with EDTA 
4Na (used in the MediCity laboratory, Turku) were both purchased from Invitrogen. Phosphate 
buffered saline (PBS) was prepared from tablets (Oxoid, UK) according to manufacturer’s 
instructions. All non–sterile solutions and glassware were autoclaved prior to use for cell 
culture. 
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2.2.2 Tissue Culture Plastics 
Sterile 5,10 and 20ml pipettes, 25 and 75 cm2 culture flasks, sterile 6–well and 24–well plates, 
sterile 15ml and 50ml tubes and sterile cryovials were all purchased from Corning Costar 
Incorporated, Bucks, UK. Sterile flat–bottomed 96–well plates were purchased from Becton 
Dickinson Labware. Tissue culture cell scrapers 25cm were purchased from Starstedt Ltd. 20ml 
plastic tubes and 5ml bijous were acquired from Ramboldi. Sterile plastic gloves used daily were 
from Premier Nitric. All tissue culture was carried out in a class II microflow safety cabinet. At 
all times aseptic technique was followed by swabbing the cabinets with industrial methylated 
spirit (IMS; Adams Healthcare, Leeds, UK) before and after use. 
 
2.2.3 Cell Culture and Passage 
All cells were cultured on tissue culture plastic in appropriate media (as indicated in the 
following sections) and maintained at 37oC in a humidified 5% CO2 incubator. Cell viability 
and growth were monitored using an inverted phase contrast microscope (Olympus IX50) 
where live cells appeared phase bright. Adherent cells formed projections and became flattened 
when attached to the growth surface and cells in suspension typically remained rounded and 
symmetrical. All cultures were examined daily by observing the morphology of cells, the colour 
of the medium and the density of cells. 
 
Adherent cells were passaged using an appropriate volume of the proteolytic enzymes TrypLE or 
trypsin (i.e 3–5ml in a 75cm2 flask, enough to cover the cell monolayer). Initially, used media 
was discarded, and cells were washed with PBS, TrypLE or Trypsin was then added and the 
flask was agitated gently to help detachment of cells. Occasionally, the cell monolayers were 
   80 
incubated at 37oC until cells had loosened. Once detachment was complete, PBS was added to 
the cell suspension and the cells were collected by centrifugation at 550g for 5min. The cell 
pellet was re–suspended in appropriate media and re–seeded in new culture flasks for further 
culture. 
 
Non–adherent cells were passaged without trypsinization by centrifugation of the suspension at 
550g for 5min. The cell pellet was re–suspended in appropriate media and cells were re–seeded 
in new culture flasks. Dependent on experimental requirements, the viability of cells was 
assessed using trypan–blue, and cells were counted using a haematocytometer (CAMLAB, 
Cambridge, UK) and finally re–seeded. 
 
2.2.4 Maintenance of Cells by Freezing and Storing 
For long–term storage, cells were cryopreserved in liquid nitrogen. After detachment and 
pelleting, cells were re–suspended in chilled freezing media consisting of 95% FCS+5% DMSO 
(Sigma-Aldrich). Cells were aliquoted into cryovials and placed into a Mr FrostyTM freezing 
container (Wessington Cryogenics, Tyne & Wear, UK), which was transferred to –80oC to 
permit gradual cooling at a rate of 1oC per minute, thus preventing ice crystal formation in cell 
cytoplasm. Once the container had reached –80oC (after 4 hours or more conveniently 
overnight), the vials of cells were immediately placed into liquid nitrogen storage. When 
required, cells were taken out of liquid nitrogen on ice, thawed as quickly as possible by 
washing in PBS and centrifuged in order to remove any cell debris. Cells were counted and 
viability was assessed with trypan–blue exclusion before re–suspension and culture in the 
appropriate media. 
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2.3  ISOLATION AND CULTURE OF PRIMARY ENDOTHELIAL CELLS 
2.3.1 Preparation of Rat tail Collagen 
Collagen for cell attachment was prepared in house from rat tails. Frozen rat–tails were thawed 
in sterile PBS and the outer skin was cut using pliers. After twisting the tail a string of collagen 
became visible, which was carefully collected and dropped into sterile PBS. Finally, the 
accumulated collagen from the whole tail was collected using forceps, drained of excess of PBS 
and weighed. The collagen was transferred into 70% ethanol for about 10min and then into an 
appropriate volume of 4% acetic acid (1gr of wet collagen to 100ml of 4% acetic acid). The 
collagen was covered with foil and left at 4oC to stir for 2days. Finally, the solution was 
transferred to bottles and centrifuged at 4oC for 30min at 550g. The collagen solution was 
sieved through fine mesh, aliquoted and stored at 4oC. Occasionally, the rat–tail collagen that 
was used was purchased from Sigma. 
 
2.3.2 Endothelial Cell Media 
Both HSEC (Hepatic Sinusoidal Endothelial Cells) and HUVEC (Human Umbilical Vein 
Endothelial Cells) were cultured in complete human endothelial basal growth medium (Gibgo, 
Invitrogen, UK) supplemented with 60µg/ml benzylpenicillin, 100µg/ml streptomycin, 2mM 
L–glutamine plus 10% heat inactivated human AB serum. Furthermore, HSEC media was 
supplemented with 10ng/ml hepatocyte growth factor (HGF) and 10ng/ml vascular endothelial 
growth factor (VEGF) (both from PeproTech, UK). The HUVEC media contained in addition 
10ng/ml epidermal growth factor (EGF) (R & D Systems, UK) and 10µg/ml hydrocortisone 
(Sigma-Aldrich, UK).  
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2.3.3 Isolation of Human Hepatic Sinusoidal Endothelial Cells 
HSEC were isolated from human liver tissue according to a previously described protocol (Lalor 
et al., 2002a). Briefly, approximately 150gr of tissue was finely chopped and enzymatically 
digested at 37oC using 0.2% collagenase Type 1A (Sigma-Aldrich, UK) for 20–40 min, 
depending on the texture of the liver. Once the liver was digested it was filtered in an excess of 
sterile PBS. The cell suspension was further washed in PBS (approximately x4) and purified via 
density gradient centrifugation over 33/77% PercollTM (Amersham Bioscience, UK) at 550g for 
30min. The layer of cells at the interface between the different solutions of PercollTM was 
collected and washed in PBS. HSEC were extracted from the mixed non–parenchymal 
population firstly via negative magnetic selection to remove biliary epithelial cells and secondly 
via positive selection for endothelial cells. Specifically, the cell suspension was incubated 
initially with mouse anti–HEA–125 antibody (Progen Biotechnic, Germany; 50µg/ml), for 
30min at 37oC. After that, cells were incubated with a secondary antibody conjugated to 
magnetic beads (10µl per prep of sheep anti–mouse Dynabeads®, Dynal, Wirral, UK) for 
30min at 4oC. HEA–125 labeled cells were removed by magnetic selection and the remaining 
cells were incubated with anti–CD31 antibody conjugated to dynabeads (Dynal, Liverpool, UK; 
10µg/ml) for 30min at 4oC. CD31 positive cells were extracted from the heterogeneous cell 
mixture by magnetic selection, re–suspended in complete HSEC media and cultured in rat–tail 
collagen coated flasks. 
 
2.3.4 Isolation of Human Umbilical Vein Endothelial Cells 
HUVEC were isolated from approximately 15cm of fresh umbilical cord according to an 
isolation procedure previously published (Jaffe et al., 1973). Firstly, the cords were rinsed 
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thoroughly with 70% (v/v) IMS to avoid any contamination and one end of vein was 
cannulated. PBS was flushed through the vein until the solution ran clear. Once washed, the 
other end of the cord was cannulated and sealed to permit infusion of 1mg/ml solution of 
collagenase Type–1A (Sigma-Aldrich, UK). Both ends of vein were clamped and the cord was 
incubated for 15 min at 37oC. Cells were then collected by gently massaging the cord, flushing 
through the vein with PBS and centrifugation for 5min at 550g. Pelleted cells were re–
suspended in complete HUVEC media and cultured in 1% gelatin coated flasks.  
 
2.4  CULTURE OF CELL LINES 
Chinese Hamster Ovary (CHO) cells, transfected with a full–length (FL)–MAdCAM-1 construct 
were used as a positive control in almost all experimental procedures. Parental CHO cells 
containing no MAdCAM-1 construct were used as negative controls. CHO cells were grown in 
nutrient F-12 Ham (Sigma-Aldrich, UK) medium supplemented with 20mM HEPES and 10% 
(v/v) FCS. For reselection of cells that expressed MAdCAM-1, hygromycin B (350µg/ml; Sigma) 
was added to their media. The JY cell line, a b–lymphoblastoid cell line which expresses α4β7 
integrin, was also used. JY cells were grown in RPMI (Invitrogen) containing L–glutamine and 
supplemented with 10% (v/v) FCS. All cell lines were available in house. Cells were maintained 
in a humidified atmosphere with 5% CO2 at 37
oC. 
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2.5  WESTERN BLOTTING 
2.5.1 Total Protein Lysates 
2.5.1.1 Preparation of total protein lysates 
Confluent cultures of HSEC and HUVEC, stimulated for 2 hours with TNFα (20ng/ml; 
Peprotech, UK) and methylamine (50 µM; Sigma-Aldrich) alone or in combination, were 
washed in ice cold PBS and harvested in RIPA buffer (table 2.7) or CelLyticTM MT lysis buffer 
(Sigma), containing protease inhibitor cocktail (Sigma-Aldrich). The cell lysates were incubated 
at 4oC under constant agitation for about 2 hours and then stored at –20oC in small aliquots 
for further use. Protein lysates were also obtained from pelleted CHO and JY cells using the 
above method. 
 
Human liver tissue blocks and tissue blocks (liver, kidney, spleen, mesenteric lymph nodes and 
Peyer’s patches) harvested from mice, were homogenised in lysis buffer and maintained under 
continuous stirring at 4oC overnight. The following day, the mixture of protein lysate and tissue 
was centrifuged at 700g for 20min at 4oC, and the supernatant was aspirated and placed in a 
clean tube. Protein concentration was measured (see section 2.5.1.3) and aliquots were 
prepared and stored at –20oC. 
 
2.5.1.2 Extraction of subcellular fractions from adherent cells 
In order to determine the exact location of MAdCAM-1 protein in hepatic sinusoidal 
endothelial cells, cytosolic, membrane, nuclear and cytoskeletal fractions were prepared. Buffers 
for cytosolic (buffer I), membrane (buffer II), nuclear (buffer III) and cytoskeletal (buffer IV) 
fragments were prepared (see tables 2.1–2.5), according to the ProteoExtract® Subcellular 
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Proteome Extraction Kit. HSEC were stimulated as previously and after the 2 hour incubation 
period, they were washed by carefully overlaying the cell monolayers with 2ml ice cold PBS. The 
cells were gently agitated for 5min at 4oC and the washing step was repeated until all 
contaminating media components were removed.  
 
To isolate cytosolic protein fragments, 1ml of extraction buffer I and protease inhibitor cocktail 
(Sigma-Aldrich, used at 1:50 dilution) were mixed and added to the flask without disturbing the 
endothelial monolayer and ensuring all cells were covered.  Cells were incubated for 10min at 
4oC under gentle agitation. The supernatant was transferred into properly labelled sample tubes 
and kept on ice. Then, 1ml of ice cold extraction buffer II was mixed with protease inhibitor 
cocktail and immediately added to the flask. Cells were incubated at 4oC for 30min under 
gentle agitation. Supernatant containing the membrane bound fragments was then removed, 
transferred into sample tubes and kept on ice. Next, 500µl of ice–cold extraction buffer III with 
protease inhibitor cocktail and DNAase (Sigma-Aldrich) were mixed and immediately added 
until all cells were covered with buffer and incubated with gentle stirring for 10 min at 4oC. 
The supernatant containing the nuclear fragments was removed, collected and stored on ice. 
Finally, 500µl of extraction buffer IV and protease inhibitor cocktail were mixed, and added to 
the flask to cover all the cells. Remaining cell structures were detached upon treatment with 
buffer IV. After complete solubilisation of the residual materials, the extract containing the 
cytoskeletal structures was removed, placed in sample tubes and stored on ice. All samples were 
stored at –20oC for further analysis by western blotting. 
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REAGENTS REQUIRED MOLECULAR WEIGHT (FW) SOURCE 
PIPES 302.37 Sigma-Aldrich 
Na2EDTA
.2H2O 372.2 Sigma-Aldrich 
Sucrose 342.3 Sigma 
NaCl 58.44 Sigma 
MgCl2 anhydrous 95.21 Sigma 
β-mercaptoethanol 78.13 Sigma 
Trisma base 121.14 Sigma 
Trisma-HCl 157.6 Sigma 
NP-40 (Igepal CA-630) - Sigma-Aldrich 
Triton X-100 - Sigma-Aldrich 
Sodium deoxycholate 414.55 Sigma-Aldrich 
Tween20 - Sigma 
Table 2.1 Source and molecular weight of all reagents required for preparation of extraction 
buffers I – IV 
 
EXTRACTION BUFFER I- CYTOSOLIC FRAGMENTS- PH 6.8 
REAGENTS FINAL CONCENTRATION 
PIPES 10mM 
EDTA 5mM 
Sucrose 300mM 
NaCl 100mM 
MgCl2 3mM 
NP-40 0.01% (v/v) 
Table 2.2 Reagents and their final concentration required for preparation of extraction 
buffer I 
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EXTRACTION BUFFER II- MEMBRANE BOUND FRAGMENTS- PH 7.4 
REAGENTS FINAL CONCENTRATION 
PIPES 10mM 
EDTA 3mM 
Sucrose 300mM 
NaCl 100mM 
MgCl2 3mM 
Triton X-100 0.5% (v/v) 
Table 2.3 Reagents and their final concentration required for preparation of extraction 
buffer II 
 
 
Table 2.4 Reagents and their final concentration required for preparation of extraction 
buffer III 
 
EXTRACTION BUFFER IV- CYTOSKELETAL FRAGMENTS 
REAGENTS FINAL CONCENTRATION 
SDS 0.3% (w/v) 
β-mercaptoethanol 200mM 
Trisma-HCl 28mM 
Trisma base 22mM 
Table 2.5 Reagents and their final concentration required for preparation of extraction 
buffer IV 
EXTRACTION BUFFER III- NUCLEAR FRAGMENTS- PH 7.4 
REAGENTS FINAL CONCENTRATION 
PIPES 10mM 
Sodium deoxycholate 0.5% (w/v) 
MgCl2 1mM 
Tween20 1% (v/v) 
NaCl 10mM 
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2.5.1.3 Protein concentration measurement 
A Bio-Rad DC Protein Assay was performed according to manufacturer’s instructions in order 
to determine the protein concentration of all samples. Dilutions of bovine serum albumin 
(BSA; Sigma) were used as protein standards. 
 
2.5.2 SDS Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were separated by electrophoresis on a 10% or 12% acrylamide gels using the 
BioRad Mini Trans Blot Cell System. Initially, glass plates were assembled, resolving and 
stacking gels were prepared (see tables 2.7-2.8), poured into the glass space and left to set. 
Solubilised protein samples (20–100µg/lane) were diluted in 5x laemli buffer, with or without 
β-mercaptoethanol and boiled either at 100oC for 10min or at 37oC for 20min dependent on 
the antibody used (see table 2.9) and its epitope recognition characteristics. Protein samples 
were centrifuged and set aside to cool before loading. In the meantime, the gel apparatus was 
assembled and 1x electrophoresis buffer was then poured onto the tank ensuring that the 
electrodes were fully covered. 30µl of each protein sample was slowly loaded into the stacking 
gel. Pre–stained rainbow molecular weight markers (Amersham, GE Healthcare) were used as 
size markers. Electrophoresis was performed at 200V for 30min until the dye front reached the 
bottom of the gel. 
 
2.5.3 Western Blot Transfer 
Resolved proteins were transferred onto hybond–ECL nitrocellulose membrane (Amersham 
Biosciences) or occasionally onto PVDF membrane (Millipore, U.S.A) using BioRad Mini-
protein system. PVDF membranes were soaked in methanol for 5min before immersion in 
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transfer buffer whereas nitrocellulose membranes were directly immersed into transfer buffer in 
order to facilitate binding of proteins. Soaked membranes were placed on top of the gel, 
sandwiched between filter papers and sponges; which were also pre–immersed in transfer buffer 
and the assembly was placed into the transfer buffer apparatus which in turn was placed in the 
transfer tank containing an ice pack. Transfer buffer was added into the tank and a current of 
100V was applied for 1hour. Efficient transfer was evident from the appearance of rainbow 
markers on the membrane. Moreover, after transfer the membrane was stained with Ponceau S 
solution [0.1% Ponceau S (w/v) in 5% acetic acid (v/v); Sigma] for 5min followed by rinsing 
with water to visualise successfully transferred protein. 
 
2.5.4 Western Blot Development 
After transfer, membranes were blocked for at least 2 hours in 0.1% PBS–Tween20 containing 
10% (w/v) non–fat dry milk with continuous agitation. The blocking buffer was removed and 
membranes were probed overnight at 4oC with primary antibodies (Table 2.9). After several 
washes in PBS–Tween20 (x3 for 30min), membranes were incubated with peroxidase–
conjugated secondary antibodies for 1 hour at room temperature. After several washes with 
PBS–Tween20, the blots were incubated with enhanced chemiluminescence reagents (ECL and 
ECLplus from Amersham Pharmacia, Biotech, UK and Immobilon Western HRP Substrate 
from Millipore Corporation, used in MediCity, Turku). Enhanced chemiluminescence 
detection film (Amersham Biosciences) was exposed to the membrane and developed using a 
Kodak X–Omat 1000 processor (Birmingham, UK) or a Curix 60, AGFA processor (Turku, 
Finland). After visualisation, bound antibodies were stripped by incubation in stripping buffer 
(Table 2.7) for 45min at 50oC and several washes in dH2O. The membranes were then blocked 
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with 10% (w/v) non–fat milk and re–probed with anti–actin or anti β–actin. The bands were 
detected with ECL and the films were exposed as previously.  
 
MAdCAM-1 and β-actin staining density was measured by staining the 120kDa and 40kDa 
bands respectively, and performing densitometry using ImageJ or Quantity One programs. All 
experiments were performed at least in triplicate. Protein lysates generated from CHO cells 
transfected with FL–MAdCAM-1 were used as a positive control. 
 
Table 2.6 Molecular weight and source of reagents required for western blot buffers 
 
 
 
 
 
 
 
 
 
 
REAGENTS MOLECULAR WEIGHT (FW) SOURCE 
Trisma base 121.14 Sigma 
NaCl 58.44 Sigma 
Glycine 75.07 Sigma 
Sodium dodecyl sulfate (SDS) 288.38 Sigma 
NP-40 (Igepal CA-630) - Sigma-Aldrich 
Sodium deoxycholate 414.55 Sigma-Aldrich 
Tween20 - Sigma 
Methanol - Fisher Scientific 
β-mercaptoethanol 78.13 Sigma 
Non-fat milk - Marvel 
   91 
 
BUFFERS CONSTITUENTS 
RIPA Buffer 50mM Trisma base, 150mM NaCl, 1% (v/v) NP-40, 0.25% (w/v) 
sodium deoxycholate, 1mM EDTA, 0.1% SDS 
10x Electrophoresis 
Buffer 
Per 1L: 30.3gr Trisma base, 144gr glycine, 10gr SDS 
Transfer Buffer Per 2L: 28.8gr glycine, 6.0gr Trisma base, 400ml MeOH, 1gr SDS 
Resolving Gel Buffer 1.5M Trisma base pH 8.8 (adjust pH with HCl) 
Stacking Gel Buffer 1.0M Trisma base pH6.8 (adjust pH with HCl) 
Stripping Buffer Per 100ml: 20.0ml 10% SDS, 12.5ml 0.5M Trisma base pH 6.8, 
67.5ml dH2O, 0.8 β-mercaptoethanol 
Blocking Buffer PBS + 0.1% (v/v) Tween20, 10% (w/v) non-fat milk (25ml per 
membrane) 
Table 2.7 Buffers used in SDS-PAGE 
 
 STACKING GEL 
(5%) 
RESOLVING GEL 
(10%) 
RESOLVING GEL 
(12%) 
ddH2O 6.8ml 4.0ml 3.3ml 
30% Acrylamide mix (BioRad) 1.7ml 3.3ml 4.0ml 
Stacking Gel Buffer 1.25ml - - 
Resolving Gel Buffer - 2.5ml 2.5ml 
10% (w/v) SDS 0.1ml 0.1ml 0.1ml 
10% (w/v) ammonium 
persulfate (APS) (Sigma-
Aldrich) * 
0.1ml 0.1ml 0.1ml 
N,N,N’,N’-
tetramethylethylenediamine 
(TEMED) (Sigma-Aldrich)* 
40µl 40µl 40µl 
 
Table 2.8 Components of SDS-PAGE gels. *APS and TEMED were added just prior to pouring of 
gels into the glass spaces, as the oxygen free radicals released from the reaction between APS 
and the tertiary amine TEMED are responsible for the polymerisation of bis-acrylamide. 
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ANTIBODIES CLONE FINAL 
CONCENTRATION 
SOURCE 
*MAdCAM-11 CA102.2C1 4µg/ml Serotec 
*MAdCAM-12 MECA367 10µg/ml Kind gift from E.Butcher, 
Stanford University 
*MAdCAM-1 (H-116) 1 
(polyclonal) 
sc-28645 1µg/ml Santa Cruz Biotechnology 
*MAdCAM-11 P1 4µg/ml Pfizer 
**VAP-11 TK8-14 5µg/ml MediCity, Turku 
**Anti- chicken T cell 
protein (negative 
control) 
FU7-3G6 5µg/ml Microbiol V. Vainio, 
MediCity, Turku 
*Anti-actin1,2 - 1µg/ml Sigma-Aldrich 
*β-actin1 Clone AC-15 1µg/ml Sigma-Aldrich 
Anti-mouse HRP - 1:2000 Dako 
Anti-human HRP - 1:2000 Sigma-Aldrich 
Anti-rabbit HRP - 1:2000 Dako Cytomation 
Anti-rat HRP - 1:2000 Dako Cytomation 
 
Table 2.9 Concentrations, clone names and sources of all antibodies used for western 
blotting and immunoprecipitation. 1Monoclonal anti-human antibodies, 2monoclonal 
anti-mouse antibodies. *Antibodies recognising reduced and denatured protein. 
**Antibodies recognising protein in its native and non-denatured form. 
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2.6  IMMUNOPRECIPITATION 
2.6.1 Immunoprecipitation using Protein G Sepharose Beads 
The presence of MAdCAM-1 in human liver and umbilical vein endothelial cells was verified by 
immunoprecipitation. Protein lysates prepared from treated HSEC and HUVEC, were 
incubated with anti–MAdCAM-1 Ab (Clone CA102.2C1; 10µg/ml) prior to addition of 
protein G beads (Sigma-Aldrich). Any MAdCAM-1 protein present bound to the antibody, was 
then immobilised on the protein G sepharose beads. Following initial capture of the protein, 
the solid support was washed several times with RIPA buffer for removal of any non–specific 
proteins. Finally the washed precipitated protein was eluted and analysed by western blotting 
using a different antibody specific for MAdCAM-1 (humanised anti–human P1; 4µg/ml from 
Pfizer, UK). 
 
2.6.2 Immunoprecipitation using DYNABEAD-Protein G from Culture Supernatants 
HSEC were treated as previously described with TNFα and methylamine alone or in 
combination. After 2 hours stimulation the supernatant–media was removed and collected in 
15ml tubes in order to test for the presence of soluble MAdCAM-1 by immunoprecipitation 
with Dynabead–protein G (Invitrogen, Dynal, UK). Firstly, the dynabeads were completely re–
suspended by constant rotation on a roller for 5min and then 50µl of beads per reaction were 
transferred to separate 1.5 ml eppendorf tubes for removal of diluent using a magnet. Then 
10µg of MAdCAM-1 polyclonal antibody H–116 was diluted in 200µl PBS plus 0.02% 
Tween20 and mixed with the cleaned beads. The mixture was incubated with rotation for 
10min at room temperature and then the beads–Ab complex was washed in PBS plus 0.02% 
Tween20 and finally re–suspended in 50µl of PBS. Next, the cleaned beads–Ab complex was 
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pipetted into the tubes containing the culture supernatant and incubated with constant 
rotation for 30min at room temperature to allow the antigen to bind to the complex. The 
complex of dynabeads–Ab –Ag was washed in PBS and re–suspended in 50µl 5x laemli buffer. 
The mixture was either stored at –20oC for further western blot analysis or heated for 10min at 
70oC, prior to removal of supernatant with the aid of a magnet to collect the Ab–Ag complex. 
Samples were loaded in SDS–PAGE gels for detection of sMAdCAM-1 using the monoclonal 
mouse anti–human antibody (CA102.2C1; 4µg/ml). 
 
BUFFERS  
REQUIRED 
Phosphate Buffered Saline (PBS) 
Phosphate Buffered Saline (PBS) + 0.02 (v/v) Tween20 
Table 2.10 Buffers required for immunoprecipitation using Dynabead-Protein G 
 
2.7  POLYMERASE CHAIN REACTION (PCR) 
2.7.1 RNA Extraction 
2.7.1.1 RNA Extraction from human endothelial cells 
Total RNA isolated from HSEC and HUVEC previously stimulated with TNFα (20ng/ml) or 
methylamine (50µM) alone or in combination for 2 hours, was extracted using the RNEasy 
mini kit (Qiagen, UK), according to manufacturer’s instructions. DNAase treatment with 
RNAase free DNAase (Qiagen) was performed as part of the protocol instructions. Total RNA 
was also extracted from HSEC after transfection with hVAP-1 adenoviral constructs (see 
paragraph 2.14.2) and stimulation with TNFα or MA alone or in combination for 2 hours. 
 
Formaldehyde, ammonia and hydrogen peroxide are produced during VAP-1 catalysed 
deamination of methylamine. In order to study whether these end products have a role in 
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induction of MAdCAM-1, non–transfected HSEC, were exposed to 1µM and 10µM hydrogen 
peroxide (30% H2O2; VWR PRoLABO BDH), ammonia (ammonia solution 32% extra pure; 
Merck) and formaldehyde (formaldehyde solution 37%; JT Baker) for 4 hours. Cells were also 
subjected to repeated dosing with H2O2 (8x 10µM at 30min intervals) and to a combination of 
all three end products (single dose). On occasion one set of HSEC was exposed to sVAP-1 
(500ng/ml; Biotie Therapies, Turku, Finland) (enzymatically active) and its substrate 
methylamine at 1µM and 10µM. After the stimulation period, cells were processed for total 
RNA extraction as above. 
 
2.7.1.2 RNA extraction from human liver tissues 
Tissue blocks from normal liver (NL), and from patients with alcoholic liver disease (ALD), 
primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) or primary sclerosis cholangitis 
(PSC) were submerged into RNA later (Qiagen) for RNA preservation. About 30mg of tissue 
was used for RNA extraction using the RNEasy mini kit, according to manufacturer’s 
instructions. A DNAase treatment step was included as previously. 
 
2.7.1.3 RNA extraction from mouse tissues 
Total RNA was isolated from the liver, Peyer’s patches (PPs), mesenteric lymph nodes (MLN), 
kidney and spleen of wild-type (WT) untreated mice, and from wild-type mice, VAP-1 deficient 
mice (VAP-1_KO), VAP-1 deficient mice that contained enzymatically active hVAP-1 as a 
transgene (VAP-1_EA) and VAP-1 deficient mice that contained enzymatic inactive hVAP-1 as a 
transgene (VAP-1_EI) (the background of these mice is described in paragraph 2.13) treated for 
14 days with methylamine. All RNA was extracted as previously using the RNAeasy mini kit 
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from Qiagen. Paraffin embedded liver tissue blocks from VAP-1_KO mice and VAP-1_KOTG 
mice expressing hVAP-1 as a transgene, which had been treated with Concavalin A (10mg/kg, 
i.v, 4 hours) to induce hepatitis, were also used for RNA isolation using the RNEasy FFPE Kit 
(Qiagen) according to manufacturer’s instructions. 
 
For all the above samples, concentration of eluted RNA was measured using the NanoDrop 
Spectrophotometer (Thermo Fisher Scientific) and RNA was stored at –80oC. Moreover, the 
260/280 nm absorbance ratio was calculated in order to determine sample purity with a value 
of 2 being indicative of pure preps. 
 
2.7.2 cDNA Synthesis 
In all cases 50µg of the extracted total RNA were transcribed into cDNA using the iScript 
cDNA synthesis kit (BioRad, Hercules, CA). The concentration of cDNA was measured using 
the NanoDrop Spectrophotometer. An OD260/OD280 ratio value of 1.8 was representative of 
a pure DNA prep. 
 
2.7.3 Conventional PCR 
The presence of MAdCAM-1 mRNA in HSEC and HUVEC was confirmed by conventional 
PCR. Reverse transcription was carried out for both human MAdCAM-1 and β–actin, which 
was used as endogenous control. PCR encoded products of 357bp and 220bp for MAdCAM-1 
and β-actin respectively, were visualised on a 1.5% (w/v) agarose gel (diluted in 0.5x TBE) 
stained with ethidium bromide. The TrackItTM 50bp DNA ladder (Invitrogen) was used as 
amplicon length marker. The primers for hMAdCAM-1 and β–actin, the reagents used and 
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their final concentrations as well as the thermal profile of each reaction are shown in the 
following tables. 
 
PRIMERS MADCAM-1 
Forward 5’- CCC CTG TGA AAG CAA AAT AGC -3’ 
Reverse 5’- AGG TTT ATT TGC CAA AGC CTC -3’ 
                           Amplicon Length: 357bp 
PRIMERS Β-ACTIN 
Forward 5’- CAT CAC CAT TGG CAA TGA GC -3’ 
Reverse 5’- CGA TCC ACA CGG AGT ACT TG -3’ 
                        Amplicon Length: 220bp 
Table 2.11 Primer sequences and amplicon lengths of hMAdCAM-1 and human β-actin 
amplified products 
 
 
REAGENTS FINAL CONCENTRATION SOURCE 
5x Green GoTaq® 
Flexi Buffer 
1x Promega, Southampton, UK 
MgCl2 1mM Promega, Southampton, UK 
dNTPs 0.2mM (total) Roche 
GoTaq® DNA 
Polymerase 
1.25U Promega, Southampton, UK 
Primers 0.25pmole/µl Alta Bioscience 
cDNA 10µg/ml Human primary endothelial cells 
Table 2.12 Components of a conventional PCR reaction mix 
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MADCAM-1 
NUMBER OF CYCLES: 35 TEMPERATURE (oC) TIME (min) 
 95 02:00 
Denaturation 95 01:00 
Annealing 60 01:00 
Extension 72 01:00 
 72 05:00 
Β -ACTIN 
NUMBER OF CYCLES: 29 TEMPERATURE (oC) TIME (sec) 
 95 05:00 
Denaturation 94 00:30 
Annealing 55 00:45 
Extension 72 00:45 
 72 05:00 
Table 2.13 Thermal profile for human MAdCAM-1 and β–actin gene amplification 
 
 
10X TBE ELECTROPHORESIS BUFFER 
REAGENTS MOLECULAR WEIGHT 
(FW) 
FINAL 
CONCENTRATION 
SOURCE 
Trisma Base 121.14 0.89M Sigma 
Boric Acid 61.83 0.89M Sigma 
Na2EDTA
.2H2O 442.5 0.5M Sigma-Aldrich 
ddH2O - Fill up to 1L  
Table 2.14 TBE buffer components for electrophoresis of PCR products 
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2.7.4 Quantitative PCR 
For analysis of relative expression of human and murine MAdCAM-1 mRNA Taqman 
Fluorogenic 5’ nuclease assays using gene–specific 5' FAM labelled probes run on an ABI Prism 
7700 sequence detector (at MediCity, Turku, Finland) as well as on an ABI Prism 7900 
sequence detector (at University of Birmingham, UK), were used. Human and murine GAPDH 
were used as internal control to which the threshold cycle (Ct) values of the target gene were 
normalised. Differential expression levels were calculated according to the 2-ΔΔCt method. 
 
 PRIMER/PROBE ASSAY ID SOURCE 
hMAdCAM-1 Hs00175533_ml 
hGAPDH Hs99999905_ml 
mMAdCAM-1 Mm00522086_g1 
mGAPDH Mm99999915_g1 
EXPENDABLES 
Taqman® Universal PCR Master Mix 
Taqman® 2x Master Mix 
MicroAmp® Optical 96-well reaction plate-0.1ml 
MicroAmp® Optical adhesive film 
Applied Biosystems 
Table 2.15 Primers and Taqman probe assay mixes for each gene as well as expendables used 
in quantitative PCR 
 
REAGENTS FINAL CONCENTRATION 
ABI Taqman 2x Master Mix 1x 
20x Assay mix 0.5x 
cDNA 100-200µg/ml 
RNAase free water Up to 10µl 
Table 2.16 Components of a quantitative PCR reaction mix 
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2.8  IMMUNOHISTOCHEMICAL STAINING 
2.8.1 Preparation of Tissue Sections 
For the examination of adhesion molecule expression in human liver and in murine liver, 
Peyer’s patches, mesenteric lymph nodes and spleen, tissue sections for immunohistochemical 
analysis were produced in house. 1–2cm3 blocks of tissue were snap–frozen in liquid nitrogen 
and stored at –80oC until required. Tissue sections 5–7µm thick were cut using a BRIGHT 
(model OTF) cryostat, mounted on glass microscope slides (BDH) and fixed in absolute acetone 
(Fisher Scientific, Loughborough, UK), before storage at –20oC. Before staining, tissue sections 
were warmed to room temperature, re–fixed in absolute acetone for 5min and a line around the 
tissue section was drawn, creating as such a small well for retaining antibody solutions, using a 
wax pen (The Binding Site, Birmingham, UK). Immunohistochemical staining was carried out 
at room temperature in a humidified chamber to prevent evaporation of antibody solutions. 
Details of the antibodies and buffers used are shown in tables 2.17 – 2.18. 
 
2.8.2 AEC–based Immunohistochemical Staining 
Expression of adhesion molecules in human liver tissues was examined by 
immunohistochemical staining using the AEC substrate kit for peroxidase (Vector Laboratories, 
Inc, Burlingame, CA). Sections were primarily incubated with 0.3% H2O2 (diluted in methanol) 
for 10 min in order to block endogenous peroxidase activity and then washed in TBS pH 7.4 
prior to incubation with 2% horse serum for 20min. Then the tissue sections were incubated 
with primary antibodies and isotype–matched control antibodies for 30–40 min, washed x2 in 
TBS pH 7.4 and incubated with secondary antibody (ImmPress Kit) for 30 min. Two washing 
steps in TBS pH 7.4 were followed, and in the meantime the AEC peroxidase substrate 
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solution was prepared and applied according to manufacturer’s instructions. Finally, sections 
were counterstained with Haematoxylin (Sigma) for 3 min, rinsed with distilled H2O, mounted 
with glass coverslips (SurgiPath, UK) using aqueous Immunomount solution (Thermoscientific, 
UK) and examined for positive staining using an upright light microscope. Images were 
captured using a digital camera and image analysis software (Axionvision, Zeiss, Germany). 
 
BUFFERS CONSTITUENTS 
Tris Buffered Saline (TBS) pH 7.4 0.607% (w/v) Trisma Base, 0.81% (w/v) NaCl in 
dH2O, pH 7.4 with HCl (all from Sigma-Aldrich) 
1x Phosphatase Buffer Saline (PBS) 
pH 7.4 
137mM NaCl, 2.7mM KCl, 10mM phosphate buffer 
pH 7.4 - equals with 1 tablet (Oxoid, UK) per 100ml 
Table 2.17 Buffers used in immunohistochemical staining 
 
MONOCLONAL ANTIBODY REFERENCE 
No. (CLONE) 
CONCENTRATION SOURCE 
IgG11 11711 20µg/ml R & D Systems 
CD311 9G11 20µg/ml R & D Systems 
MAdCAM-1 (MCA2320) 1 314G8 20µg/ml Serotec 
ImmPress secondary Ab - - Vector Laboratories 
MAdCAM-12 MECA367 100µg/ml Kind gift from E.Butcher, 
Stanford, CA 
VAP-11 JG2.10 20µg/ml Kind gift from E.Butcher, 
Stanford, CA 
HERMES-11 9B5 20µg/ml Kind gift from E.Butcher, 
Stanford, CA 
Anti-rat IgG FITC - 10µg/ml Sigma 
Alexa anti-fluorescein 488 
conjugate 
- 10µg/ml Invitrogen 
 
Table 2.18 Concentration and source of the primary and secondary antibodies used for 
immunohistochemical staining. Antibodies were used for staining of frozen human 
liver sections and were diluted in TBS pH 7.4 to the appropriate concentration. 1 Mouse 
anti-human monoclonal antibodies, 2 rat anti-mouse monoclonal antibodies.  
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2.8.3 DAB–based Immunohistochemical Staining 
The specificity of the MAdCAM-1 antibody that was used for detection in human liver tissues 
was tested in lymph node sections where MAdCAM-1 is abundantly expressed. The initial steps 
of the procedure were the same as described in the previous section (2.8.2). During the washing 
steps after incubation with secondary Ab, the 3,3’-diaminobenzidine tetrahydrochloride (DAB) 
chromogenic substrate solution (ImmPactTM DAB Diluent, solution 2, and ImmPACTTM DAB 
chromogen solution 1, Vector Laboratories) was prepared according to manufacturer’s 
instructions. Sections were incubated with the DAB solution for 3min, washed in TBS pH 7.4 
x2 and counterstained with haematoxylin for 3min. Following this, sections were washed under 
running tap water with a final wash with ddH2O, air dried, dehydrated in ascending ethanol 
series (70% for 2min, 96% for 2min, absolute ethanol for 2min), cleared in xylene (Surgipath) 
for 2min and finally mounted in DPX (depex mounting media, Surgipath) under a coverslip. 
Before viewing slides were left to dry thoroughly. 
 
2.8.4 Immunofluorescent Staining 
MAdCAM-1 expression in mouse liver, Peyer’s patches, mesenteric lymph nodes and spleen was 
demonstrated by immunofluorescent staining. Frozen tissue sections were incubated with anti–
mouse MAdCAM-1 (MECA 367), VAP-1 (JG2-10) and isotype–matched negative control (9B5) 
antibodies for 30–40min. Then sections were washed twice in PBS solution and then 
appropriate FITC–conjugated second stage anti–rat FITC antibodies diluted in 5% (v/v) mouse 
serum were used. For enhanced signal generation, Alexa anti fluorescein/Oregon (green goat 
IgG fraction, Alexa Fluor 488 conjugate, Invitrogen) was also used (Table 2.18). At the end, 
sections were washed in PBS and mounted using VECTASHIELD mounting media (Vector 
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Laboratories) to preserve fluorescence. Images were obtained using an Olympus Bx60 
microscope (Olympus Optical, Hamburg, Germany) equipped with UPlanFI 20x /0.50 numeric 
aperture (NA) Ph1. Images were acquired using a ColorView 12 camera (Olympus Soft Imaging 
Solutions, Munster, Germany).  
 
2.9  FLOW CYTOMETRY 
2.9.1 Single Colour Flow Cytometry 
CHO cells transfected with a FL–MAdCAM-1 construct and the CHO parental cell line that 
did not express MAdCAM-1, were used for validation of antibody specificity and the ability of 
trypsin to cleave membrane bound proteins from the cell surface. CHO cells cultured on 
gelatin coated flasks, were either trypsinised or detached using a non–enzymatic cell 
dissociation solution (Sigma-Aldrich) and pelleted after centrifugation. The pellet was re–
suspended in wash buffer and mouse anti–human MAdCAM-1 Ab conjugated to FITC 
(CA2320F) was applied. Control samples were labelled with isotype–matched control IgG1 Ab 
conjugated to FITC.  
 
For detection of intracellular versus extracellular MAdCAM-1 on adherent HSEC, the non–
enzymatic dissociation solution was used. Initially, HSEC were stimulated as previously with 
TNFα (20ng/ml) or methylamine (50µM) alone or in combination for 2 hours (untreated 
samples were used as control). Cells were then washed in ice cold PBS, scraped very gently in 
the presence of non–enzymatic dissociation solution and centrifuged. The cell pellet was re-
suspended in wash buffer [PBS containing 10% (v/v) FCS] and surface marker staining was 
performed using mouse anti–human MAdCAM-1 conjugated to FITC before fixation and 
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permeabilization of cells with fixation medium (Reagent A) and permeabilization medium 
(Reagent B) respectively (GAS-003, Caltag Laboratories). Surface marker staining was also 
carried out for CD31, as a control. Intracellular staining was performed after fixation and 
permeabilisation with the same Reagents A and B and the same MAdCAM-1 Ab. Control 
samples were labeled with matched isotype control IgG1 conjugated to FITC. All samples were 
run on a Cyan flow cytometer and results were analysed using Summit Software (Dako 
Cytomation). 
 
Occasionally, Brefeldin A from penicillium brefeldianum, (≥99% Sigma) was used in order to 
disrupt the structure and function of the Golgi apparatus to prevent the transfer of new 
synthesised proteins from the cytoplasm to membrane. Cells were incubated for 2 hours in 
complete media supplemented with Brefeldin A (BFA at 1µg/ml) and then stimulated with 
TNFα or methylamine as previously. Control samples did not receive BFA treatment. Surface 
and internal labelling was performed as previously referred.  
 
Single color flow cytometry was also used to detect VAP-1 in adherent HSEC that had been 
transfected with hVAP-1 adenoviral constructs. In this case cells were detached with enzymatic 
dissociation solution (TrypLE or Trypsin). Staining was performed with mouse anti–human 
VAP-1 antibody (TK8–14 FITC conjugated), and control samples were labeled with matched 
isotype control (3G6 and IgG1 FITC) conjugated antibodies. 
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ANTIBODY 
(FITC conjugated) 
CLONE CONCENTRATION SOURCE 
MAdCAM-1 314G8 (CA2320F) 10µg/ml Serotec 
IgG1 DAK-G01 10µg/ml Dako 
CD31 WM59 10µg/ml BD Pharmingen 
VAP-1 TK8-14 10µg/ml MediCity, Turku 
Anti- chicken T cell 
protein (negative 
control) 
FU7-3G6 10µg/ml Microbiol V. Vainio, 
MediCity, Turku 
Table 2.19 Clone name, source and concentration of antibodies used for single colour flow 
cytometry 
 
 
2.10  FLOW BASED ADHESION ASSAY 
A flow based adhesion system was developed in order to assess the functional role of 
MAdCAM-1 under conditions comparable to those seen in vivo. 
 
2.10.1 Microslide Preparation 
Glass microslides obtained from Gamlab Ltd, Cambridge, UK, are 5cm long capillary tubes that 
have a rectangular cross section of 0.3 x 0.03cm (Figure 2.1A). They have good optical qualities 
and support laminar flow of perfused fluids. Before use in flow based adhesion assays, 
microslides were treated with 3–aminopropyltriethoxysilane (APES; Sigma-Aldrich), to aid cell 
attachment. Here, microslides were washed in 70% v/v nitric acid (Sigma-Aldrich) overnight 
and then washed with copious volumes of tap water finishing with a wash in distilled water for 
removing all traces of acid. Microslides were blotted dry, washed thoroughly in several changes 
of anhydrous acetone to remove any residual water and then submerged in APES solution [4% 
(v/v) in anhydrous acetone] for 10–15 min. The slides were then rinsed in 2–3 changes of 
anhydrous acetone with a final wash in distilled water to remove all traces of acetone. Finally, 
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microslides were left to dry overnight in the glass oven at 60oC. Before use, silicone adaptor 
tubing (Portex Ltd, Kent UK) was securely attached to one end of the microslides (Figure 2.1 
B), which were then autoclaved prior to use in cell–based adhesion assays.  
 
 
 
Figure 2.1 The flow based adhesion assay. (A) Glass microslides, 5cm long capillary tubes with a 
rectangular cross section of 0.3 x 0.03cm with good optical qualities were used for supporting laminar 
flow of perfused fluids. Before use, silicone adaptor tubing (B) was attached to one end to aid the uptake 
of fluids and connection to the culture dish. (C) For the flow based adhesion assay to occur the 
microslides with the treated endothelial monolayers were glued onto a glass microscope slide and placed 
on the stage of heated videomicroscope. One end of microslide was connected to a syringe pump and 
the other on an electronic switching valve allowing the flow of cells or wash buffer. Lymphocytes were 
perfused over the microslides at a constant shear stress of 0.05Pa. Video clips were recorded and 
experiments were analysed offline. 
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2.10.2 Preparation of Endothelial Cell Monolayers 
To ensure good adhesion of endothelial cells to the slides, APES coated microslides were pre–
coated with 1% gelatin (when HUVEC were seeded) or rat–tail collagen (when HSEC were 
seeded). Endothelial cells from one confluent T75 were trypsinised and used for seeding 6 
microslides (3x106 cells per microslide). After seeding, ECs were incubated at 37oC in a 
humidified 5% CO2 incubator for approximately 2–3 hours until cells had formed a confluent 
monolayer. Then microslides containing confluent monolayers of endothelial cells were 
connected to a culture dish, which was filled with 40ml of complete media. The culture dish 
was then connected to a pump to permit automatic changing of media in the tubes every two 
hours. The following day, microslides were disconnected from the dish, and the cells were 
treated with TNFα and methylamine for 2 hours prior to the flow based adhesion assay. 
 
Occasionally, HSEC were seeded in microslides as previously described and the cell monolayers 
were infected with a viral construct containing full–length MAdCAM-1 protein (FL–MAd–
GFP–Adenovirus) or empty vector, at a concentration previously determined to induce 
maximal gene expression and minimal cell damage (MOI of 10) (Miles et al., 2008). The 
transfected monolayers were then incubated for 24 hours or 48 hours prior to flow based 
adhesion assays to permit induction of protein expression. Occasionally, purified human 
recombinant chemokines (CCL25, CCL28, CCL21 and CXCL12; at 10µg/ml, PeproTech, 
London, UK) were immobilised on the HSEC monolayer transduced with FL–MAdCAM-1 for 
30min before lymphocyte perfusion, in order to examine the effects of different chemokines on 
lymphocyte adhesion to MAdCAM-1. 
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2.10.3 Preparation of CHO Cell Monolayers in Microslides 
APES coated microslides were pre–coated with fibronectin (50µg/ml; Sigma-Aldrich) for 2 
hours at 37oC. Any excess of fibronectin was removed with PBS and CHO cells transfected with 
FL–MAdCAM-1 were seeded and incubated at 37oC in a humidified 5% CO2 incubator for 2–
3 hours until cells had formed a confluent monolayer. 
 
2.10.4 Preparation of the JY Cell Line 
The JY cell line, which expresses α4β7, was cultured in RPMI (Invitrogen) supplemented with 
10% (v/v) FCS. Cells were maintained in suspension in T75 flasks. Prior to the flow based 
adhesion assay, JY cells were centrifuged at 550g for 5min. The pellet was resuspended in 1ml 
of RPMI+10% (v/v) FCS and a small aliquot was removed for cell number counting and 
viability assessment with trypan–blue exclusion. After counting, the remaining cells were 
resuspended to 106 cells/ml in complete basal endothelial medium (SFM; Gibco, Invitrogen) + 
0.1% (v/v) BSA (Sigma). 
 
2.10.5 Preparation of Peripheral Blood Lymphocytes (PBL) 
PBL were isolated as indicated in section 2.15. Prior to the flow based adhesion assay PBL were 
collected, centrifuged and pelleted, had their viability confirmed, and were resuspended to 106 
cells/ml in SFM + 0.1% (v/v) BSA as in 2.10.4. 
 
2.10.6 The Flow-based Adhesion Assay 
After the treatment of endothelial monolayers with TNFα and/or methylamine for 2 hours, 
microslides were glued to a glass microscope slide and placed on the stage of a thermostatically 
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controlled videomicroscope (Figure 2.1C). The microslides were attached via silicon rubber 
tubing (2mm diameter; Fisher Scientific) to a Harvard pump (Harvard Apparatus, South Natic, 
USA) to permit perfusion of cells or cell–free buffer (wash buffer) through the microslide at a 
constant flow rate of 0.05Pa. An electronic valve (Lee products, UK) allowed rapid alteration 
between wash buffer [SFM plus 0.1% (v/v) BSA or HAMsF10 for CHO cells], and a lymphocyte 
or cell line suspension. JY or PBL suspensions were perfused over the endothelial monolayers at 
a constant shear stress of 0.05Pa for 5min, then wash buffer was perfused over for 1min before 
lymphocyte adhesion was analysed. Adherent lymphocytes that were captured via molecular 
interactions with the functionally expressed MAdCAM1 on the stimulated HSEC, or in 
chemokine stimulated HSEC transduced to express MAdCAM-1, were visualised by phase 
contrast microscopy (x10 magnification), and video clips were recorded of a minimum of 10 
fields along the length of microslide, for offline analysis. Adherent cells were classified as 
rolling, static and activated/migrated cells. Total cell adhesion was determined by counting all 
visible adherent cells in a number of fields of known dimension, then converted to give a value 
of adhesion/mm2 and normalised according to the number of lymphocytes perfused. Static 
adhesion was either expressed as adhesion/mm2/106 cells perfused or percentage of total 
adhesion, as indicated. Migration of cells was also expressed as migration/mm2/106 cells 
perfused or percentage of total migration. 
 
2.10.7 Adhesion Molecule Blockade and Pertussis Toxin Treatment 
In order to confirm that lymphocyte adhesion to stimulated HSEC was MAdCAM-1 specific, 
endothelial monolayers were treated with a function–blocking antibody against MAdCAM-1 
(humanised anti–human P1 Ab, for 30 min at 37oC) prior to perfusion of lymphocytes. 
   110 
Moreover, JY cells were incubated with a blocking antibody directed against α4β7 integrin, 
(ACT-1). An isotype–matched antibody (IgG1) was used as negative control at equivalent 
concentration. In order to determine that the chemokine effects were mediated via specific G–
protein mediated signalling, PBL were incubated with 200ng/ml pertussis toxin (a Ga protein 
inhibitor) (PTX; Sigma-Aldrich), for 30 min at 37oC, prior to perfusion over the MAdCAM-1 
transduced hepatic endothelial cells. 
 
ANTIBODY FINAL CONCENTRATION SOURCE 
P1 10ng/ml Pfizer 
ACT-1 50ng/ml Kind gift from M.Briskin, 
Millenium, USA 
IgG1 10ng/ml Dako 
Table 2.20 Function-blocking antibodies used in flow based adhesion assay 
 
 
2.11  CELL BASED ELISA 
HSEC and HUVEC were grown to confluency on collagen coated 96–well ELISA plates 
(Microtest Tissue Culture Plate, BD Bioscience UK). Before ELISA development, cells were 
stimulated with TNFα (20ng/ml; PeproTeck, UK), rVAP-1 (100ng/ml, gift from Biotie 
Therapies, Turku, Finland) and the amines methylamine and benzylamine (25–200µM; both 
from Sigma-Aldrich) alone or in combination with TNFα or rVAP-1 for 2–48hours. After the 
end of the incubation period, cells were fixed with methanol. Non–specific binding of 
antibodies was prevented by pre–incubation of cells with 5% goat serum (Sigma) for at least 45 
min. Endothelial cells were then incubated with anti–human primary antibodies (ICAM-1, 
VCAM-1, CD31, IgG1 or MAdCAM1) for 45min. After washing, cells were incubated either 
with a peroxidase conjugated goat anti–mouse secondary antibody or streptavidin conjugated 
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anti–mouse antibody for 45min. OPD tablets from Dako or Sigma (Sigma FastTM OPD) were 
used to visualise antibody binding. The ELISA substrate was used according to manufacturer’s 
instructions and the absorbance values were determined at 490nm and 450nm respectively. All 
treatments were performed in triplicate for each experiment. 
 
ANTIBODY FINAL CONCENTRATION SOURCE 
ICAM-1 2µg/ml R & D Systems 
VCAM-1 2µg/ml R & D Systems 
CD31 5µg/ml BD Cytomation 
MAdCAM-1  5µg/ml Pfizer 
IgG1 5µg/ml Dako 
Goat anti-mouse HRP 
(GAM-HRP) 
1:3000 Dako 
Streptavidin conjugated 
anti-mouse HRP 
1:3000 Serotec 
Table 2.21 Concentrations and sources of antibodies used for detection of adhesion molecule 
expression with ELISA 
 
 
2.12  METHYLATION ANALYSIS 
2.12.1 Overview of Methylation Analysis 
DNA methylation is an epigenetic event that affects cell function by altering gene expression. 
The majority of DNA methylation occurs at CpG islands typically found in or near promoter 
regions of housekeeping genes. Many techniques have been developed for determination of 
DNA methylation including high–performance capillary electrophoresis (Fraga et al., 2000), 
and methylation–sensitive arbitrarily primed PCR (Gonzalgo and Jones, 1997). However, the 
most common technique used today remains the bisulfite conversion method (Frommer et al., 
1992) (EZ DNA Methylation–DirectTM Kit, ZymoResearch). This method consists of treating 
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DNA with sodium bisulfite, which converts the unmethylated cytosine bases to uracil while the 
methylated cytosines remain unaffected. The bisulfite–modified DNA is then amplified by PCR 
and the resulting PCR products are analysed either by DNA sequencing or by restriction 
endonuclease digestion. In the present study, PCR products were analysed by DNA sequencing 
(Figure 2.2). 
 
 
Figure 2.2 Schematic illustration of the bisulfite conversion method, a technique for 
determining DNA methylation. An example of DNA sequence containing CpG islands is shown 
(on top). After bisulfite treatment unmethylated cytosines (C) are converted into uracils (U) whereas 
methylated cytosines (mC) remain the same. After further amplification and sequencing of bisulfite 
modified products all unmethylated cytosines are measured as the relative content of T at the CpG sites 
(or A dependent on which sequence the primer is complementary to), and all methylated cytosines, mC, 
are measured as the relative content of C (or G) at the CpG sites. 
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2.12.2 Bisulfite Treatment of DNA 
HSEC and HUVEC were treated with stimulating agents as before for 2 hours. Then, cells were 
counted and up to 2x103 cells (to ensure optimal and complete bisulfite conversion) were 
collected for digestion with proteinase K and release of DNA according to the EZ DNA 
methylation–DirectTM Kit from ZymoResearch. The released DNA was then treated with 
sodium bisulfite and the eluted bis–DNA was amplified with forward and reverse primers (see 
below) specific for not annealing to any of the CpG islands examined. Primers were designed 
using the MethylPrimer Express® Software, provided online from Applied Biosystems. After 
electrophoresis of the PCR products in a 1.5% (w/v) agarose gel the bis–DNA bands were 
extracted from the gel and purified according to the instructions of the QIAquick gel extraction 
kit (Qiagen, UK). After elution of purified bis–DNA and prior to sequencing, the purified 
products were electrophorised again in a 1.5% (w/v) agarose gel. 
 
PRIMERS MADCAM-1 
methForward 5’- GTG TTT GAA TAT GAG GTT TGG A-3’ 
methReverse 5’- AAT CCA TAG TCA ATC CCC TCT A-3’ 
                             Amplicon Length: 258bp 
Table 2.22 Primers specifically designed to anneal with bisulfite converted DNA, amplifying 
MAdCAM-1 gene replacing the uracils with thymines 
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REAGENTS FINAL CONCENTRATION SOURCE 
10x PCR Cold Buffer 1x Applied Biosystems 
MgCl2 1.5mM Applied Biosystems 
dNTPs 0.2mM(total) Roche 
methF+R primers 0.32pmole/µl (total) Alta Bioscience 
AmpliTaq Gold Hot Start 
Polymerase 
1.25U Applied Biosystems 
bis-DNA 2-10µl from purified bis-DNA Human primary endothelial 
cells 
Table 2.23 Constituents of PCR reaction mix 
  
NUMBER OF CYCLES: 40 TEMPERATURE (oC) TIME (sec) 
 95 05:00 
Denaturation 94 00:30 
Annealing 55 00:45 
Extension 72 00:45 
 72 10:00 
Table 2.24 Thermal profile for amplification of bisulfite treated DNA 
 
 
2.12.3 Sequencing 
In order to determine the methylation profile of the untreated versus TNFα, methylamine and 
TNFα plus methylamine treated cells, sequencing was carried out according to standard 
protocols in the Genomics Laboratory of Biosciences Department in the University of 
Birmingham. 
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SEQUENCING 
CONSTITUENTS FINAL CONCENTRATION 
Purified bis-DNA 1µg/ml 
methForward primer 3.2µM 
sterile ddH2O adjust 
Total Volume 10µl 
Table 2.25 Constituents of sequencing reaction 
 
TEMPERATURE (oC) TIME (sec) 
NUMBER OF CYCLES: 25 
96 00:10 
50 00:50 
60 04:00 
Table 2.26 Thermal profile of sequencing reaction 
 
 
2.12.4 Methylation Analysis 
The CpG islands that were assayed were identified by the MethylPrimer Express® Software 
which performs in-silico bisulfite conversion. After sequencing, alignment between the bisulfite 
converted and sequenced products and the non–methylated MAdCAM-1 sequence as given by 
GenBank was performed, using the Sequence Scanner software (Applied Biosystems). The 
average of methylated cytosines/non–methylated cytosines (mC/C) ratio observed was then 
calculated in order to give the methylation index (MtI). 
 
2.13  MOUSE MODELS 
Wild-type mice (WT), VAP-1 deficient mice that lack mouse VAP-1 (VAP-1_KO) (C57BL 
background), and VAP-1 transgenic animals, specifically VAP-1 deficient mice that contain 
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enzymatically active hVAP-1 as a transgene (VAP-1_EA) and VAP-1 deficient mice that contain 
enzymatically inactive hVAP-1 as a transgene (VAP-1_EI), expressing human VAP-1 on the 
endothelial cells under the control of the mouse Tie-1 promoter, as previously described (Stolen 
et al., 2005), were used in the MediCity Laboratory in Turku for determination of the role of 
methylamine in MAdCAM-1 expression in vivo. 
 
2.13.1 VAP-1 Dependent Signalling In Vivo 
Methylamine [0.4% (w/v)], a VAP-1 substrate, was administered in the drinking water of the 
above animals for 14 days. After sacrifice, tissue samples from liver, kidney, spleen, mesenteric 
lymph nodes and Peyer’s patches were excised. Parts of the same tissue were snap–frozen, lysed 
for extraction of protein and RNA (see sections 2.5.1, 2.7.1.3 and 2.8.4). 
 
2.14  ADENOVIRAL INFECTION OF HUMAN HSEC WITH VAP-1 CONSTRUCTS 
2.14.1 Determination of The Enzymatic Activity of VAP-1 Constructs by the AMPLEX 
Ultra Red Method 
HSEC were seeded in a 24–well plate and cultured until confluency. Then, cells in each row 
were transfected with viral constructs containing hVAP-1 enzymatically active, hVAP-1 
enzymatically inactive, or adenoviral constructs without any VAP-1 (LacZ only). Non–
transfected cells were used as an additional control. The adenoviral transfection process is 
described below (paragraph 2.14.2).  
 
The AMPLEX Red assay is based upon detection of H2O2 released by the enzymatic activity of 
VAP-1. More precisely, the reaction between VAP-1 and its substrate, i.e. benzylamine, results in 
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the production of H2O2, ammonia and aldehyde. Firstly, transfected and non–transfected cells 
were treated with a mixture of PBS plus benzylamine (2mM, Sigma), clorgyline and pargyline 
(both at 200µM, Sigma). Clorgyline and pargyline are inhibitors of monoamine oxidases type A 
and B respectively (MAO–A and MAO–B) and they are used in order to block the enzymatic 
activity of other amine oxidases (i.e. not VAP-1) that would lead to false positive results. 
Similarly, to ensure the specificity of the reaction, 5’ bromoethylamine (specific VAP-1 
inhibitor) (BEA, at 400µM) was added to some wells (with PBS plus pargyline, clorgyline and 
benzylamine). Next the AMPLEX Red reagent was added, which is consisted of 1/100 Amplex 
Red Ultra (20mM stock; Invitrogen) and 1/100 HRP (200U/ml stock, Invitrogen). In the 
presence of HRP, the Amplex Red reagent (10–acetyl-3, 7–dihydroxyphenoxazine) reacts with 
H2O2 with a 1:1 stoichiometry resulting in the production of a red fluorescent product, which 
can be detected in a fluorescent plate reader detecting for 3 hours, as it is a kinetic reaction. 
 
2.14.2 Adenoviral Transfection of Human HSEC 
Adenoviral constructs encoding wild-type hVAP-1 and enzymatically inactive hVAP-1 (Y471F) 
have been previously described (Koskinen et al., 2004). HSEC were plated in T25 tissue culture 
flasks and cultured until confluency. Before transfection, complete medium containing human 
serum was removed, cells were washed in PBS, to ensure complete removal of any human 
serum present, and fresh EBM–2 media (Clonetcis, Lonza) supplemented with 10% (v/v) FCS 
was added for at least one hour before adenoviral transfection. Meanwhile the number of cells 
per T25 flask was counted according to the mathematical formulae represented below (Table 
2.27). The medium was discarded, cells were washed again and finally adenoviral transfection at 
a multiplicity of infection of 600 occurred for 4 hours. After the 4 hour transfection period the 
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adenoviral transfected cells were washed, fresh HSEC media was added (see paragraph 2.3.2) 
and cells were incubated overnight at 37oC in a humidified atmosphere containing 5% CO2. 
The following day, transfected cells were stimulated with TNFα or methylamine as previously 
described for 2 hours, in SFM basal endothelial medium containing 2.5% (v/v) HIHS without 
any growth factors. Finally, RNA and protein lysates were extracted and single–color flow 
cytometry was performed for detection of hVAP-1 positivity. Table 2.28 describes the adenoviral 
constructs used in the experiment. 
METHOD 1 
N= Average Number of cells from 2 fields
 
 x 931 x 2.6 
 
• cells were counted using a 100 squared gridlined microscope lense. 
• 931: multiplicity factor when cells counted at 10x magnification. 
• 2.6: multiplicity factor for cells cultured on a surface of T25 flask. 
METHOD 2 
 
Average number of cells from 2 fields  x 100cm2  x 25 
N= 
0.1496 
 
• cells counted in a field of 0.1496mm2 at  x10 magnification. 
 
Table 2.27 Methods used for calculation of number of cells/T25 flask. Method 1 was used in 
the MediCity Laboratory, in Turku and method 2 in the Centre for Liver Research, in 
Birmingham. 
 
ADENOVIRAL CONSTRUCTS CONCENTRATION (PFU/ML) LOT NUMBER 
Padre hVAP-1 1.4 x 1010 842
hVAP-1_Y471F 4.8 x 1010 493 
hVAP-1_Y471F 2.6 x 1010 1025 
LacZ 4.2 x 1010 950 
Table 2.28 Adenoviral constructs used for HSEC transfection 
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2.15  ISOLATION AND CULTURE OF HUMAN PERIPHERAL BLOOD LYMPHOCYTES (PBL) 
Peripheral venous blood was collected into EDTA and the mononuclear fraction was isolated 
by density gradient centrifugation over Lymphoprep (Sigma-Aldrich) according to 
manufacturer’s instructions. Contaminating monocytes were depleted by adhesion to tissue 
culture plastic for 30min, and the lymphocyte–rich supernatant was transferred to a fresh tissue 
culture flask containing RPMI–1640 media (Invitrogen) supplemented with streptomycin, 2mM 
glutamine and 10% (v/v) FCS, and rested overnight at 37oC in a humidified incubator 
containing 5% CO2. The following day, cells were counted, and resuspended to a concentration 
of 106 cells/ml, in basal endothelial medium containing 0.1% (v/v) bovine serum albumin 
(BSA) (Sigma). 
 
2.16  STATISTICAL ANALYSIS 
Data were analysed using Student’s t–test when comparing numerical variables between two 
groups, and one–way ANOVA analysis followed by Bonferroni’s post test for between more 
than two groups comparisons. Statistical analysis was performed using the GraphPad Prism 
software. A value of P≤0.05 is considered statistically significant. Generally statistical data are 
expressed as follows: *≤0.05, **≤0.01, ***≤0.001. 
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CHAPTER 3  
 
EXPRESSION OF MADCAM-1 IN HUMAN LIVER TISSUES 
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3.1  INTRODUCTION 
Human MAdCAM-1 is an endothelial adhesion molecule particularly expressed in high 
endothelial venules of Peyer’s patches, in flat–walled venules of the lamina propria and in other 
gut associated lymphoid tissues including appendix and mesenteric lymph nodes (Streeter et al., 
1988)(M. Briskin et al., 1997). In intestinal inflammation elevated levels of MAdCAM-1 have 
been reported, and more particularly in the inflammatory bowel disease (IBD), Crohn’s disease 
(CrD) and ulcerative colitis (UC), where its over–expression has been suggested to be important 
for the establishment of chronic bowel inflammation via the sustained recruitment of 
circulating α4β7+ lymphocytes (Eksteen et al., 2004b). 
 
IBD is an idiopathic inflammatory disorder of the gastrointestinal tract, the aetiology of which 
still remains elusive, although both genetic and environmental factors have been linked to this 
disorder (Shih et al., 2008). A common characteristic of both CrD and UC is a massive influx 
of destructive inflammatory cells into the gut. Pro–inflammatory cytokines are highly up–
regulated during IBD which lead to increased expression of vascular adhesion molecules that 
promote sustained leukocyte recruitment and lead to chronic inflammation and symptomatic 
disease (Koizumi et al., 1992). The up–regulation of MAdCAM-1 during gut inflammation has 
been suggested to be responsible for the sustained recruitment of circulating α4β7+ 
lymphocytes and as such for the establishment of bowel inflammation (Eksteen et al., 2004b).  
 
Interestingly, Hillan et al. were the first to report expression of MAdCAM-1 in tissues where 
previously none had been detected (Hillan et al., 1999). In this study MAdCAM-1 expression 
was observed in adult human liver in association with portal tract inflammation in a variety of 
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liver diseases. Subsequently, strong expression of MAdCAM-1 protein on hepatic endothelium 
was demonstrated by our group, in the context of chronic inflammation. Using tissue–binding 
assays, it was shown that MAdCAM-1 on liver endothelium could support the adhesion of 
α4β7+ lymphocytes (Grant et al., 2001). This ectopic expression of a molecule previously 
thought to have a more restricted localisation, parallels recent observations relating to the 
chemokine CCL25. Expression of CCL25 was considered restricted to the small intestine and 
thymus (Kunkel et al., 2000)(Kunkel et al., 2003a), but expression has also been reported in the 
liver of patients with PSC, an autoimmune liver disease which is frequently an extra–intestinal 
complication of IBD (Eksteen et al., 2004a). Here CCL25 was responsible for the recruitment 
of mucosal lymphocytes that express α4β7 integrin and the CCL25 receptor, CCR9 (Figure 
3.1). Therefore, in the current chapter, expression of MAdCAM-1 in human liver tissues at the 
protein and mRNA levels, as well as co–localisation of MAdCAM-1 with CCL25 in human 
liver, were studied. 
 
 
 
 
   123 
 
 
Figure 3.1 Alpha4 beta7 integrin activation by CCL25/CCR9 interaction. Recruitment of 
lymphocytes in the gut requires not only the MAdCAM-1/α4β7 integrin interaction but also a 
chemokine signal provided by CCL25. CCL25 is selectively expressed in the thymus and small intestine 
but not in the colon. The only known receptor for CCL25 is CCR9, which is highly expressed on 
developing thymocytes, small intestinal lamina propria lymphocytes and intraepithelial lymphocytes. 
CCL25 presented by glycosaminoglycans on the endothelial surface interacts with CCR9 on the 
leukocyte surface leading to activation of the Rho/Rac intracellular signalling pathways, which in turn 
induce conformational changes in the α4β7 integrin. The activated integrin is then able to bind to 
MAdCAM-1 with high affinity. 
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3.2  RESULTS 
3.2.1 MAdCAM-1 Protein and mRNA Expression In Human Liver Tissues 
The efficacy of our immunohistochemical technique and the specificity of the antibodies used 
were validated by staining human liver and lymph node tissues for CD31, MAdCAM-1 and 
LYVE-1 respectively. Figure 3.2 shows that CD31 antibody stained the endothelial cells of 
central veins, small vessels and hepatic sinusoidal endothelial cells in both diseased and normal 
livers. It was apparent that in diseased liver CD31 expression levels were higher than in normal 
liver where it was faintly expressed (Figure 3.2A and 3.2B). As expected, MAdCAM-1 staining 
of high endothelial venules in lymph nodes (Figure 3.2D) and LYVE-1 expression on lymphatic 
endothelial cells, was also demonstrated (Figure 3.2E). 
 
Immunohistochemical detection of MAdCAM-1 in human liver samples, revealed an 
inconsistent pattern of expression. In all of the diseased livers tested (3AIH, 3ALD, 3PBC, 
3PSC), MAdCAM-1 was detected on the endothelial cell lining of central veins and small 
vessels (Figure 3.3B–E). Of note, not all vessels in a particular tissue section stained positive, 
showing a patchy distribution of MAdCAM-1 protein. In only 1/3 NL samples tested there was 
faint staining for MAdCAM-1 in hepatic sinusoidal endothelial cells (Figure 3.3A). 
Occasionally, MAdCAM-1 expression was seen in structures inside the hepatocyte cytoplasm 
(Figure 3.4A), as well as in structures that had the morphology of dendritic cells (Figure 3.4B, 
3.4D & 3.4E). Moreover, in some cases a brownish smear was stained, which could represent 
soluble MAdCAM-1 in the stroma matrix (Figure 3.4C). In all cases the isotype–matched 
control antibody used displayed no reactivity.  
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The presence of MAdCAM-1 protein in the same liver tissues was confirmed by 
immunoprecipitation, which revealed the existence of MAdCAM-1 in all of the livers tested. 
Weak bands were detected in three normal tissues and MAdCAM-1 levels were increased in 
PSC livers although variation in the levels of expression was apparent (Figure 3.5). When the 
order of the antibodies used for immunoprecipitation (IP) (i.e. using the polyclonal for IP and 
the monoclonal for detection) was reversed, much higher levels of MAdCAM-1 protein in the 
same normal livers were detected. For this reason, it was tested whether the folding of 
MAdCAM-1 protein in normal livers is such that the monoclonal antibody cannot easily detect 
its specific epitope. Western blotting of the unbound protein in the supernatant from 
immunoprecipitated samples with the polyclonal anti–MAdCAM-1 Ab (H–116) revealed the 
presence of high levels of MAdCAM-1 protein. After stripping the same membrane and re–
probing with the monoclonal Ab that was used during IP, no MAdCAM-1 was detected (Figure 
3.6), which confirmed that MAdCAM-1 protein in normal liver tissues may have a structural 
conformation that is not recognised by the monoclonal antibody. 
 
Immunoprecipitation and western blotting of additional different liver tissues (ALD, PBC, 
PSC, AIH and NL livers) again confirmed MAdCAM-1 protein expression (Figure 3.7). 
Intriguingly, the chemokine CCL25 had previously been detected in the same samples 
(unpublished data from Dr. C. Weston, Centre for Liver Research). Analysis of the MAdCAM-
1 mRNA in all the above liver tissues, revealed higher mRNA levels in the diseased livers 
relative to the normal livers (**P<0.01, **P<0.001) (Figure 3.8A), with statistically significant 
higher expression in AIH (*P<0.05) and PSC (**P<0.01) liver tissues (Figure 3.8B). As an extra 
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confirmatory step we verified the identity of the bands attributed to MAdCAM-1 in the normal 
liver samples by sequencing (Figure3.9). 
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Figure 3.2 Expression of phenotypic markers in human liver and lymph nodes. 
Immunohistochemical staining for the CD31 endothelial marker in human (A) PBC and (B) normal 
liver. (D) MAdCAM-1 and (E) LYVE-1 expression in human lymph nodes. Staining with isotype–
matched control antibodies is also shown (C and F). Fields were captured using 20x objectives 
resolution.  
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Figure 3.3 MAdCAM-1 expression in human liver tissues. Immunohistochemical staining for 
MAdCAM-1 in (A) sinusoidal endothelium of normal liver, (B) in small vessels of PBC, (C) and (D) in 
central vein of AIH and PSC respectively and in (E) central vein and small vessel in ALD. (F) 
Representative image of isotype–matched control stained tissue. Images are representative from staining 
of sections from 3 different livers of each disease/group. Fields were captured using 20x objectives 
resolution.  
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Figure 3.4 MAdCAM-1 expression in human liver tissues. Immunohistochemical staining for 
MAdCAM-1 protein in human (A) normal (B) PSC (C) AIH (D) PBC and (E) ALD liver tissues. (A) 
MAdCAM-1 staining of defined structures in the hepatocyte cytoplasm. (B), (D) and (E) MAdCAM-1 
staining of immune cells and (C) a smear of staining suggests the presence of soluble MAdCAM-1. (F) 
Representative image of isotype–matched control stained tissue. The specificity of MAdCAM-1 staining 
is indicated by the fact that bile ducts (in B and C) were not stained. Fields were captured using 20x 
objectives resolution.  
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Figure 3.5 MAdCAM-1 protein expression in human liver tissues. MAdCAM-1 protein was 
detected in immunoprecipitated protein lysates from 3 different NL, PBC, AIH, ALD and 9 different 
PSC liver tissues. During immunoprecipitation MAdCAM-1 protein was pulled out by monoclonal 
antibody (CA102.2C1) and then a 60kDa molecular weight protein was detected by western blot using a 
polyclonal antibody (H-116). 
 
 
 
  
 
 
Figure 3.6 MAdCAM-1 protein folds differently in normal livers. (A) MAdCAM-1 protein was 
detected in the non–beaded samples of 3 normal liver tissues after immunoprecipitation with the 
monoclonal antibody and detection with the polyclonal Ab. In (B) MAdCAM-1 could not be revealed by 
the monoclonal Ab after stripping and re–probing the same membrane.  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Figure 3.7 Detection of MAdCAM-1 protein in tissue lysates from samples where CCL25 is 
known to be expressed. Immunoprecipitation of the protein lysates where CCL25 was detected 
revealed also the expression of MAdCAM-1. During immunoprecipitation MAdCAM-1 was captured 
with the polyclonal H-116 Ab and then detected by the monoclonal CA102.2C1 Ab.  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Figure 3.8 MAdCAM-1 mRNA expression in human liver tissues. RNA extracted from fresh 
human normal (NL), PBC, AIH, ALD and PSC liver tissues, was transcribed into cDNA and used to 
evaluate MAdCAM-1 transcripts by quantitative PCR. (A) Data represent relative expression levels 
(mean ± SD) from n=9 PSCs and n=3 of all other diseased and normal livers. The y–axis shows the N–
fold change of MAdCAM-1 mRNA expression in each liver relatively to one normal liver (NL1). (B) 
Overall MAdCAM-1 mRNA expression in diseased livers relatively to normal liver tissues. In panel (A) 
statistical analysis performed by Student’s t-test revealed significance in all samples (**P<0.01, 
***P<0.001) with exception of NL2, ALD1 and PSC6 samples. In panel (B) Student’s t-test also revealed 
significance in AIH and PSC liver tissues (*P<0.05, **P<0.01).   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Figure 3.9 Sequencing of MAdCAM-1 mRNA extracted from a normal liver. Representative 
sequencing data from amplified cDNA transcribed from total RNA extracted from a normal liver, 
indicating consensus between sequenced material and MAdCAM-1 sequence information from 
GenBank.  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3.3  DISCUSSION 
The expression of MAdCAM-1 has previously been reported in human livers in a variety of liver 
diseases, most prominently in AIH and PSC, the autoimmune hepatic complications of IBD 
(Hillan et al., 1999)(Grant et al., 2001). Therefore, in this study, a more detailed analysis of 
MAdCAM-1 mRNA and protein expression in normal and diseased human liver tissues was 
carried out. 
 
Immunohistochemical analysis revealed that in all the disease livers but not normal liver tissue 
(3AIH, 3PBC, 3PSC, 3ALD), MAdCAM-1 was detected in the endothelial cell lining of central 
veins and small vessels. Sinusoidal staining was mostly absent except in one normal liver, where 
it was faintly expressed. These results are in accordance with what was previously found by 
Grant et al., who detected sinusoidal MAdCAM-1 in 2/10 (20%) patients with AIH and 2/11 
(18%) patients with PBC (Grant et al., 2001). However, we cannot draw any absolute 
conclusions regarding expression of MAdCAM-1 in particular diseases, such as AIH and PSC, 
because the number of samples tested in the present study was small (n=3). 
 
Interestingly, in addition to the expression of MAdCAM-1 in vascular endothelium, positive 
staining was also detected in structures that seemed to be inside the hepatocyte cytoplasm. 
There are no published studies reporting expression of MAdCAM-1 in hepatocytes, thus our 
data may suggest either that hepatocytes make MAdCAM-1 protein, which is unlikely given 
what is known about MAdCAM-1 expression, or that circulating soluble MAdCAM-1 can be 
taken up and transported into cytoplasmic vehicles in hepatocytes in order to be processed or 
degraded. A third explanation is that the staining was non–specific but this is unlikely given the 
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negative staining seen with an isotype–matched control antibody. Intriguingly, expression of 
MAdCAM-1 in epithelial type cells has been reported in choroid plexus epithelium, where 
MAdCAM-1 is expressed de novo during experimental autoimmune encephalomyelitis (EAE) 
and also participated in leukocyte adhesion to the epithelium (Steffen et al., 1996). Hence, our 
hepatic epithelial MAdCAM-1 expression may be genuine. In addition, in most cases tested, 
there was a smeary brownish stain of the tissue, which does not appear to be associated with 
specific cellular structures. It is unclear what this staining represents, it could be staining of 
soluble MAdCAM-1 immobilised on matrix. In all cases the isotype–matched control antibody 
used displayed no reactivity, suggesting that the staining with anti–MAdCAM-1 was real. 
 
Occasionally, MAdCAM-1 staining was seen in immune cells with the morphology of dendritic 
cells. Previous studies (Szabo et al., 1997) have demonstrated expression of MAdCAM-1 on 
follicular dendritic cells, throughout the B cell zone in Peyer’s patches in normal mice, as well 
as in the follicular dendritic cells within the germinal centres of chronically inflamed spleen. In 
addition, dendritic cells within some germinal centres and mantle zone in the follicular cortex 
of both mesenteric and peripheral lymph nodes, dendritic cells within germinal centres of 
Peyer’s patches in humans (M. Briskin et al., 1997), and in lymphoid aggregates of several 
human liver diseases (Grant et al., 2001), also stain for MAdCAM-1. Recently, our laboratory 
(Eksteen et al., 2009) has demonstrated that the imprinting of α4β7+CCR9+ T cells requires 
primary activation by gut dendritic cells a process that is retinoic acid dependent, meaning that 
the α4β7+CCR9+ T cells that infiltrate the liver during inflammation are primed in the gut. 
Therefore, the expression of MAdCAM-1 by hepatic dendritic cells might serve to retain α4β7+ 
gut specific lymphocytes to the liver. In addition, it has been reported that isolated primary 
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follicular dendritic cells express VCAM-1 (Freedman et al., 1990) and ICAM-1 (Koopman et al., 
1991) through which they can support the clustering with and presentation of antigen to α4β1 
and LFA-1 expressing B cells, respectively, in germinal centres, thus leading to their affinity 
maturation and differentiation into memory cells, and a similar role might be served by 
MAdCAM-1. However, more extensive dual staining using cell specific markers for different 
dendritic cell subsets is required to define exactly where MAdCAM-1 protein is expressed. If 
MAdCAM-1 is expressed on DCs within the liver this would suggest it may play a broader role 
than just acting as an addressin in the chronic liver disease. 
 
In accordance with the staining results, MAdCAM-1 protein was also detected by 
immunoprecipitation of the same liver tissue samples. Only a very faint protein band was 
detected in the normal liver tissue samples, whereas all the diseased livers showed strong 
MAdCAM-1 protein bands. When the order of antibodies used was reversed during the 
immunoprecipitation procedure, with the polyclonal Ab used for detection, it was noted that 
MAdCAM-1 protein in the normal samples appeared similar to the levels in the diseased livers. 
Thus, the possibility of MAdCAM-1 existing in a different conformational structure in the 
normal livers, which changes during inflammation, was further investigated. Surprisingly, 
western blotting of the non–beaded supernatant of immunoprecipitated samples with the 
polyclonal Ab revealed the presence of MAdCAM-1, which was not detected when probing with 
the monoclonal Ab. Currently, the epitope where the monoclonal Ab binds is not known, but 
as it acts as a function–blocking Ab it is likely that it recognises an epitope in either of the two 
extracellular Ig domains. Thus, it is possible that MAdCAM-1 is present in normal liver where 
it exists with a divergent structural folding. This divergence could also explain the low 
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expression levels of MAdCAM-1 detected after immunostaining of normal tissue samples with 
certain antibodies in other studies.  
 
Our findings for MAdCAM-1 expression have interesting parallels with the chemokine CCL25, 
which also shows expression restricted to the gut (Kunkel et al., 2000)(Kunkel et al., 2003a). 
CCL25 is responsible for the activation of α4β7 integrin and its subsequent binding to 
MAdCAM-1. As with MAdCAM-1, CCL25 was found to be up–regulated in the liver during 
inflammatory liver diseases including PSC (Eksteen et al., 2004a). Of note, CCL25 was also 
found to be present in human liver tissues including normal livers (unpublished data from Dr. 
C. Weston, Centre for Liver Research), and we detected CCL25 in the same livers as we had 
observed the presence of MAdCAM-1 protein in the current study. This supports the 
relationship between these two molecules and their role in sustained recruitment of 
α4β7+CCR9+ lymphocytes both in gut and in extra–intestinal sites. A pharmaceutical inhibitor 
of CCR9 (the CCL25 chemokine receptor) has been developed, named TRAFICET–EN 
(Chemocentryx) which is currently in a Phase II/III clinical trial in moderate–to–severe 
Crohn’s disease highlighting the potential therapeutic importance of these molecules. 
 
To confirm the MAdCAM-1 protein results and to determine whether MAdCAM-1 is expressed 
in the liver, MAdCAM-1 mRNA expression was examined and was detected in both normal 
and diseased livers. Furthermore, sequence analysis of mRNA from a normal liver revealed 
complete alignment with the MAdCAM-1 gene sequence provided by GenBank validating the 
presence of MAdCAM-1. Additional mRNA analysis by Northern blot or in situ hybridization 
would be also useful in validating the presence of MAdCAM-1 mRNA in human liver tissue. 
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There was not a constant pattern of MAdCAM-1 expression between particular types of disease 
and some patients had higher expression than others. However, in general, statistically 
significant higher levels in the diseased livers of AIH and PSC were observed. This aberrant 
expression of MAdCAM-1 could be a factor explaining the link between liver inflammation in 
PSC and colitis as manifest by the findings that PSC develops in 2.4–7.5% of people with 
ulcerative colitis and 70–85% of people with PSC will eventually develop inflammatory bowel 
disease (Grant et al., 2002b). The fact that much higher percentage of people with liver disease 
go on to develop gut disease may suggest that there is a missing mechanistic link relating to the 
liver microenvironment (e.g. expression of divergent roles for molecules or immune priming 
roles) which predisposes to bowel inflammation. 
 
In conclusion, in this chapter the presence of MAdCAM-1 protein in the human liver tissues 
was demonstrated, with a most prominent staining in the endothelial lining cells of the portal 
veins. Very faint expression was detected in normal livers, and a novel possibility that this 
MAdCAM-1 exists in a non–functional state is suggested. Under inflammatory conditions a 
conformational change and increased expression results in increased functional MAdCAM-1 
that leads to the recruitment of gut–derived lymphocytes to the liver tissues. Interestingly, 
MAdCAM-1 protein was detected in the same liver tissues as the gut associated chemokine 
CCL25, which can trigger α4β7/MAdCAM-1 binding. The activation of this pathway could 
lead to the sustained recruitment of gut–derived lymphocytes and the establishment of chronic 
inflammation.  
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CHAPTER 4  
 
EXPRESSION AND FUNCTION OF MADCAM-1 IN HUMAN 
PRIMARY ENDOTHELIAL CELLS 
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4.1  INTRODUCTION 
The significant role of MAdCAM-1 in inflammatory bowel disease (IBD), as well as its aberrant 
expression in chronic inflammatory liver diseases complicating IBD, led to the hypothesis that 
an “entero–hepatic” link promotes the recirculation of long–lived memory lymphocytes 
originally activated in the gut, between the gut and the liver. Such cells could trigger hepatic 
inflammation in the presence of gut antigens that had entered the liver via the portal 
circulation (Grant et al., 2002b)(Eksteen et al., 2004b). 
 
Another element supporting “entero–hepatic” lymphocyte recirculation is vascular adhesion 
protein–1 (VAP-1). VAP-1 has adhesive functions and is also an enzyme member of the 
semicarbazide–sensitive amine oxidase family (SSAO) (Smith et al., 1998). Under normal 
conditions VAP-1 is strongly expressed on liver endothelium but is only faintly present on 
mucosal vessels. However, gut expression of VAP-1 is greatly increased in IBD suggesting that 
liver derived lymphocytes expressing the VAP-1 ligand may be able to enter the inflamed gut 
(Salmi et al., 1993). Our observations of the expression pattern of VAP-1 and MAdCAM-1, 
suggested that there is an association between the two. Further support for this association 
comes from previous studies in our group (Lalor et al., 2007) reporting that binding of the 
amine substrate benzylamine to VAP-1 expressed on hepatic endothelial cells leads to rapid 
activation of NF-κB. This results in expression of pro–inflammatory proteins such as E–selectin 
and ICAM-1 and in the up–regulation of leukocyte adhesion. Similar mechanisms may operate 
in the induction of MAdCAM-1 (see below) suggesting to us that VAP-1 enzyme activity could 
be a factor for the aberrant expression of MAdCAM-1 in the liver. 
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Many studies support the role of TNFα and other stimulatory cytokines in induction of 
MAdCAM-1 expression in vivo. Induction of MAdCAM-1 expression on endothelial cells in 
vitro has been more difficult to demonstrate although some studies have reported that TNFα 
induces MAdCAM-1 expression in murine endothelial cells (Oshima et al., 2001a)(Oshima et 
al., 2001b)(Watanabe et al., 2002), including murine hepatic endothelial cells (HEC), exposed 
to TNFα and IL-1β (Ando et al., 2007). In addition, in an in vivo mouse model it has been 
demonstrated that intraluminal administration of butter significantly increases TNFα 
production by lamina propria macrophages, which leads to an increased expression of the 
adhesion molecules, MAdCAM-1, ICAM-1 and VCAM-1 and subsequently to increased 
lymphocyte adherence to intestinal microvessels (Fujiyama et al., 2007). 
 
The ability of TNFα to induce MAdCAM-1 expression is also evident in cells that do not 
belong to the endothelial cell family. In NIH 3T3 fibroblasts and B16F10 melanoma cells it was 
shown that TNFα induced MAdCAM-1 expression and also that the induced MAdCAM-1 
protein in NIH 3T3 was biologically active as it could support adhesion of TK–1 cells in an 
α4β7–dependent manner (Leung et al., 2003).  
 
Moreover, in cultured human stomach explants, increased expression of MAdCAM-1 following 
TNFα and IFNγ stimulation of endothelial cells has been reported (Lindholm et al., 2004). 
More recent studies using primary cultures of human gut–derived microvascular endothelial 
cells (HIMEC) have shown that MAdCAM-1 expression is strongly induced by TNFα, LPS and 
IL-1β by distinct signalling mechanisms involving both NF-κB and PI3-k/Akt (Ogawa et al., 
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2005). All these studies support a role for TNFα in the expression of MAdCAM-1 in gut 
endothelial cells, non–gut endothelium and even in non–endothelial cells.  
 
Both the human and murine MAdCAM-1 genes share common characteristics as indicated by 
their genomic organisations. They are both encoded by 5 exons located on chromosomes 
19p13.3 and chromosome 10, respectively (Figure 4.1A), and the sequences of their N–terminal 
Ig–like domains show homology (59%–65%). The DNA sequence of the 5’ flanking promoter 
region of the human MAdCAM-1 gene contains potential transcription factor binding sites 
(Figure 4.1B), many of which are conserved in the mouse homologue MAdCAM-1 gene (Leung 
et al., 1997). These transcription factor–binding sites (Figure 4.1C) include sites for NF-κB 
docking which may explain the inducibility of MAdCAM-1 following stimulation with 
cytokines such as TNFα, which activate NF-κB. Although cytokines are clearly important for the 
regulation of expression of many pro–inflammatory genes including MAdCAM-1, additional 
complexity can be provided by epigenetic events such as promoter methylation. 
 
DNA methylation occurs naturally in both prokaryotic and eukaryotic organisms. In higher 
eukaryotes, DNA methylation has been proven to play a central role in a number of biological 
processes such as X chromosome gene silencing, embryonic development, gene imprinting and 
cell cycle regulation (Warnecke et al., 1997). DNA methylation usually occurs in CpG islands, 
which are often located around the promoters of housekeeping genes or other genes frequently 
expressed in a cell. Human MAdCAM-1 is encoded by a gene located on chromosome 19p13.3. 
Of note, chromosome 19, which contains the human MAdCAM-1 gene, has the highest gene 
density of all human chromosomes, and its high G + C content and density of CpG islands and 
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repetitive DNA sequences indicate a chromosome rich in biological and evolutionary 
significance (Grimwood et al., 2004). The density of CpG islands on this chromosome suggests 
that MAdCAM-1 gene may be a candidate for regulation by methylation. 
 
In the current chapter, the effects of TNFα, VAP-1 and its substrates methylamine and 
benzylamine on the expression of MAdCAM-1 by primary human hepatic endothelial cells were 
studied. Furthermore, the methylation pattern of the human MAdCAM-1 promoter region was 
investigated in order to determine whether the ectopic expression of MAdCAM-1 was due to 
switching on the gene in hepatic cells. Finally, a flow based adhesion assay was developed in 
order to evaluate whether the induced MAdCAM-1 protein was functional. 
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Figure 4.1 Schematic representation of the murine and human MAdCAM-1 genes. (A) The 
murine MAdCAM-1 gene is located on chromosome 10 and (B) the human MAdCAM-1 gene is located 
on chromosome 19p13.3. Both consist of five exons (in purple). (C) Representative part of the DNA 
sequence of the 5’ flanking region of the human MAdCAM-1 gene and comparison with the mouse 
MAdCAM-1 promoter region. Transcriptional regulatory elements identified both in human and mice 
are underlined. Two tandem NF-κB sites (highlighted in blue) located 100bp upstream of the start site of 
transcription in the mouse promoter are conserved. Numbers refer to nucleotide positions and are all 
relative to the transcriptional start codon (ATG). The transcriptional start site identified in the mouse 
MAdCAM-1 gene is denoted by an asterisk [figure C is published by (Leung et al., 1997)].  
 145 
4.2  RESULTS 
4.2.1  The Induction of MAdCAM-1 Expression In HSEC and HUVEC 
In order to investigate whether MAdCAM-1 expression in HSEC and HUVEC could be 
regulated, the effects of adding TNFα and recombinant enzymatically active VAP-1 and its 
substrates methylamine and benzylamine were tested. Monolayers of HSEC and HUVEC were 
stimulated with different combinations of TNFα (20ng/ml), rVAP-1 (100ng/ml which is 
equivalent to serum levels of shed VAP-1), methylamine and benzylamine (25–200µM) for 2 to 
48 hours. In some experiments, the VAP-1 enzyme inhibitor 2’–bromoethylamine (BEA) was 
used at 0.5mM. Low levels of cell surface MAdCAM-1 protein were detected by cell–based 
ELISA and the combination of TNFα (20ng/ml) and methylamine (50µM or 200µM) (*P=0.01 
and *P=0.04, respectively) significantly increased MAdCAM-1 expression in HSEC after 2 
hours stimulation (Figure 4.2A). Similarly in HUVEC, TNFα plus methylamine (at 50µM) 
(Figure 4.2B) increased MAdCAM-1 expression but this did not achieve significance. The 
effects of the stimulants described above, were further examined by conventional and 
quantitative PCR and western blotting. MAdCAM-1 mRNA was detected in HSEC isolated 
from different liver diseases as well as in HUVEC (Figure 4.3), in both untreated (control 
samples) and treated samples. Quantitative PCR confirmed that stimulation of endothelial cells 
with TNFα alone (*P=0.02) or in combination with methylamine (*P=0.01) for 2 hours, 
significantly increased expression of MAdCAM-1 mRNA in HSEC (Figure 4.4A). Although, 
there was more expression when cells were stimulated with TNFα plus methylamine compared 
to TNFα alone, statistical analysis did not reveal a significant difference. In HUVEC, statistical 
analysis also confirmed significant differences in MAdCAM-1 mRNA expression levels relative 
to untreated samples under all three stimulatory conditions of TNFα (***P=0.0002), 
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methylamine (*P=0.04), and their combination (***P=0.0001) (Figure 4.4B). Of note, the 
expression levels of MAdCAM-1 in HSEC stimulated with TNFα (*P=0.01) and TNFα plus 
methylamine (**P=0.004) were higher than in HUVEC (Figure 4.4C). MAdCAM-1 protein was 
also detected in resting and stimulated HSEC and HUVEC by western blotting. In contrast to 
the mRNA analysis however, no differences between the divergent stimulations were observed 
(Figure 4.5A and 4.5B). The molecular weight of the MAdCAM-1 protein identified was 
120kDa, which represents the dimer form of the glycosylated monomer (60kDa). In our 
positive control, CHO cells, a band of different molecular size (80kDa) was detected which 
probably represents the dimeric form of the unprocessed precursor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 147 
 
 
Figure 4.2 Expression of MAdCAM-1 on HSEC and HUVEC. (A) HSEC and (B) HUVEC were 
stimulated with TNFα (20ng/ml) and methylamine (MA; 25µM-200µM) for 2 hours. Data represent 
mean ± SEM of MAdCAM-1 expression minus the signal from isotype control Ab in n=4 HSEC and 
n=3 HUVEC. Statistical analysis performed by Student’s t-test [*P=0.04, TNFα+MA (50µM); *P=0.01, 
TNFα+MA (200µM), both compared to untreated control samples].  
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Figure 4.3 MAdCAM-1 mRNA expression in HSEC and HUVEC. Endothelial cells were 
stimulated with TNFα (20ng/ml), methylamine (MA; 50µM) and their combination for 2 hours, prior 
to extraction of RNA, cDNA synthesis and conventional PCR. MAdCAM-1 mRNA in CHO cells was 
used as positive control and in JY cells as a negative control (Neg.Co). Images represent PCR products 
from 3 different representative HSEC and HUVEC, after electrophoresis in 1.5% (w/v) agarose gels. β-
actin was used as endogenous control. 
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Figure 4.4 MAdCAM-1mRNA expression in HSEC and HUVEC by quantitative PCR. 
Endothelial monolayers were stimulated with TNFα (20ng/ml), methylamine (MA; 50µM) and their 
combination for 2 hours, prior to relative expression analysis by qPCR. MAdCAM-1 mRNA expression 
in (A) n=7 HSEC and (B) n=3 HUVEC. Data represent relative expression of treated versus non-treated 
endothelial cells (Cntr). (C) MAdCAM-1 mRNA expression in HSEC shown relative to HUVEC. 
Statistical analysis performed by Student’s t-test revealed significantly elevated levels in stimulated versus 
untreated control samples [(A) *P=0.02, TNFα; *P=0.01, TNFα+MA (B) ***P=0.0002, TNFα; *P=0.04, 
MA; ***P=0.0001, TNFα+MA (C) *P=0.01, TNFα; **P=0.004, TNFα+MA]. 
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Figure 4.5 MAdCAM-1 protein expression in HSEC and HUVEC. Endothelial monolayers were 
stimulated with TNFα, methylamine (MA) and their combination for 2 hours as previously described, 
prior to lysis and western blot analysis. Protein lysates extracted from CHO cells transfected with FL-
MAdCAM-1 and after hygromycin B reselection were used as positive control (CHO) and protein lysate 
from a JY cell line was used as negative control (Neg. Co). (A) Representative images of western blots 
from 3 different HSEC and HUVEC isolates. (B) Densitometric analysis of replicate blots. Data 
represent mean ± SEM of percentage of relative intensity [compared to expression in un–stimulated cells 
(set to 100%)] from n=8 different HSEC and n=3 different HUVEC. 
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4.2.2 Optimisation of Cytometric Analysis of MAdCAM-1 Expression 
CHO cells stably transfected with a FL–MAdCAM-1 expression plasmid and untransfected 
parental CHO cells, were used as positive and negative control respectively, for confirmation of 
anti–MAdCAM-1 antibody specificity. Cytometric analysis confirmed CHO–FL–MAdCAM-1 
cells stained with anti–MAdCAM-1 antibody in contrast to the parental cells (Figure 4.6). The 
CHO–FL–MAdCAM-1 cells were then used to test the effects of trypsin on surface expression 
of MAdCAM-1 prior to later experiments, which required trypsinisation of treated HSEC. 
Figure 4.7 confirms that MAdCAM-1 is cleaved by trypsin, since the median channel 
fluorescence (MCF) values for expression on trypsinised cells (Figure 4.7B and 4.7C) are lower 
than those on cells detached non–enzymatically (Figure 4.7A and 4.7C). The expression of 
CD31 was also confirmed on HSEC populations by cytometry as this marker is used to isolate 
hepatic endothelial cells and is a good marker of endothelial phenotype (Lalor et al., 2006). 
Figure 4.8 shows a representative cytometry histogram for CD31 expression in HSEC. 
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Figure 4.6 MAdCAM-1 expression in CHO cells. Expression of cell surface MAdCAM-1 protein 
was examined in CHO cells by flow cytometry. Representative histograms for MAdCAM-1 staining (in 
purple), compared to staining with isotype–matched control antibody (in black) in CHO transfected 
with a full length MAdCAM-1 construct (top panel) compared to the parental CHO (bottom panel). 
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Figure 4.7 MAdCAM-1 protein is cleaved by trypsinization. Representative histograms for 
MAdCAM-1 expression (in purple) after detachment of CHO cells using (A) non-enzymatic dissociation 
solution or (B) trypsin, compared to staining with an isotype–matched control antibody (in black). (C) 
The percentage of positive cells and median channel fluorescence (MCF) values for a representative 
experiment are presented. 
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Figure 4.8 CD31 expression in hepatic endothelial cells. Representative cytometry histogram for 
CD31 expression (in purple) on HSEC compared to staining with an isotype–matched control antibody 
(in black). 
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4.2.3 Localisation of MAdCAM-1 Protein Expression In Hepatic Endothelial Cells 
The localisation of MAdCAM-1 in hepatic endothelium following stimulation was subsequently 
examined. Cells isolated from different livers were labelled fresh (surface expression) or after 
fixing and permeabilisation (internal expression). The data confirm that MAdCAM-1 is 
expressed on the endothelial surface as well as in the cytoplasm of both treated and untreated 
samples (Figure 4.9A and 4.9B) and that levels are similar on HSEC from normal and diseased 
livers. Interestingly, no differences in MAdCAM-1 protein expression levels (% positive or 
MCF) were noted after treatment (Table 4.1). 
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Figure 4.9 Extracellular and intracellular MAdCAM-1 protein expression. Endothelial cells 
were stimulated with TNFα, methylamine (MA) and their combination for 2 hours. Panels illustrate 
representative histograms for (A) surface and (B) internal MAdCAM-1 expression (purple) on two HSEC 
isolates (normal and PBC liver, respectively) compared to staining with an isotype–matched control 
antibody (in black). 
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SURFACE EXPRESSION 
MAdCAM-1 % Positivity MCF 
Control (No Treatment) 38.33 ± 12.03 22.36 ± 5.65 
TNFα 37.86 ± 11.38 21.72 ± 6.45 
MA 34.06 ± 11.42 20.79 ± 4.94 
TNFα+MA 39.79 ± 12.00 22.31 ± 8.04 
INTERNAL EXPRESSION 
MAdCAM-1 % Positivity MCF 
Control (No Treatment) 86.25 ± 5.24 11.16 ± 1.08 
TNFα 80.63 ± 7.66 10.55 ± 1.03 
MA 81.18 ± 7.62 10.88 ± 1.04 
TNFα+MA 81.31 ± 8.33 10.34 ± 0.85 
 
Table 4.1 Surface and internal expression of MAdCAM-1 protein is unaffected by treatment. 
Pooled data from 7 different HSEC isolates (2Normal, 2Resections, 2PBC, 1AIH) showing 
percentage of positive cells and median channel fluorescence values (MCF) for MAdCAM-1 
on live cells (surface expression) and fixed and permeabilised cells (internal expression). Data 
represent mean±SEM and no significant differences were noted between control and 
stimulated cells. 
 
 
4.2.4 Different Cellular Compartments Contain Distinct MAdCAM-1 Species 
Endothelial cells were treated as previously, prior to extraction of protein from the cytosolic, 
membrane, and cytoskeletal compartments. Western blotting of these fractions revealed that 
MAdCAM-1 protein species of different molecular sizes were present at different densities in 
the different compartments (Figure 4.10A and 4.10B). The glycosylated MAdCAM-1 monomer 
(60kDa) was present only in the cytoplasmic fraction. The dimeric form (120kDa) was present 
in both the cytoplasm and membrane but much higher levels were apparent in the membrane 
fragments. The presence of a larger protein was also noted, possibly trimeric MAdCAM-1 
(180kDa) in some cell fractions. 
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Figure 4.10 MAdCAM-1 species of different molecular weights are detected in different cell 
compartments. Protein lysates from the cytosolic and membrane compartments were prepared from 
n=3 different HSEC after stimulation with TNFα, methylamine (MA) and their combination for 2 
hours. Blotted proteins were probed using the mouse anti-human MAdCAM-1 Ab (CA102.2C1; 
4µg/ml). Representative images of western blot from two different HSEC isolates (A) and (B) from 
resected liver. 
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4.2.5 Soluble MAdCAM-1 Is Released From Endothelium After Stimulation 
Stimulation of endothelial cells with TNFα or methylamine alone or in combination for 2 
hours resulted in significantly increased levels of MAdCAM-1 mRNA. However, extracellular 
and intracellular protein levels remained the same. A previous study of Leung et al. revealed 
that soluble MAdCAM-1 is secreted into serum and urine of both normal individuals and 
chronically inflamed patients (Leung et al., 2004). Therefore, we tested whether MAdCAM-1 
protein was cleaved from our cells under stimulatory conditions.  
 
After stimulation cell supernatant was collected and examined for the presence of sMAdCAM-1 
by immunoprecipitation. Figure 4.11 shows that MAdCAM-1 (60kDa) was detected in the 
supernatant from control and stimulated cells, and that statistically significant increased 
amounts were present after treatment with TNFα plus methylamine (*P=0.017). Moreover, 
under brefeldin A treatment (a chemical substance that disrupts the normal function of Golgi 
complex thus preventing the transport of the newly synthesised proteins to the membrane) of 
endothelial cells prior to stimulation with TNFα, methylamine and their combination for 2 
hours, increased levels of intracellular MAdCAM-1 were detected (about 45%) after TNFα plus 
methylamine stimulation when compared to the TNFα plus methylamine treated HSEC that 
were not pre–treated with brefeldin A (Figure 4.12). 
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Figure 4.11 Soluble MAdCAM-1 is detected in the supernatants of HSEC after stimulation. 
Soluble MAdCAM-1 protein released in the culture media of HSEC after 2 hours treatment with 
TNFα, MA and their combination, was captured by the polyclonal Ab (H-116) and then (A) a 60kDa 
molecular weight band was revealed after detection with the monoclonal Ab (CA102.2C1). (B) 
Densitometric analysis of n=6 different HSEC isolates (2Resections, 2PBC, 1AIH, 1ALD). Data 
represent mean ± SEM of percentage of integrated density compared to expression in un–stimulated 
HSEC (Cntr; set to 100%). Statistical analysis performed by Student’s t-test (*P=0.017). 
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Figure 4.12 Brefeldin A prevented the transfer of newly synthesised MAdCAM-1 protein to 
the endothelial surface. Endothelial cells under stimulation with TNFα, methylamine and their 
combination synthesised new MAdCAM-1 protein whose transfer to the membrane was prevented from 
the disruptive Golgi apparatus caused by BFA. The percentage of positive cells under treatments with or 
without pre-treatment with Brefeldin A, BFA+ or BFA-, respectively, from one HSEC isolate, are 
presented. 
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4.2.6 Analysis of The Methylation Pattern of The MAdCAM-1 Promoter Region 
MAdCAM-1 genomic sequence was accessible via GenBank and in order to investigate the 
methylation status of the MAdCAM-1 promoter region, 16 CpG islands located upstream of 
the transcription start site of the gene were identified by the MethylPrimer Express® Software 
(Applied Biosystems) and were assayed (Figure 4.13). DNA was extracted from 4 different 
HSEC (2PBC, 1NL and 1Resected liver) and 4 different HUVEC samples. Cells were left un–
stimulated or were stimulated with TNFα and methylamine and bisulfite conversion was 
performed prior to methylation analysis by sequencing. In order to calculate an overall 
methylation figure per endothelial cell type, the methylation index (MtI) was calculated as the 
average of the mC/C ratio observed in all of the 16CpGs identified in each sample (Figure 
4.14). Statistical analysis did not reveal a significant difference in the methylation status of 
MAdCAM-1 promoter regions before and after stimulation in both HSEC and HUVEC.  
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Figure 4.13 Methylation analysis of human MAdCAM-1 promoter region. The yellow 
highlights indicate 16CpG islands located upstream of the transcription start site (ATG highlighted in 
red) which were assayed. Two tandem NF-κB sites are also present (highlighted in blue). 
 
 
 
 
 
 
 
Figure 4.14 Methylation in HSEC and HUVEC. Endothelial cells were stimulated with TNFα 
and methylamine (MA) as before prior to bisulfite treatment of their DNA and sequence 
analysis. Data represent the average percentage change in methylation index (MtI: average ratio 
of the mC/C) of the MAdCAM-1 promoter region after treatment compared to control level of 
methylation (set to 100%). Data are mean ± SEM of the percentage of MtI from n=4 HSEC and 
n=4 HUVEC.  
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4.2.7 MAdCAM-1 Is Functional In Flow Based Adhesion Assays 
In recent years the development of in vitro methodologies mimicking in vivo physiological flow 
conditions has enabled the detailed examination of leukocyte morphological change as well as 
leukocyte–endothelium interactions within a shear environment modelling that seen in vivo 
(Kulkarni et al., 2004). In the current study, a flow based adhesion assay was used in order to 
investigate the function of the MAdCAM-1 protein that was detected in HSEC and HUVEC. 
JY cells which express high levels of α4β7 integrin were perfused over control or stimulated 
endothelial monolayers at a shear stress of 0.05Pa and adhesion was recorded. Figure 4.15 
shows that the combination of TNFα and methylamine caused a significant increase in the total 
number of adherent cells (**P=0.002) and that treatment with TNFα alone also increased 
adhesion (*P=0.02). In order to confirm that the binding of α4β7+ JY cells to the endothelium 
was due to MAdCAM-1 expression, a blocking antibody directed against MAdCAM-1 (P1) was 
used (Figure 4.16). This antibody significantly inhibited cell adherence (***P=0.0006, Figure 
4.16). Moreover, treatment of JY cells with ACT-1 antibody directed against the α4β7 integrin 
caused also a decrease in the percentage of adherent cells (*P=0.04, Figure 4.16). Confirmation 
of the specificity of the inhibitory effect of these antibodies is shown by lack of effect of isotype–
matched control antibody IgG1 (Figure 4.17). Similar adhesion responses were noted in 
HUVEC (Figure 4.18), but less adhesion was observed to these cells after treatment when 
compared to HSEC (number of adherent cells binding under TNFα stimulation: 78.57±26.8 in 
HSEC and 55.7±9.73 in HUVEC and under TNFα plus methylamine stimulation: 100.2±24.9 
and 73.1±25.8 in HSEC and HUVEC respectively). 
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Figure 4.15 MAdCAM-1 expression supports JY cell adhesion in a flow-based adhesion assay 
to HSEC. Hepatic sinusoidal endothelial cells were treated with TNFα (20ng/ml) and methylamine 
(MA; 50µM) for 2 hours and JY cells were perfused over the monolayer at a shear stress of 0.05Pa. 
Adherent cells per field were counted and converted to adherent cells/mm2/106 perfused. (A) Total 
adhesion of JY cells in presence of TNFα and methylamine. Data represent mean ± SEM from 7 
different experiments. (B) Representative images captured from experimental videos. Statistical analysis 
performed by Student’s t-test (*P=0.02, **P=0.002). 
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Figure 4.16 Adhesion of JY cells to stimulated endothelium is α4β7-dependent. (A) Total 
adhesion data for binding of JY cells to HSEC stimulated with both TNFα and methylamine for 2 
hours. Where indicated, HSEC were treated with MAdCAM-1 function-blocking antibody (P1, 
10ng/ml) or JY cells were treated with anti-α4β7 ACT-1 antibody (50ng/ml, Millenium) for 30 min 
prior to experiment. Data represent mean adhesion ± SEM in 5 different experiments. (B) 
Representative images captured from experimental videos. Statistical analysis performed by one–way 
ANOVA analysis (*P=0.04. ***P=0.0006). 
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Figure 4.17 Isotype control antibodies have no effect on adhesion. HSEC were stimulated as 
before prior to treatment with control antibody IgG1 (5µg/ml, for 30min) and perfusion of JY cells at a 
shear stress of 0.05Pa. Data represent mean total number of adherent cells/mm2/106 perfused ± SEM in 
5 different experiments. 
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Figure 4.18 MAdCAM-1 expression supports JY cell adhesion to HUVEC. Human umbilical 
vein ECs were stimulated with TNFα (20ng/ml) and methylamine (MA; 50µM) for 2 hours and JY cells 
were perfused over the monolayer at a shear stress of 0.05Pa. Where indicated HUVEC were pretreated 
with anti-MAdCAM-1 P1 Ab (5µg/ml). Data represent mean total number of adherent cells/mm2/106 
perfused ± SEM in 3 different experiments. 
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4.3  DISCUSSION 
The fact that MAdCAM-1 is expressed in human liver endothelium in liver diseases associated 
with IBD, led us to investigate the factors responsible for this ectopic expression. This is 
important for disease pathogenesis because hepatic MAdCAM-1 has been shown to support the 
adhesion of α4β7+ gut associated lymphocytes (Grant et al., 2001), thus leading to sustained 
recruitment and chronic inflammation. In this study, we report that treatment of liver 
endothelial cells with the pro–inflammatory cytokine TNFα in combination with other 
stimulants can induce expression of functionally active MAdCAM-1. 
 
For the first time, our study shows constitutive MAdCAM-1 mRNA and protein expression in 
hepatic endothelial cells and umbilical vein endothelial cells cultured in vitro. A basal level of 
MAdCAM-1 mRNA was detected in both HSEC and HUVEC, which in the case of HSEC was 
significantly increased by TNFα (*P=0.02) and TNFα plus methylamine (*P=0.01) stimulation. 
An obvious difference in MAdCAM-1 mRNA levels induced by TNFα alone and TNFα plus 
methylamine was apparent, however although it did not reach statistical significance, suggests 
that methylamine may have an additive effect to that of TNFα in MAdCAM-1 up–regulation. 
The role of TNFα in inducing MAdCAM-1 expression in human hepatic endothelial cells has 
not been reported previously, however Ando T. et al. have demonstrated that TNFα can 
stimulate MAdCAM-1 in a dose– and time–dependent manner in a murine hepatic endothelial 
cell line (Ando et al., 2007). Moreover, in primary human intestinal microvascular endothelial 
cells, MAdCAM-1 has been reported to be strongly induced by TNFα (Lindholm et al., 
2004)(Ogawa et al., 2005) via activation of NF-κB (Oshima et al., 2001b)(Lindholm et al., 
2004)(Sasaki et al., 2002)(Takeuchi and Baichwal, 1995). TNFα has been also reported to 
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induce MAdCAM-1 in cultured HUVEC (Lindholm et al., 2004) which is in complete 
accordance with our findings, where in HUVEC the response to all stimulants [TNFα 
(***P=0.0002), methylamine (*P=0.04) and their combination (***P=0.0001)] was more 
pronounced. We believe that this could be because in HUVEC there is relatively little 
MAdCAM-1 expression under basal conditions, and such basal expression has not been 
reported before.  
 
The expression of MAdCAM-1 mRNA and protein was also supported by the promoter region 
DNA methylation analysis. In both HSEC and HUVEC, there was no significant differences in 
the methylation status between treated and non–treated endothelial cells indicating that the 
MAdCAM-1 gene is transcriptionally active in both states. This fits with our data showing that 
MAdCAM-1 protein is present in both HSEC and HUVEC even in the absence of stimulation. 
Interestingly, although TNFα and methylamine stimulation induced an increase in mRNA, 
protein levels remained the same under the different treatments as indicated by the percentage 
of intensity normalised to the endogenous levels of β–actin. In order to validate the presence of 
MAdCAM-1, the more sensitive technique of flow cytometry was used. MAdCAM-1 protein 
was again detected on the surface of HSEC isolated from different diseases. A variation in the 
expression levels between the different diseases was apparent. Specifically, in one set of HSEC 
from a PBC liver, the levels of membranous MAdCAM-1 were much higher than those in 
HSEC from a normal liver. However, this pattern was not consistent to a particular type of 
disease, suggesting that the background of the individuals that the livers came from might play 
an important role. Moreover, apart from the membrane bound protein, cytoplasmic protein 
was also detected. Interestingly, in accordance with our previous data, the cytometry confirmed 
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that the levels of cytoplasmic and membranous MAdCAM-1 protein were unchanged by 
treatment with TNFα or methylamine.  
 
The western blotting studies revealed that MAdCAM-1 protein of different molecular sizes was 
present in different cell compartments. A 60kDa protein, which represents the glycosylated 
monomer of MAdCAM-1, was detected only in the cytoplasm of HSEC, whereas MAdCAM-1 
protein of 120kDa and 180kDa was present in both membrane and cytoplasmic compartments. 
Additional studies of sub–compartmental analysis of MAdCAM-1 protein using membrane and 
cytoplasmic control proteins, will further enhance our current findings. Previous studies have 
reported that MAdCAM-1 can exist in a dimeric form (Dando et al., 2002) through an 
extensive interface formed by residues in the first Ig domain, which might be important for 
integrin recognition and binding. In support of this, higher levels of the dimeric form were 
detected at the membrane, consistent with a role in integrin recognition/binding at the cell 
surface. Dimerisation of Ig domains has been also previously observed in other proteins 
including human ICAM-1 (Reilly et al., 1995)(Casasnovas et al., 1998). Currently no studies 
report the presence of any MAdCAM-1 oligomers, however, a MAdCAM-1 protein of 180kDa 
was detected in our study, which we believe is a trimeric form of the glycosylated monomer. 
Intriguingly, it seems that the oligomerisation occurs after synthesis and post–translational 
modification, primarily through O–linked glycosylation on the membrane stalk extending 
beyond Ig domain II, and N–glycosylation within the Ig domain I (Asn61) (though the latter 
site has been reported as not essential for activity) (Tan et al., 1998). Both the dimeric and 
trimeric forms are also present in the cytoplasm. The mechanisms that regulate the 
oligomerisation of MAdCAM-1, the factors or signals that cause their transfer to the membrane 
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as well as the role of MAdCAM-1 oligomers, still remain unknown. One possible function of 
oligomerisation would be to confer mechanical stability upon interaction with ligands in the 
leukocyte recruitment process, as happens with selectins and their ligands (Alon and Rosen, 
2007). It should be noted that MAdCAM-1 protein in our positive control transfected CHO 
cells was of different molecular size (80kDa) to the endothelial form, which is probably due to 
the fact that CHO cells lack the appropriate glycosyltransferases responsible for glycosylation of 
MAdCAM-1. 
 
Our finding of constant levels of protein expression, despite increased mRNA levels was 
explained by the immunoprecipitation studies. Analysis of HSEC supernatants after 
stimulation, revealed the presence of a 60kDa soluble MAdCAM-1 protein, which was 
significantly increased after TNFα plus methylamine stimulation. This finding was in line with 
our previous findings (see chapter 3), where a brownish smear was apparent above all liver 
tissue samples. 
 
Release of soluble protein forms upon activation and their circulation in the blood has been 
reported for other adhesion molecules like E–selectin (Pigott et al., 1992)(Leeuwenberg et al., 
1992)(Newman et al., 1993), ICAM-1 (Seth et al., 1991)(Rothlein et al., 1991), VCAM-1 (Pigott 
et al., 1992)(Gearing et al., 1992), L–selectin (Schleiffenbaum et al., 1992)(Kahn et al., 1994), 
P–selectin (Dunlop et al., 1992)(Katayama et al., 1992) and VAP-1 (Abella et al., 2004). 
Generally, soluble adhesion molecules can be released either by enzymatic cleavage of the 
membrane–bound molecules by proteinases in a process named shedding, or can arise at the 
level of RNA processing by alternative splicing of mRNA resulting in a non–membrane bound 
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form that lacks transmembrane domain. The enzyme(s) that catalyse the cleavage of membrane–
bound forms of adhesion molecules are believed to include specific matrix metalloproteinases, 
expressed on the cell surface, containing a potential transmembrane domain at the C–terminus, 
which does not exist in other metalloproteinases (MMPs) (Sato et al., 1994). In case of L–
selectin it has been supported that its soluble form is a result of proteolytic cleavage near to the 
cell membrane by ADAM17 (TACE) and at least another “sheddase” (Smalley and Ley, 2005). 
Recent studies have also demonstrated that chemoattractant stimulation of neutrophils bound 
to E–selectin substrate, or to activated endothelium, results in ADAM17 and L–selectin 
redistribution and clustering to the trailing edge of cells (Schaff et al., 2008), validating the 
previous reports supporting that the L–selectin sheddase should be tightly associated with the 
membrane rather than being a secreted enzyme, since this molecule was found unable to cleave 
L–selectin from adjacent cells, and its function could be dictated by its precise location on the 
cell surface near to L–selectin (Preece et al., 1996).  
 
The soluble forms of E–selectin (Leeuwenberg et al., 1992), VCAM-1 (Pigott et al., 1992) 
(Gearing et al., 1992), ICAM-1 (Tsujisaki et al., 1991), and P–selectin (Katayama et al., 1992) 
are produced in a similar way. Generation of circulating forms of some of the above adhesion 
molecules, generated at the RNA level by alternative splicing, has been demonstrated for 
ICAM-1 (Seth et al., 1991)(Rothlein et al., 1991), P–selectin (Johnston et al., 1990)(Dunlop et 
al., 1992), and for platelet endothelial cell adhesion molecule–1 (PECAM-1) (Goldberger et al., 
1994). 
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The shedding of membrane–bound molecules might reduce their density on the membrane, 
thereby regulating the adhesiveness of cells carrying the relevant ligands. In addition, inhibition 
of adhesion could be also caused by competition between the functional soluble adhesion 
molecules and their membrane bound forms (Leeuwenberg et al., 1992). Regarding MAdCAM-
1, it is not clear if the soluble form detected in our experiments is a truncated form of the 
oligomeric surface expressed protein released by shedding, or is a different splice variant that 
does not contain the transmembrane domain. In our study, the molecular weight of the soluble 
MAdCAM-1 appeared the same as the monomeric protein. Thus we believe that the 
sMAdCAM-1 is produced either by cleavage of the oligomeric membrane bound protein or the 
monomeric form is transferred via vesicles from the cytoplasm where it seems to be stored, and 
released through the cell membrane. An alternatively spliced variant of MAdCAM-1 has been 
identified that lacks exon 4 encoding the mucin domain (Leung et al., 1996) but no splice 
variants lacking transmembrane domain have been reported, thus the generation of 
sMAdCAM-1 through proteolytic cleavage of membrane bound MAdCAM-1 or release of the 
monomeric form from the cytoplasm, appears more likely. Moreover, it is not clear if the 
soluble MAdCAM-1 released is biologically active.  
 
A possible purpose of shedding of membrane bound MAdCAM-1 could be to reduce the 
number of molecules expressed on the cell surface, thus decreasing the number of leukocytes 
recruited to the site. Another possible role for sMAdCAM-1 could be to interact with its 
receptor α4β7 integrin on leukocytes competing with the membrane bound form for the same 
receptor, thus preventing leukocyte recruitment. In addition, an in vivo role for sMAdCAM-1 
could be to facilitate de–adhesion of leukocytes bound to endothelium so that transendothelial 
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migration can occur, a role also suggested for other soluble adhesion molecules (Gamble et al., 
1990)(Seth et al., 1991)(Leeuwenberg et al., 1992)(Stoddart et al., 1996). Finally, sMAdCAM-1 
might result from endothelial activation and might not have any biological function. However, 
even in the absence of a physiological role the presence of soluble MAdCAM-1 in the serum 
and urine as previously reported (Leung et al., 2004), may be of value as an immunological 
marker for monitoring the state and progression of the inflammatory disorders in which it is 
involved. 
 
The treatment of HSEC with Brefeldin A (a chemical substance which prevents the transfer of 
newly synthesised proteins to the membrane) prior to TNFα and methylamine stimulation 
resulted in 45% more MAdCAM-1 protein accumulating in the cytoplasmic compartment 
when compared with stimulated cells without pre–treatment with Brefeldin A. This emerging 
evidence supports a model where new MAdCAM-1 protein is synthesised after stimulation, a 
portion of which remains in the cytoplasm and a portion is transferred to the membrane, then 
under as yet unknown mechanisms soluble MAdCAM-1 protein is released in the circulation.  
 
The function of MAdCAM-1 was determined using flow based adhesion assays, which revealed 
that MAdCAM-1 in untreated cells was non–functional as it did not support the recruitment of 
α4β7+ JY cells. However, when HSEC were stimulated with TNFα (*P=0.02) and its 
combination with methylamine (**P=0.002) there was a significant increase in the total number 
of adherent cells, which was inhibited by humanised anti–MAdCAM-1 monoclonal Ab (P1; 
***P=0.0006). Interestingly, the decrease in adherent cells was also seen after treatment with 
antibodies against the α4β7 integrin on the surface of JY cells (ACT-1; *P=0.04). However, in 
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both cases, there was residual binding of JY cells to the endothelium indicating that other 
adhesion molecules were also present. Indeed the JY cell line expresses α4β1 (B. M. Chan et al., 
1992) and LFA-1 (Dustin and Springer, 1988) whose ligands are VCAM-1 and ICAM-1, 
respectively. Up–regulation of ICAM-1 and VCAM-1 by hepatic sinusoidal endothelial cells 
upon TNFα stimulation has been previously demonstrated by our group (Adams et al., 1991) 
(Lalor et al., 2002a). Therefore, we believe that the adherence of JY cells observed under TNFα 
stimulation and after blocking MAdCAM-1 in the TNFα plus methylamine stimulated cells is 
due to ICAM-1 and VCAM-1. Similarly, in HUVEC, the number of adherent JY cells on TNFα 
and TNFα plus methylamine stimulated cells where MAdCAM-1 was blocked (with P1) were 
almost similar, also supporting that JY cells may adhere to other adhesion molecules such as 
ICAM-1 and VCAM-1, which are both expressed on HUVEC treated with TNFα (Zhou et al., 
2007). In HUVEC as well, increased levels of adherent cells were observed under TNFα and 
methylamine stimulation, which however did not achieve statistical significance. Of note, 
unstimulated HUVEC supported higher levels of adhesion (20.8±3.8) compared to HSEC 
(4.6±1.9) (adherent cells/mm2/106 cells perfused ± SEM), which might suggest differences in 
basal expression of adhesion molecules other than MAdCAM-1. In accordance with our 
findings in the previous chapter (see chapter 3), our data suggest that under non–inflamed 
conditions MAdCAM-1 in HSEC and HUVEC is present in a non–functional state that cannot 
support leukocyte recruitment. 
 
However, under inflammatory conditions, TNFα induces MAdCAM-1 expression, which in the 
presence of methylamine adopts a functional conformation, possibly by mechanisms similar to 
integrin activation through folding alterations from a low–affinity bent form to a high–affinity 
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and extended form where the ligand–binding “pocket” opens, leading to leukocyte–integrin 
recognition and binding. Methylamine is a primary amine produced endogenously by the 
metabolism of adrenaline, sarcosine, creatinine and lecithin or exogenously by ingestion from 
food, wine and cigarette smoke (Pirisino et al., 2001). Therefore, we propose that consumption 
of compounds rich in methylamine would lead to increased levels entering the liver through the 
portal vein. Here, methylamine could be catabolised by VAP-1 triggering the conformational 
change of MAdCAM-1 to a functional adhesion molecule. This would also explain the 
prominent staining for MAdCAM-1 we observed in the endothelium of portal vessels (see 
chapter 3). In support of this, experimental and clinical studies highlight the importance of 
methylamine, as well as ammonium and other basic compounds such as neurotoxins, which are 
increased in liver or renal diseases or Alzheimer’s disease and vascular dementia (Pirisino et al., 
2004). Thus, dietary habits or changes in nutrients in portal blood as a consequence of colitis 
might contribute to ectopic MAdCAM-1 expression and the “entero-hepatic” recirculation of 
lymphocytes.  
 
In conclusion, in this chapter we describe the constitutive presence of MAdCAM-1 in both 
HSEC and HUVEC. TNFα and methylamine treatment significantly increased MAdCAM-1 
mRNA levels which were translated into protein, part of which were transferred into the 
membrane where the surface expressed protein seemed to be cleaved in order to release soluble 
MAdCAM-1, and part remained in the cytoplasm, where it was post–translationally modified 
(Figure 4.20). Interestingly, the MAdCAM-1 protein present on unstimulated endothelial cells 
was non–functional being unable to support the binding of α4β7+ JY cells, whereas under 
TNFα and methylamine stimulation elevated functional MAdCAM-1 protein levels led to an 
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increase in the total number of adherent cells, which was decreased after blockade of either 
MAdCAM-1 or its ligand α4β7 integrin.  
 
 
 
 
Figure 4.19 MAdCAM-1 expression in endothelial cells. Under normal conditions MAdCAM-1 
mRNA and protein are present in endothelial cells. In the cytoplasmic compartment as well as in the 
surface, MAdCAM-1 protein of different molecular weights is present. Under stimulation with TNFα 
alone or in combination with methylamine, intracellular signalling pathways seem to be activated 
through VAP-1 and TNFR, that lead to NF-κB transcription factor activation and subsequently to the 
increased production of MAdCAM-1 mRNA levels. MAdCAM-1 protein of 60kDa, 120kDa and 
180kDa is synthesised and part of it is transferred to the membrane where previously surface expressed 
protein seems to be cleaved to secrete soluble form of MAdCAM-1. Another potential pathway for 
sMAdCAM-1 could be the transfer of the 60kDa monomer from the cytoplasm through the cell 
membrane to the circulation. 
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CHAPTER 5  
 
ROLE OF VAP-1 ENZYMATIC ACTIVITY IN MADCAM-1 EXPRESSION IN HUMAN 
HEPATIC SINUSOIDAL ENDOTHELIAL CELLS 
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5.1  INTRODUCTION 
VAP-1 is a membrane bound homodimeric protein composed of two identical 90kDa subunits. 
It is constitutively expressed on the luminal surface of high endothelial venules of peripheral 
lymph nodes and tonsils, as well as within the cytoplasm of discrete venules, indicating that it is 
stored intracellularly (Jalkanen and Salmi, 1993). VAP-1 is also detected on hepatic sinusoidal 
endothelial cells and in other vascular endothelial cells particularly at sites of inflammation. 
Weak staining of VAP-1 has been reported in the high endothelial venules of Peyer’s patches 
and the flat walled vessels within the lamina propria (McNab et al., 1996). VAP-1 is not 
restricted to endothelial cells since it is also detected in the smooth muscle cells of arteries, the 
bowel wall and in adipocytes, pericytes and follicular dendritic cells within germinal centres 
(Salmi et al., 1993)(Jaakkola et al., 1999), but VAP-1 expression has not been reported on 
leukocytes or epithelial cells (Salmi et al., 1993). Interestingly, under inflammatory conditions 
VAP-1 is rapidly up–regulated in non–lymphoid tissue such as the skin and synovium, gut and 
heart (Salmi et al., 1993)(Arvilommi et al., 1996)(Smith et al., 1998).  
 
VAP-1 is an endothelial adhesion molecule that supports leukocyte rolling, firm adhesion and 
transmigration (Tohka et al., 2001)(Lalor et al., 2002a)(Salmi and Jalkanen, 2006). Of note, 
VAP-1 can operate in an L–selectin independent manner supporting the binding of both L–
selectin negative and L–selectin positive lymphocytes via sialic acids present on oligosaccharides 
in the extracellular domain, which are important for lymphocyte binding (Salmi and Jalkanen, 
1996). VAP-1 can also mediate leukocyte subtype–specific adhesion. Among mononuclear cells, 
the VAP-1 dependent pathway is important for binding of CD8+ T killer cells and natural killer 
cells but early studies suggested not for B cells or monocytes (Salmi et al., 1997). However 
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controversy remains concerning which particular leukocytes subsets can interact with VAP-1, 
and recent studies including those from our own group, have demonstrated that VAP-1 
supports monocyte transendothelial migration in vitro and in vivo to sites of inflammation in 
models of air pouch inflammation (Merinen et al., 2005), and CD4+ Th2 helper cell adhesion 
in hepatic post–sinusoidal venules and sinusoids during ConA induced inflammation (Bonder 
et al., 2005). 
 
What is particularly interesting about this molecule is its enzymatic activity. Cloning of VAP-1 in 
1998 (Smith et al., 1998) revealed significant sequence similarity to the copper–containing amine 
oxidases, which are a subfamily of monoamine oxidases. Therefore, apart from being an 
endothelial adhesion molecule, VAP-1 is also an enzyme, or more accurately an ectoenzyme, as its 
extracellular domain contains its catalytic activity (Jalkanen and Salmi, 2001). VAP-1 catalyses the 
general reaction: 
 
in which a primary amine is oxidatively deaminated to the corresponding aldehyde with a 
simultaneous release of hydrogen peroxide and ammonia (Salmi and Jalkanen, 2001). More 
precisely, this reaction consists of two stages. In the reductive half reaction, the NH2–group of the 
substrate (primary amine) binds to the topa–quinone cofactor located in the active site of the 
enzyme, leading to the formation of a covalent Schiff base between the enzyme and the substrate 
and the release of an aldehyde. Thereafter, in the oxidative half reaction, the enzyme is re–
oxidised by the reaction with molecular oxygen resulting in the release of H2O2 and NH3 
(Jalkanen and Salmi, 2008). 
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All the end products released as a result of oxidative deamination of primary amines by VAP-
1/SSAO are biologically active. The H2O2 end product is particularly significant, as this reactive 
oxygen species is toxic at higher concentrations, whereas at lower concentrations it has been 
recognised as a signal–transducing element (Schreck et al., 1991)(Schreck et al., 1992)(Finkel, 
1998)(Kunsch and Medford, 1999)(Bogdan et al., 2000), and has been shown to be involved in 
up–regulation of adhesion molecules such as P–selectin and E–selectin (Jalkanen et al., 2007), 
and ICAM-1 (Bradley et al., 1993). 
 
All amines can be substrates for VAP-1 but the most widely used substrate in experimental 
procedures is benzylamine, which is not physiological. In vivo, at least two endogenously formed 
amines, methylamine and aminoacetone, can serve as VAP-1/SSAO substrates. Methylamine is 
formed during endogenous degradation of sarcosine, creatinine, lecithin and adrenaline, and its 
oxidation results in the formation of formaldehyde (Pirisino et al., 2001). Aminoacetone is 
produced from the metabolism of glycine or threonine, and the corresponding aldehyde is 
methylglyoxal (2–oxopropanal). Both formaldehyde and methylglyoxal are potentially toxic 
(O'Sullivan et al., 2004). 
 
As well as the membrane bound form of VAP-1, soluble enzymatically active VAP-1 has been also 
reported. sVAP-1 is found in the serum of healthy individuals and levels are increased in patients 
with certain inflammatory conditions particularly inflammatory liver diseases (Kurkijarvi et al., 
1998). Precisely, higher levels of sVAP-1 are detected in the livers of patients with active cirrhosis 
due to ALD, and lower levels in patients with PBC. However, in patients with PSC, the levels of 
sVAP-1 have not been reported to significantly differ from those in serum of normal individuals. 
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On the other hand, in the inflammatory diseases of rheumatoid arthritis and inflammatory bowel 
diseases not elevated levels of sVAP-1 have been reported (Kurkijarvi et al., 1998). 
 
As there is a precedent role for the metabolites of VAP-1 enzyme activity promoting adhesion 
molecule up–regulation, it was investigated whether the effects of methylamine on MAdCAM-1 
expression observed in the previous chapter were due to VAP-1 enzymatic activity. Initially, the 
ability of VAP-1 expressing HSEC to up–regulate MAdCAM-1 expression after methylamine and 
TNFα stimulation was tested, using HSEC transduced with adenoviral constructs to ensure 
maximal VAP-1 expression for these experiments. Finally, the effects of the end products of 
methylamine deamination by VAP-1 (hydrogen peroxide, ammonia and formaldehyde) on 
MAdCAM-1 expression by HSEC were investigated.  
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5.2  RESULTS 
5.2.1 Confirmation of The Enzymatic Capacities of our VAP-1 Adenoviral Constructs 
The two adenoviral constructs that were used were described in section 2.14.2. In particular, 
the enzymatically inactive VAP-1 construct contained a single amino acid change at position 
471, which changed a tyrosine residue to a phenylalanine rendering the protein enzymatically 
non–functional. We began by testing whether the adenoviral constructs we were supplied with, 
were indeed enzymatically active and inactive respectively, by using the Amplex Red assay. Here 
H2O2 released upon VAP-1 activity reacts with HRP and the Amplex Red reagent to produce a 
red fluorescent signal. HSEC were infected with adenoviral constructs containing wild–type 
hVAP-1 (hVAP-1), enzymatically dead (hVAP-1_Y471F), or constructs without any VAP-1 
(LacZ). Non–infected HSEC were used as controls. When HSEC transfected with wild–type 
hVAP-1 were exposed to benzylamine a signal was detected over the 3 hour period (Figure 5.1A 
shows the first 80 minutes of the reaction), which was not observed for HSEC transfected with 
hVAP-1 mutant or LacZ vectors or in non–transfected cells. This signal was abolished when the 
endothelial cells were additionally treated with bromoethylamine (BEA), the SSAO activity 
inhibitor (Figure 5.1B). 
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Figure 5.1 Cells transfected with wild-type VAP-1 adenoviral constructs produce 
enzymatically active hVAP-1. HSEC seeded on 24-well plates were transfected with adenoviral 
constructs containing wild-type hVAP-1, an enzymatically dead mutant of hVAP-1 (hVAP-1_Y471F) or 
adenoviral constructs without any hVAP-1 (only LacZ), at a plasticity of 600pfu/cell. Non-transfected 
HSEC were used as an additional control. (A) Cells were treated with 2mM benzylamine and (B) with 
benzylamine and 400µM SSAO inhibitor 5’ bromoethylamine (BEA), and generation of H2O2 was 
detected using Amplex Red reagent. Data represent mean of triplicate wells for each sample in 
representative experiment. y axis shows the fluorescent signal released (signal x 103) over the time (x axis). 
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5.2.2 Role of VAP-1/SSAO Enzymatic Activity In Expression of MAdCAM-1 
Hepatic sinusoidal endothelial cells were transfected with the adenoviral vectors described 
above and VAP-1 expression was confirmed by flow cytometry. Figure 5.2 and Table 5.1 show 
that greater than 95% of cells stained positively for hVAP-1 and hVAP-1_Y471F and that the 
median channel fluorescence (MCF) values were similar for both hVAP-1 and hVAP-1_Y471F 
constructs. We noted that not all endothelial cells accepted transduction with wild–type hVAP-
1 adenoviral vector in the same way. In particular, a set of HSEC isolated from an AIH liver 
appeared apoptotic and detached from culture surface after transfection (Figure 5.3B), whereas 
another HSEC isolate from a PBC liver appeared normal after transduction with the same 
vector (Figure 5.3A).  
 
Non–transfected HSEC, and HSEC transfected with the adenoviral constructs were treated 
with methylamine and TNFα either alone or in combination for 2 hours prior to analysis of 
MAdCAM-1 mRNA and protein expression. In non–transfected HSEC statistically significant 
elevated MAdCAM-1 mRNA levels were observed (*P<0.05)(Figure 5.4A), whereas the 
endothelial cells transfected with either enzymatically active or enzymatically dead hVAP-1 
responded similarly after TNFα alone or TNFα plus methylamine stimulation. In both cases a 
15–fold increase in MAdCAM-1 mRNA levels was observed (Figure 5.4B). Although there was 
no detectable difference in the effect of enzymatically active and dead mutant hVAP-1 at the 
transcription level, increased levels of MAdCAM-1 protein were observed in HSEC transfected 
with the wild–type hVAP-1 (Figure 5.5). In HSEC transduced with enzymatically active hVAP-1 
there was an obvious increase in MAdCAM-1 protein levels when compared with HSEC 
transfected with the hVAP-1 mutant and non–transfected HSEC (Figure 5.5). Western blotting 
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experiments also revealed that the trimeric form of MAdCAM-1 (180kDa) was present in 4 out 
of the 7 cases tested (Figure 5.6, Table 5.2). The specificity of the band was confirmed by 
staining with an isotype–matched control antibody. 
 
 
 
Figure 5.2 Confirmation of VAP-1 positivity of transfected cells. HSEC were transfected with 
adenoviral constructs containing wild-type hVAP-1 or an enzymatically inactive mutant of hVAP-1 
(hVAP-1_Y471F) and stained with anti-VAP-1 or negative control mouse anti-human antibodies prior to 
FACs analysis. Representative data for 7 different HSEC. 
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HSEC+hVAP-1 % POSITIVE CELLS MCF 
Control 96.62 ± 1.38 197.58 ± 40.35 
TNFα 97.11 ± 0.83 201.04 ± 47.18 
MA 96.12 ± 2.09 206.60 ± 53.01 
TNFα+MA 95.35 ± 2.93 212.83 ± 63.36 
HSEC+hVAP-1_Y471F % POSITIVE CELLS MCF 
Control 95.57 ± 2.06 216.75 ± 40.02 
TNFα 97.18 ± 1.44 215.16 ± 39.02 
MA 91.68 ± 6.85 202.17 ± 34.49 
TNFα+MA 98.03 ± 0.67 199. 14 ± 22.25 
 
Table 5.1 Expression of VAP-1 after treatment of transduced HSEC. Pooled data from n=7 
different HSEC transfected with adenoviral constructs containing wild-type hVAP-1 
(HSEC+hVAP-1) or enzymatically-dead mutant hVAP-1 (HSEC+hVAP-1_Y471F), showing 
mean values ± SEM for percentage of positive cells and median channel fluorescence (MCF) 
for VAP-1 staining of HSEC. 
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Figure 5.3 Representative images of cell morphology after adenoviral transfection. Selected images of HSEC after transfection with adenoviral 
constructs containing wild-type hVAP-1, enzymatically inactive hVAP-1 (hVAP-1_Y471F) or LacZ. HSEC that were not transfected were used as positive 
control. HSEC isolated from (A) PBC and (B) AIH liver. Pictures obtained with a 20x and 10x objectives in (A) and (B) respectively. 
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Figure 5.4 MAdCAM-1 mRNA expression in HSEC after adenoviral transfection. Non–
transfected HSEC, and HSEC transfected with hVAP-1 enzymatically active or hVAP-1_Y471F, an 
enzymatically inactive mutant of hVAP-1, were stimulated with TNFα (20ng/ml) or methylamine (MA; 
50µM) alone or in combination for 2 hours prior to RNA extraction and mRNA expression analysis 
using quantitative PCR. Data represent the N-fold change in MAdCAM-1 mRNA expression levels 
(mean ± SEM) from n=8 different HSEC (3PBC, 1AIH, 1NL, 3Resected). (A) MAdCAM-1 mRNA levels 
expressed relatively to non–transfected and untreated HSEC. (B) MAdCAM-1 mRNA levels expressed 
relatively to untreated HSEC transfected with hVAP-1_Y471F. Statistical analysis performed by 
Student’s t-test (*P<0.05). 
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Figure 5.5 MAdCAM-1 protein expression in transfected HSEC. HSEC transfected with 
adenoviral constructs containing wild-type hVAP-1 or enzymatically dead hVAP-1 (hVAP-1_Y471F), as 
well as non-transfected HSEC, were stimulated with TNFα (20ng/ml) or methylamine (MA; 50µM) 
alone or in combination for 2 hours, prior to protein lysis and western blot analysis. (A) Data represent 
percentage of MAdCAM-1 protein expression relatively to endogenous β-actin levels, compared to 
expression in un–stimulated and non-transfected HSEC, (Cntr; set to 100%). Data represent mean ± 
SEM of percentage of relative intensity from n=7 different HSEC (3NR, 3PBC, 1AIH). (B) 
Representative image after western blot analysis. CHO cells were used as positive control and JY cells as 
negative control.  
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Figure 5.6 MAdCAM-1 of 180kDa molecular size is apparent in HSEC. HSEC transfected with 
adenoviral constructs containing wild-type hVAP-1 or enzymatically dead hVAP-1 (hVAP-1_Y471F), as 
well as non-transfected HSEC, were stimulated with TNFα (20ng/ml) or methylamine (MA; 50µM) 
alone or in combination for 2 hours, prior to protein lysis and western blot analysis. Representative 
images of MAdCAM-1 expression after western blot analysis from two different (A) and (B) HSEC 
isolates. (C) Representative image after striping and re-probing membranes with an isotype–matched 
control antibody (3G6). CHO cells were used as positive control and JY cells as negative control.  
 
LIVER MOLECULAR WEIGHT OF MADCAM-1 PROTEIN DETECTED 
 120kDa 180kDa 
Resected Liver 1 + - 
Resected Liver 2 + + 
Resected Liver 3 + + 
PBC 1 + - 
PBC 2 + + 
PBC 3 + + 
AIH + - 
 
Table 5.2 Expression of different MAdCAM-1 proteins in HSEC isolates. Table represents 
pooled data from n=7 HSEC from different liver diseases (3 Resected non-diseased, 3PBC, 
1AIH) and summarises the nature of MAdCAM-1 protein species found in each isolate.  
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5.2.3 The End Products of VAP-1 Enzyme Activity Induce MAdCAM-1 Expression in 
HSEC 
In order to further investigate the effects of VAP-1 enzymatic activity on MAdCAM-1 
expression, the direct effects of the end products released after the oxidative deamination of 
methylamine by VAP-1, were studied. Non–transfected HSEC were stimulated with hydrogen 
peroxide (H2O2), formaldehyde (HCHO) and ammonia (NH3) for 4 hours. Fresh H2O2 was 
added every 30min, in order to compensate for loss due to decomposition by endogenous cell 
peroxidases. The results show that the combination of all three end products used at a dose of 
10µM significantly increased MAdCAM-1 expression (*P=0.04) (Figure 5.7). Interestingly, when 
enzymatically active sVAP-1 and methylamine were administered directly to HSEC in order to 
generate end products in real–time in situ, MAdCAM-1 expression was induced in the same 
pattern (Figure 5.8). 
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Figure 5.7 End products of VAP-1 enzyme activity induce MAdCAM-1 expression by HSEC. 
Non-transfected HSEC were stimulated with single doses of hydrogen peroxide (H2O2), formaldehyde 
(HCHO) and ammonia (NH3) at 1 and 10µM for 4 hours. Where indicated, HSEC were treated 
repeatedly with 10µM H2O2 (x8 every 30min) or with the combination of all three end products (each at 
1µM or 10µM, single dose, H2O2 repeatedly). RNA was extracted from cells and MAdCAM-1 mRNA 
expression was measured using real-time PCR. Data represent relative expression of treated versus non- 
treated HSEC [mean ± SEM from n=9 different HSEC (2NL, 3NR, 3PBC, 1AIH)]. Statistical analysis 
performed by Student’s t-test (*P=0.04). 
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Figure 5.8 End products of methylamine deamination by VAP-1 produced locally or 
exogenously added, induce MAdCAM-1 expression in HSEC. Non-transfected HSEC were 
stimulated with single doses of hydrogen peroxide (H2O2), formaldehyde (HCHO) and ammonia (NH3) 
at 1 and 10µM for 4 hours. Where indicated, HSEC were treated repeatedly with 10µM H2O2 (x8 every 
30min) or with the combination of all three end products (each at 1µM or 10µM, single dose, H2O2 
repeatedly). In separate wells, HSEC were stimulated with sVAP-1 (500ng/ml) and methylamine (MA) at 
1 and 10µM for 4 hours. RNA was extracted from all cells and MAdCAM-1 mRNA expression was 
measured using quantitative PCR. Representative graph for one sample of HSEC showing the response 
of non-transfected cells to sVAP-1 and methylamine. Data represent relative expression of treated versus 
non-treated HSEC (mean ± SEM of a triplicate). 
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5.3  DISCUSSION 
In this study adenoviral constructs containing human wild–type and mutant VAP-1, which were 
enzymatically active and inactive respectively, were used. In the mutant version a single amino 
acid change at position 471, changed a tyrosine residue into a phenylalanine rendering the 
protein enzymatically dead. The tyrosine residue is the precursor of the topa–quinone, the 
organic cofactor of the SSAO, which is located in the active site of the enzyme and plays a key 
role in the first half of the enzymatic reaction. Phenylalanine cannot be processed into topa–
quinone meaning that this amino acid change (Y471F) encodes an enzymatically dead mutant, 
which is structurally similar to VAP-1 (Koskinen et al., 2004). The activity states of the two 
constructs were confirmed using the Amplex Red Assay. These viruses have previously been 
used by Jalkanen et al. in human umbilical vein endothelial cells to show the role of VAP-
1/SSAO activity on P– and E– selectin expression (Jalkanen et al., 2007) and here, they were 
used in order to confirm the role of VAP-1 in MAdCAM-1 expression. 
 
Interestingly, one sample of HSEC transfected with the wild–type hVAP-1 construct, showed 
dramatic morphological change and cell apoptosis, whilst others appeared unaffected by 
transfection. This may suggest as yet unidentified, disease specific changes inherent in isolated 
endothelial cells, which render them particularly sensitive to products of VAP-1 metabolism. 
However, since that effect was obvious in only 1/7 livers tested it is not feasible to draw a 
general conclusion regarding the role of VAP-1/SSAO in a particular liver disease. The higher 
molecular weight species of MAdCAM-1 protein (180kDa) was detected in 4 out of 7 samples 
suggesting that there may be disease–specific differences between endothelial isolates which may 
alter protein expression or function. It is not clear yet why some cells express the trimeric 
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MAdCAM-1 and some do not and the sample numbers in the current study are too small to 
draw disease–specific conclusions. 
 
MAdCAM-1 mRNA levels appeared almost similar between the cells transduced with wild–type 
hVAP-1 and the cells transduced with the mutant hVAP-1 with no statistically significant 
differences among them. Statistical analysis revealed significantly elevated levels under TNFα 
and TNFα plus methylamine stimulation (*P<0.05) (Figure 5.4B) in both hVAP-1 and hVAP-1 
mutant transfected cells, suggesting that the enzymatic activity of VAP-1 has little effect or no 
effect on MAdCAM-1 expression in HSEC. It should be noted, that the transfection of HSEC 
with the adenoviral constructs occurred in human serum free medium, as it is known that 
sVAP-1 is present in the human serum and its presence prevents transfection. Recent 
unpublished studies from our group (C. Weston et al.) demonstrate the ability of HSEC to take 
up sVAP-1 from circulation and present it on the endothelial cell surface where it retains its 
enzymatic function. Since the endothelial cells were cultured in complete endothelial medium 
containing human serum after transfection in order to help them recover from the shock of the 
procedure, it is possible that the induction of MAdCAM-1 mRNA expression seen in the 
presence of mutant hVAP-1 was due to the sVAP-1 from serum that was presented on the 
endothelial cells. Thus the magnitude of MAdCAM-1 mRNA expression in cells transduced 
with mutant hVAP-1 may decrease if the experiments were performed in sera depleted of sVAP-
1. 
 
In support of this hypothesis and in contrast to the relative mRNA expression data, cells that 
were transfected with enzymatically active hVAP-1 expressed more MAdCAM-1 protein when 
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compared with non–transfected cells and cells transfected with enzymatically inactive hVAP-1, 
suggesting that VAP-1/SSAO is involved in the translational or post–translational regulation of 
MAdCAM-1 expression rather than in transcriptional or post–transcriptional regulation.  
 
Our data from non–transfected HSEC validate the role of the VAP-1/SSAO activity in 
MAdCAM-1 up–regulation. The combination of all the three potential end products either 
when added exogenously or when locally generated in real–time by sVAP-1 and methylamine, 
significantly induced MAdCAM-1 expression in HSEC (*P=0.04). Many studies now implicate 
H2O2 in the regulation of adhesion molecule expression. In particular, the hydrogen peroxide 
either alone or in combination with the other end products released by VAP-1/SSAO 
deamination reaction, has been shown to modulate endothelial expression of E–selectin and P–
selectin (Jalkanen et al., 2007). Moreover, a variety of studies have supported the ability of the 
reactive oxidant H2O2 to induce endothelial cell expression of ICAM-1 as well as ICAM-1 
dependent adhesion of polymorphonuclear cells (Lo et al., 1993)(Bradley et al., 1993)(Ichikawa 
et al., 1997)(Ng et al., 2002), and induction of ICAM-1 expression on human epidermal 
keratinocytes (Ikeda et al., 1994). The role of H2O2 in induction of ICAM-1 expression in 
human umbilical vein endothelial cells, as well as in induction of P–selectin has been also 
reported (Patel et al., 1991)(Lo et al., 1993). Of note, it has been demonstrated that H2O2 
activates ICAM-1 gene transcription via AP-1 (composed of Jun and Fos protein dimers) and 
Ets transcription factors, but not via NF-κB (Roebuck et al., 1995). In contrast to H2O2, TNFα 
could induce ICAM-1 transcription via activation of promoter sequences containing C/EBP 
and NF-κB binding elements. The ability of H2O2 to activate the AP-1 and NF-κB transcription 
factors has been also reported in mouse osteoblastic cells in HeLa and Jurkat cells (Nose et al., 
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1991), and in T cells H2O2 activates the AP-1 signal transduction pathway through tyrosine 
phosphorylation of kinase intermediates (K. Nakamura et al., 1993a). Although, it appears that 
H2O2 cannot induce ICAM-1 activation through NF-κB, Schreck et al. have reported that in 
some cell lines H2O2 activates NF-κB, possibly through post–translational modification of the 
NF-κB subunits themselves or by regulation of other transcriptional cofactors that influence the 
transcriptional activity of NF-κB (Schreck et al., 1991). These data support the presence of 
distinct intracellular regulatory mechanisms involving unique sequence elements within the 
promoter region of a gene. Interestingly, although Bradley et al. showed that H2O2 did not 
induce endothelial expression of E–selectin and VCAM-1, Marui et al. demonstrated that when 
using the antioxidant pyrrolidine dithiocarbamate (PDTC, an inhibitor of H2O2), the activation 
of VCAM-1 transcription and expression in HUVEC was inhibited through inhibition of NF-
κB regulatory proteins (Bradley et al., 1993)(Marui et al., 1993). Studies of the human VCAM-1 
promoter region have suggested that activation of VCAM-1 transcription in endothelial cells by 
TNFα is dependent at least in part on the activation of NF-κB (Iademarco et al., 1992)(Neish et 
al., 1992). Thus, although some of the above data are controversial, there is a precedent role for 
H2O2 to alter adhesion molecule expression in endothelial cells via activation of different 
transcription factors, and thus similar mechanisms may operate in case of MAdCAM-1 when 
HSEC are stimulated with hydrogen peroxide, since MAdCAM-1 promoter region contains NF-
κB transcription factor sites. In support of this, recent studies from our group (Lalor et al., 
2002a) show that the H2O2 produced during VAP-1 mediated amine oxidation induces 
expression of P– and E–selectin, ICAM-1 and VCAM-1 and a chemokine CXCL8 by 
stimulating the PI3K, MAPK and NF-κB pathways.  
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We believe that our study supports the hypothesis that the H2O2 released from the deamination 
reaction between VAP-1/SSAO and its substrate methylamine activates NF-κB and its binding 
element on the promoter region of MAdCAM-1 (Leung et al., 1997). Moreover, TNFα a 
classical activator of NF-κB also induced expression of MAdCAM-1, which supports NF-κB–
dependent regulation of MAdCAM-1 transcription (Figure 4.19). Although it is not clear how 
formaldehyde and ammonia could induce MAdCAM-1 expression, other studies suggest that 
released aldehydes can function as direct cross–linkers between endothelial cells and 
lymphocytes. Ammonium ion generated by ammonia can be transported through cell 
membranes by special transporter proteins (Biver et al., 2008) and be processed in the liver, 
kidneys and skeletal muscles for conversion into urea and to glutamine.  
 
In conclusion, in this chapter the role of methylamine in induction of MAdCAM-1 expression 
in hepatic endothelial cells was validated, since the use of adenoviral constructs containing 
enzymatically active and inactive hVAP-1 demonstrated that the end products of methylamine 
deamination by VAP-1 are responsible for MAdCAM-1 expression. 
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CHAPTER 6  
 
MADCAM-1 EXPRESSION IN MICE 
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6.1  INTRODUCTION 
Murine MAdCAM-1 is a 60kDa endothelial cell surface molecule, member of the Ig 
immunoglobulin supergene family, selectively expressed in mesenteric lymph nodes, high 
endothelial venules of Peyer’s patches, lamina propria of the small and large intestine, in the 
lactating mammary gland (Shyjan et al., 1996), spleen (Kraal et al., 1995) and very weakly in 
pancreas (Hanninen et al., 1993) and brain (O'Neill et al., 1991). 
 
An abundance of murine models support the contribution of MAdCAM-1 and its ligand α4β7 
to lymphocyte homing to the gut (Schweighoffer et al., 1993) and chronically inflamed 
intestines (Arihiro et al., 2002). Interestingly, the functional significance of elevated levels of 
MAdCAM-1 protein in chronic inflammatory diseases is supported by several reports which 
show that immunoneutralisation of either MAdCAM-1 or its ligand α4β7 integrin, causes 
attenuation of inflammation and mucosal damage in animal models (Fong et al., 1997)(Kato et 
al., 2000), as well as in patients with colitis (Ghosh et al., 2003)(Feagan et al., 2005), and 
Crohn’s disease (Guagnozzi and Caprilli, 2008)(Feagan et al., 2008). 
 
The induction of VAP-1 in inflamed gut where MAdCAM-1 is expressed and the induction of 
MAdCAM-1 in chronically inflamed liver tissues where VAP-1 is normally expressed led us to 
investigate the role of VAP-1/SSAO activity in MAdCAM-1 expression. The results in the 
previous chapter show that the end products released from the enzymatic reaction of VAP-1 
with its substrate methylamine induce MAdCAM-1 expression in primary cultures of human 
hepatic endothelial cells. In the studies described in this chapter it was investigated whether 
VAP-1/SSAO would have a similar role in induction of MAdCAM-1 expression in vivo. 
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6.2  RESULTS 
6.2.1  VAP-1/SSAO induces MAdCAM-1 expression in PPs and MLN 
To investigate the role of VAP-1/SSAO dependent methylamine deamination on MAdCAM-1 
expression in vivo, we used mouse models available in Prof. Jalkanen’s group in Turku, Finland. 
We used wild–type mice, VAP-1 deficient mice (VAP-1_KO) and murine VAP-1 deficient mice 
that expressed hVAP-1 as a transgene on endothelial cells (the cDNA for hVAP-1 was inserted 
under the control of the mouse Tie-1 promoter). The hVAP-1 transgene was provided as both 
enzymatically active and enzymatically inactive forms in different mice. We used these model 
systems to test whether in vivo VAP-1 enzymatic activity can induce MAdCAM-1 expression 
when supplied with methylamine (exogenously provided to the animals in drinking water for 14 
days). 
 
The expression of human VAP-1 in transgenic murine endothelial cells was confirmed by 
immunofluorescent staining (Figure 6.1) of several organs [Peyer’s patches (PPs), liver and 
spleen]. We then exposed our mice to methylamine treatment and investigated the effects on 
MAdCAM-1 expression. Immunofluorescent staining revealed MAdCAM-1 expression in the 
high endothelial venules of PPs and MLN (Figure 6.2) and in the sinus–lining endothelial cells 
surrounding the splenic lymphoid white pulp (Figure 6.4) in all mice both before and after 
methylamine stimulation. Interestingly no MAdCAM-1 protein was detected in murine livers 
either before or after methylamine treatment (Figure 6.3). Western blotting confirmed also this 
pattern of protein expression. MAdCAM-1 was completely absent from the livers and kidneys 
of all mice studied. In PPs, MLN and spleen however high levels of MAdCAM-1 protein were 
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observed. Re–probing of the same membranes for actin expression, confirmed the presence of 
protein in the liver and kidney samples (Figure 6.5).  
 
Relative mRNA expression analysis performed by quantitative PCR revealed significantly 
elevated MAdCAM-1 mRNA levels in PPs and MLN after methylamine stimulation of 
transgenic animals expressing enzymatically active hVAP-1, when compared with wild–type 
mice that were not given methylamine. In PPs a 10–fold change, and in MLN a 16–fold change 
in MAdCAM-1 mRNA levels were observed. Interestingly, MAdCAM-1 mRNA levels were 
significantly diminished in MLN of the transgenic animals expressing the enzymatically dead 
form of VAP-1 (compared to those with the active forms). Similarly, an obvious decrease was 
noted in mRNA levels in the PPs of VAP-1_EI mice but this was not statistically significant 
(Figure 6.6A and 6.6B). MAdCAM-1 mRNA was also significantly increased in the spleen of 
VAP-1_EA and VAP-1_EI mice relative to untreated WT mice. Again relative expression 
analysis suggested no changes in MAdCAM-1 mRNA levels in murine liver (Figure 6.6D) 
(Figure 6.7). This lack of inducibility of MAdCAM-1 in the liver was also observed under 
inflammatory conditions in mice exposed to Concavalin A induced hepatitis. Here MAdCAM-
1 mRNA levels were unchanged by induction of hepatitis in either VAP-1 deficient mice or 
VAP-1 deficient mice expressing human VAP-1 as a transgene (Figure 6.8). 
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Figure 6.1 In vivo expression of hVAP-1 by transgenic mice. Representative images of 
immunofluorescent staining of Peyer’s patches, liver and spleen of VAP-1 deficient mice that expressed 
hVAP-1 enzymatically active as a transgene. Murine tissues were stained with anti-human VAP-1 (left 
panels) or isotype-matched control antibodies (right panels), which were detected with FITC-conjugated 
secondary antibodies. Pictures were captured using 20x objectives. 
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Figure 6.2 MAdCAM-1 expression in murine Peyer’s patches (PPs) and mesenteric lymph nodes (MLN). Wild-type mice (WT), VAP-1 
deficient mice (VAP-1_KO), VAP-1 deficient mice expressing enzymatically active human VAP-1 (VAP-1_EA), and VAP-1 deficient mice expressing 
enzymatically inactive human VAP-1 (VAP-1_EA) were supplied with 0.4% (w/v) methylamine (MA+) in their drinking water for 14 days. Wild-type mice 
without any methylamine treatment were used as control (WT_MA-). Images are representative of immunofluorescent staining for MAdCAM-1 or isotype- 
matched control. Fields were captured using 20x objectives. 
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Figure 6.3 MAdCAM-1 protein is absent from mouse livers. Wild-type mice (WT), VAP-1 deficient mice (VAP-1_KO), and VAP-1 deficient mice 
that expressed either enzymatically active (VAP-1_EA) or enzymatically inactive (VAP-1_EI) hVAP-1 were fed with 0.4 % (w/v) methylamine for 14 days 
(MA+). WT mice that were not treated with methylamine were used as control (WT_MA-). Images are representative of immunofluorescent staining of liver 
for MAdCAM-1 or isotype-matched control and were captured using 20x objectives. White arrows point to central veins. 
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Figure 6.4 MAdCAM-1 expression in murine spleen. Wild-type mice (WT), VAP-1 deficient mice (VAP-1_KO), and VAP-1 deficient mice that 
expressed either enzymatically active (VAP-1_EA) or enzymatically inactive (VAP-1_EI) hVAP-1 were fed with 0.4 (w/v) methylamine for 14days. WT mice 
that were not treated with methylamine were used as a control (WT_MA-). Images are representative of immunofluorescent staining of spleen for 
MAdCAM-1 or isotype-matched control and were captured using 20x objectives. White arrows point to the sinus-lining endothelial cells of the splenic 
white pulp (WP).  
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Figure 6.5 MAdCAM-1 protein is absent from murine liver and kidney. Protein lysates were 
prepared from PPs, MLN, liver, kidney and spleen of wild-type mice (WT), VAP-1 deficient mice (VAP-
1_KO), and VAP-1 deficient mice that expressed either enzymatically active (VAP-1_EA) or 
enzymatically inactive (VAP-1_EI) hVAP-1 (n=3 animals in each group), after exposure to 0.4% (w/v) 
methylamine for 14days in their drinking water (MA+). WT mice (n=3) without any methylamine 
treatment were used as control (WT_MA-). MAdCAM-1 expression was determined by western blotting 
(left panels) and the same membranes were also probed for actin expression (right panels). Images are 
representative from single animals. 
 
 
 
 
 
 
 210 
 
 
 
Figure 6.6 VAP-1/SSAO activity induces MAdCAM-1 mRNA expression in PPs and MLN 
but not in murine liver. RNA was extracted and transcribed into cDNA from PPs, MLN, liver and 
spleen tissues of wild-type mice (WT), VAP-1 deficient mice (VAP-1_KO), and VAP-1 deficient mice that 
expressed either enzymatically active (VAP-1_EA) or enzymatically inactive (VAP-1_EI) hVAP-1 after 
being fed with 0.4% (w/v) methylamine for 14 days in their drinking water (MA+), and was used for 
MAdCAM-1 mRNA analysis using real-time PCR. RNA from WT mice that had not received any 
methylamine in their drinking water was used as a control (WT_MA-). Data represent relative expression 
levels of MAdCAM-1 (mean ± SD) in (A) PPs, (B) MLN, (C) spleen and (D) liver from n=3 different 
mice in each group. Statistical analysis was performed by Student’s t-test and one–way ANOVA (PPs, 
*P=0.04; MLN, *P=0.04 and *$P=0.03). 
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Figure 6.7 Summary of the effects of methylamine on MAdCAM-1 mRNA up-regulation. 
Figure shows combined data for MAdCAM-1 mRNA expression analysis in WT mice, VAP-1_KO, VAP-
1_EA and VAP-1_EI after 14 days of methylamine stimulation in their drinking water. WT mice 
without any methylamine stimulation were used as a control. Relative expression analysis in PPs, MLN, 
liver and spleen compared to MAdCAM-1 levels in WT_MA-. Statistical analysis performed by Student’s 
t-test and one–way ANOVA (PPs, *P=0.04; MLN, *P=0.04 and *$P=0.03). 
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Figure 6.8 MAdCAM-1 mRNA is not induced by hepatic inflammation. RNA was extracted 
and transcribed into cDNA from VAP-1 deficient mice (VAP-1_KO) and VAP-1 deficient mice 
expressing human VAP-1 as a transgene (VAP-1_KOTG+) after induction of hepatitis in response to 
ConA (10mg/kg i.v./4 hours) treatment, and was analysed for MAdCAM-1 mRNA expression. Relative 
expression levels (mean ± SD) from n=3 KO/ConA-, n=4 KO/ConA+, n=3 VAP-1_KOTG+/ConA- and 
n=4 VAP-1_KOTG+/ConA+ animals. 
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6.3  DISCUSSION 
In earlier chapters we demonstrated that the end products, released from the oxidative 
deamination of methylamine by VAP-1 induced the expression of MAdCAM-1. In the current 
chapter we extended these observations using an in vivo model system. Interestingly, in contrast 
to our human studies, where MAdCAM-1 was constitutively expressed in hepatic endothelial 
cells, in all the murine livers tested MAdCAM-1 was completely absent (at both mRNA and 
protein level). Moreover, stimulation of mice, either the VAP-1_KO or those expressing hVAP-
1 as a transgene, with methylamine did not induce MAdCAM-1 expression. In addition, in 
mice suffering from acute Concavalin A induced hepatitis, a model which is representative of 
human inflammatory liver disease, MAdCAM-1 was still absent suggesting that human and 
mouse systems differ significantly. Our finding is consistent with other studies (Bonder et al., 
2005), where MAdCAM-1 was also undetectable in the portal venules and no increase or very 
faint increase was observed in the postsinusoidal venules and sinusoids after ConA 
administration. We believe this finding is important since animal models are widely used in the 
development of drugs. Since the importance of MAdCAM-1 in both IBD and autoimmune 
hepatic complications has been well established, it is essential to know the similarities between 
human and animal models used for drug testing. 
 
Western blotting revealed the expression of a 60kDa MAdCAM-1 protein in PPs, MLN and 
spleen. Of note, in all the above organs a second band was also apparent which we believe is a 
different splice variant of MAdCAM-1. The existence of an alternatively spliced mouse 
MAdCAM-1 mRNA transcript that lacks exon 4 containing the mucin domain and the third 
IgA domain has been previously reported (Sampaio et al., 1995). This truncated molecule can 
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still support adhesion independent of L–selectin binding and so may be functionally relevant at 
these sites. Further Northern blot studies have also revealed the presence of two transcripts in 
murine and rat tissues, formed by alternative splicing with the shorter variant lacking the exon 
4 (Iizuka et al., 1998). 
 
Although we demonstrated abundant expression of VAP-1 in our transgenic animal livers, VAP-
1/SSAO enzymatic activity did not up–regulate MAdCAM-1 expression in mouse liver. In 
contrast, in those mice with enzymatically active hVAP-1, MAdCAM-1 expression was induced 
in Peyer’s patches and mesenteric lymph nodes, compared with the wild–type mice. The 
importance of VAP-1 enzyme activity in this induction was confirmed by the comparison of 
MAdCAM-1 expression in mesenteric lymph nodes of transgenic mice with enzymatically 
inactive hVAP-1, compared to mice with the enzymatically active hVAP-1. A similar but not 
significant effect was also observed in PPs of transgenic mice expressing the dead mutant of 
hVAP-1. Interestingly, in both these organs, a slight increase in MAdCAM-1 mRNA levels was 
also observed in KO mice lacking VAP-1 after stimulation with methylamine, which led us to 
suggest that methylamine might regulate MAdCAM-1 expression in other non–VAP-1 
dependent ways or in combination with other factors present in the microenvironment.  
 
There are varied potential roles for MAdCAM-1 at extra–hepatic sites. The critical role of 
MAdCAM-1 in the development of the normal structure of secondary lymphoid tissues 
including Peyer’s patches, has been demonstrated in animals that received anti–MAdCAM-1 
treatment, and their PPs were much smaller containing much fewer lymphocytes (Hanninen et 
al., 1998). Recent studies in MAdCAM-1 knock out mice have shown that the size of PPs is 
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dramatically reduced when compared with that of wild–type mice (Schippers et al., 2009). This 
abnormal PPs phenotype is due to reduced numbers of IgM+ B cells being recruited, thus 
leading to the formation of small and hypocellular PPs. Of note, this important role for 
MAdCAM-1 in seeding the PPs with B cells and therefore for its role in normal growth of these 
lymphatic organs, is not observed during the embryonic development of PPs. This suggests that 
only the postnatal recruitment of lymphocytes into the PPs concomitant with increased antigen 
exposure in the gastrointestinal tract is dependent on MAdCAM-1.  
 
Furthermore, MAdCAM-1 in the spleen might contribute to the normal marginal sinus (MS) 
organisation of the developing spleen endothelial cells in the postnatal period (Zindl et al., 
2009), and thus to the proper trafficking of cells from the marginal zone to the white pulp, after 
response to a microbial challenge. MAdCAM-1 expression in the MS endothelium seems to be 
responsible for the maintenance of the splenic endothelial structures integrity, thereby affecting 
the distribution of other adhesion molecules on the MS endothelium, that lead to the 
recruitment of immune cells to the white pulp, since in vivo experiments where antibodies 
against α4β7 integrin were used, had no effect on the immune cell immigration into the splenic 
white pulp (Kraal et al., 1995). 
 
In accordance with the studies of Kraal et al. and Zindl et al., we also detected MAdCAM-1 in 
the sinus lining endothelial cells of the splenic white pulp, and we also observed increased 
MAdCAM-1 mRNA levels in the presence of enzymatically active hVAP-1. Of note, increased 
MAdCAM-1 mRNA levels were also observed in mice expressing enzymatically inactive hVAP-1 
after methylamine treatment, suggesting that VAP-1/SSAO does not play a role in MAdCAM-1 
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induction in spleen. Knockout mice also showed an increase in MAdCAM-1 mRNA expression 
after methylamine treatment supporting the hypothesis that microenvironmental factors in 
combination with the presence of methylamine might also play a critical role in MAdCAM-1 
induction, which is important for maintenance of splenic architecture.  
 
In conclusion, our data reveal significant differences between the human and mouse system. In 
primary cultures of human hepatic endothelial cells and in human liver tissues MAdCAM-1 was 
detectable at both protein and mRNA levels. However, in mice, MAdCAM-1 was completely 
absent from the liver and neither the enzymatic activity of VAP-1/SSAO nor Concavalin A–
induced hepatitis induced expression. However, a role for VAP-1/SSAO activity in MAdCAM-1 
expression was revealed in PPs and MLN where MAdCAM-1 was significantly increased after 
methylamine stimulation. Importantly, this effect was significantly diminished in mice 
expressing the enzymatically dead mutant hVAP-1 although some induction was seen with 
methylamine in VAP-1 KO mice suggesting it is not completely specific for SSAO. Overall we 
believe that the up–regulation of VAP-1 reported in vivo during gut inflammation (Salmi et al., 
1993) in combination with increased levels of methylamine received via dietary intake or 
endogenous generation might contribute to induction of MAdCAM-1 expression in Peyer’s 
patches and mesenteric lymph nodes, therefore leading to sustained recruitment and 
establishment of bowel inflammation. Future in vivo studies, in which blocking antibodies 
directed against either MAdCAM-1 or its leukocyte ligand α4β7 under hVAP-1 stimulation 
with methylamine, might help to identify critical intermediate steps of this signalling pathway, 
and therefore might lead to the recognition of potential therapeutic targets. 
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CHAPTER 7  
 
TRANSDUCTION OF HSEC WITH MADCAM-1 
ENHANCES PBL RECRUITMENT 
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7.1  INTRODUCTION 
The continuous recirculation of lymphocytes between the blood, secondary lymphoid tissues 
and peripheral tissues, provides continuous surveillance against foreign invaders and facilitates 
a rapid and specific response to foreign antigens (Shetty et al., 2008). Inflammation enhances 
leukocyte extravasation into the inflamed areas as a result of interactions between specific 
adhesion molecules and chemokine receptors on circulating lymphocytes that allow them to 
recognise signals on endothelial cells and within inflamed tissue (Berg et al., 1989)(Salmi et al., 
1998)(Butcher and Picker, 1996). 
 
Chemokines have a fundamental role in regulating both homeostatic and inflammatory 
leukocyte trafficking (Rollins, 1997)(Baggiolini et al., 1997). The stimulatory signals provided by 
chemokines binding to specific seven transmembrane spanning receptors, result in 
modification of the leukocyte integrin affinity and avidity for its ligand, thereby enabling a 
rolling cell to firmly adhere to the vessel wall by shear–resistant adhesion and activation of 
motile phenotype that allows the leukocyte to migrate through the endothelium and 
subendothelial tissue (Cinamon et al., 2001a).  
 
In the gut–associated lymphoid tissues, the expression of MAdCAM-1 and its critical role in 
physiological lymphocyte trafficking are well recognised. MAdCAM-1 can bind α4β7low naïve 
lymphocytes through L–selectin and to α4β7high cells by direct integrin binding to MAdCAM-1 
(Berlin et al., 1995)(Schweighoffer et al., 1993). At these sites, the gut expresses high levels of 
the tissue specific chemokine CCL25, which signals through CCR9 on gut lymphocytes to 
activate α4β7 integrin binding to MAdCAM-1 (Figure 3.1).  
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CCL25 is preferentially expressed in the thymus and small intestine by crypt and glandular 
epithelium, but not in colonic mucosa (Kunkel et al., 2003a). The only known receptor for 
CCL25 is CCR9, the expression of which is restricted to thymocytes and subsets of 
CD3+CD4+ and CD3+CD8+ gut tropic lymphocytes that express α4β7 integrin (Zaballos et al., 
1999)(Kunkel et al., 2000). In addition, the majority of small intestinal lamina propria 
lymphocytes (LPL) and intraepithelial lymphocytes and a subset of small intestinal IgA antibody 
secreting plasma cells are CCR9+ (Zabel et al., 1999)(Sundstrom et al., 2008). In the colon and 
in peripheral blood, CCR9 is expressed at low frequencies (about 20%) on CD4 and CD8 cells 
(Papadakis et al., 2000), suggesting a more selective localisation of CCR9+α4β7+ cells in the 
small bowel, where CCL25 is predominantly expressed. In CCR9–/– and CCL25–/– deficient 
mice there is only a subtle decrease in T cells in both intestinal epithelium and lamina propria, 
suggesting that other chemokines might compensate for the CCL25 and CCR9 deficiency to 
promote lymphocyte recruitment into the small intestine (Wagner et al., 1996)(Wurbel et al., 
2001). Inhibitors of α4β7 (MLN02 and vedolizumab) (Soler et al., 2009) and CCR9 
(TRAFICET–EN, Chemocentryx) are being evaluated in patients suffering from Crohn’s 
disease. Such clinical trials will provide proof of concept of the role of these molecules in 
homing to the human gut, and the use of such compounds might not only be beneficial for 
IBD patients but also for those suffering from the hepatic complications of IBD such as PSC 
and autoimmune hepatitis, because these diseases are characterised by aberrant hepatic 
expression of MAdCAM-1 and CCL25 associated with infiltration of α4β7+CCR9+ T cells 
(Eksteen et al., 2004a). 
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Three other chemokines, CCL28, CCL21, CXCL12, are also implicated in lymphocyte 
recruitment to the gut, although they are not tissue specific. CCL28 is expressed by epithelial 
cells within the colon and at lower levels in the small intestine as well as in salivary gland, 
bronchial and mammary glands and trachea (Pan et al., 2000)(W. Wang et al., 2000), and 
mediates its effects through binding to its receptor CCR10. This chemokine receptor is found 
on almost all IgA–secreting plasma cells, resident in many mucosal tissues and lymphoid 
organs, including tonsils, salivary gland, stomach, small and large intestine and appendix. 
CCR10 is also expressed in memory lymphocytes and eosinophils (Pan et al., 2000)(Kunkel et 
al., 2003b), and numerous studies have reported the role of CCL28 in localisation and 
recruitment of CCR10+ cells to both small and large intestine, as indicated by the efficacy of 
blocking antibodies (anti–CCL28) in inhibiting homing to both sites (Hieshima et al., 2004). 
Interestingly, IgA plasmablasts arising in intestinal lymphoid tissues co–express CCR10 and 
α4β7 and it has been proposed that these plasma cells may be able to enter CCL28 containing 
mucosal sites, where either MAdCAM-1 or VCAM-1 are expressed (Kunkel et al., 2003b). 
 
CCL21 is a homeostatic chemokine expressed on high endothelial venules in areas of T cell 
accumulation in lymph nodes, spleen and Peyer’s patches, where it plays a significant role in the 
recruitment of CCR7+ naïve lymphocytes (Gunn et al., 1998)(J. J. Campbell et al., 2001). The 
CCR7 receptor is expressed on B and T lymphocytes and on activated mature dendritic cells 
(Forster et al., 1999). Apart form CCL21, CCL19 is also a ligand for CCR7 and both 
interactions are important for T cell homing into Peyer’s patches (Luther et al., 2000). On the 
other hand, B cell homing into Peyer’s patches depends on coordinated signalling provided by 
CCR7 as well as CXCR4, CXCR5 and CCR6 (Okada et al., 2002). Evidence for the critical 
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role of the CCL21/CCR7 interaction comes from CCR7 deficient mice, where lymphocyte 
migration is not only affected at the level of entry to secondary lymphoid organs but also at the 
level of positioning these cells in their corresponding functional microenvironment (Forster et 
al., 1999).  
 
The chemokine CXCL12, also called stromal (cell)–derived factor (SDF–1a), is constitutively 
expressed in secondary lymphoid tissues and in gut epithelium, inducing its effects via 
interaction with its specific receptor CXCR4, expressed at high levels on circulating B and T 
lymphocytes, including CD4+ and CD8+ cells, and on monocytes (Bleul et al., 1996)(Hori et 
al., 1998)(Terada et al., 2003). Recent studies have suggested that platelets store CXCL12 and 
can deposit this chemokine dynamically onto the endothelium upon activation. The presence 
of CXCL12 on the luminal endothelial surface is sufficient to induce increased leukocyte 
recruitment (Jin et al., 2006). 
 
All of the above chemokines, CCL25, CCL21, CCL28 and CXCL12 have been reported to 
trigger α4β7–mediated adhesion to MAdCAM-1 in the gut (Pachynski et al., 1998)(von 
Andrian and Mackay, 2000), and in addition CXCL12 is capable of triggering α4β7 mediated 
binding of CD4+ T cells to fibronectin under conditions of shear stress (Wright et al., 2002).  
 
The aim of the studies reported in this chapter was to investigate whether CCL25, CCL28, 
CCL21 and CXCL12 can trigger activation of α4β7 integrin to mediate lymphocyte arrest on 
hepatic endothelial cells under conditions of flow. For these experiments, HSEC were 
transduced to express MAdCAM-1 by transfection with adenoviral constructs. Some of the 
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preparatory work described in this chapter, was carried out by a previous PhD student Alice 
Miles, as indicated on the figures. 
 
7.2  RESULTS 
7.2.1 MAdCAM-1 Expression In Human Hepatic Endothelial Cells After Induction With 
Adenoviral Constructs 
Hepatic endothelial cells were transfected with adenoviral constructs previously described by 
our group (A. Miles, PhD Thesis, University of Birmingham, 2006) (Miles et al., 2008) 
containing full–length (FL)–MAdCAM-1 protein at different multiplicity of infection (MOI). 
MAdCAM-1 protein expression was detected by western blotting, and optimal MAdCAM-1 
transgene expression was achieved at a MOI of 10 (Figure 7.1). Thereafter, this viral 
concentration was used for the subsequent adhesion assay experiments with FL–MAdCAM-1. 
In addition, MAdCAM-1 expression in transfected HSEC was confirmed by fluorescence–
activated cell sorter analysis (FACS) (Figure 7.2).  
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Figure 7.1 MAdCAM-1 expression in HSEC after adenoviral transfection. The expression of 
MAdCAM-1 was examined in protein lysates prepared from HSEC following infection with (1) FL-MAd-
GFP-Ad (MOI 5), (2) FL-MAd-GFP-Ad (MOI 10), (3) GFP-Ad (MOI 50). Lysates from CHO cells 
transfected with (4) SV-MAdCAM-1 and (5) FL-MAdCAM-1 were included as positive controls. 
(Experiments performed by A. Miles). 
 
 
 
 
Figure 7.2 MAdCAM-1 expression in adenoviral transfected HSEC. Hepatic endothelial cells 
transfected with FL-MAd-GFP-Ad (at MOI 10), 24 hours post infection were analysed for GFP 
expression by flow cytometry. Representative histograms from two different primary isolates (A) and (B) 
showing MAdCAM-1 expression (filled histograms) compared with non-infected cells (un-filled 
histograms). (Experiments performed by A. Miles). 
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7.2.2 Chemokine Receptor Expression In α4β7+ PBL Populations 
Prior to functional assays, the expression of α4–integrins, CCR9, CCR7, CCR10 and CXCR4, 
was determined on peripheral blood lymphocytes (Table 7.1). About 50% of the peripheral 
blood CD3+ lymphocytes expressed α4–integrin, and of those 15–20% were also positive for 
β7–integrin (Figure 7.3). If CD3+ T cells were subdivided into α4β7 positive and α4β7 negative 
populations, CXCR4 was expressed in 78% of CD3+ PBL and 74% and 75% of α4β7+ and 
α4β7– subpopulations, respectively. The median channel fluorescence values did not differ 
significantly between the different populations. CCR7 levels were reduced on α4β7– cells when 
compared with the whole CD3+ population and the α4β7+ population (P<0.001). CCR9 
expression on the α4β7+ population was increased, but CCR10 expression (percentage of 
positive cells and median channel fluorescence) was not significantly different between the 
α4β7+ and α4β7–populations (Figure 7.3). 
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Figure 7.3 Expression of α4– and β7– integrins on T cells subpopulations. Representative dot 
blots showing the co expression of α4– and β7– integrins (x–axis) on CD3+ T cells (y–axis) from a single 
donor. Values in quadrant represent percentage of dual-positive cells and median channel fluorescence 
(MCF) staining intensity. Histograms on the right represent pooled data from 4 normal donors showing 
the percentage of CD3+ cells staining positive for α4–, β7– and α4β7– integrin. (Experiments 
performed by A. Miles). 
 
 
 CD3 Positive Population α4β7 negative population α4β7 positive population 
 % positive MCF % positive MCF % positive MCF 
CXCR4 78.45±4.49 285.5±10.8 74.2±5.37 274.75±19.9 75.05±4.77 265.5±19.36 
CCR7 49.42±6.41 281±4.69 9.25±1.1 161±9.6 47.37±7.37 271.75±9.7 
CCR9 3.75±2.71 111.3±9.21 2.23±1.29 103.75±6.65 4.25±4.03 112.25±9.71 
CCR10 1.78±2.31 59.3±8.18 1.55±1.79 55.25±9.57 1.73±2.26 51.5±9.39 
 
Table 7.1 Expression of CXCR4, CCR7, CCR9 and CCR10 on circulating α4+ and α4β7+ T-
cell populations. Pooled data from 4 normal donors showing percent of positive staining 
and median channel fluorescence values for chemokine receptor staining on total peripheral 
blood CD3+ cells. Cells were gated into α4β7 negative and α4β7 positive cells. Values are 
means ± SEM. (Experiments performed by A.Miles). 
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7.2.3 Lymphocyte Adhesion To Hepatic Endothelium Transduced To Express MAdCAM-1 
Is Triggered by CCL21, CCL28, CCL25 and CXCL12 
In order to determine the role of chemokine signalling in triggering binding of lymphocytes to 
MAdCAM-1 expressed by human hepatic endothelial cells, a flow based adhesion assay was 
developed in which PBL isolated either from normal individuals or from patients with IBD 
(which show higher levels of α4β7 integrin expression) were perfused over the adenovirally 
transfected endothelial monolayers at a constant shear stress of 0.05Pa. As expected, no 
significant adhesion of normal lymphocytes to resting endothelium was observed. However, 
induction of MAdCAM-1 expression permitted increased leukocyte adhesion (Figure 7.4) 
(***P=4.5E-08), which was inhibited when the endothelium was treated with an antibody 
directed against MAdCAM-1 (P1, **$P=0.004). Moreover, blockade of lymphocyte α4β7 
integrin also resulted in a modest reduction of adhesion (Figure 7.4). Immobilization of 
recombinant chemokines on transduced hepatic endothelial cells resulted in a change in the 
adhesive behaviour of captured lymphocytes. The total number of adherent lymphocytes from 
normal individuals was modestly increased by the presence of all chemokines, but no significant 
effects were revealed by statistical analysis (Figure 7.5A). Similarly, the presence of chemokines 
did not induce increased migration of normal PBL through the MAdCAM-1 transduced 
hepatic endothelium (Figure 7.5B). On the other hand, while the total number of adherent 
patient lymphocytes was almost unchanged in the presence of chemokines (Figure 7.6A), 
CXCL12 resulted in an increase in the number of lymphocytes migrating (*P=0.012) (Figure 
7.6B). Moreover, there was a trend for increased migration of patient lymphocytes in the 
presence of CCL28 and CCL25 (Figure 7.6B), which was not the case for normal lymphocytes 
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(Figure 7.5), and which was abolished when chemokine signalling was blocked by pertussis 
toxin (PTX) treatment of PBL (**$P=0.007) (Figure 7.8). 
 
 
 
 
Figure 7.4 Induction of MAdCAM-1 expression in endothelial cells results in enhanced 
binding of lymphocytes. PBL were perfused over non-transfected HSEC (control) or cells transduced 
to express MAdCAM-1 (MAd) at a shear stress of 0.05Pa. Where indicated endothelial cells or 
lymphocytes were pre-treated with MAdCAM-1 (P1) or α4β7 integrin (ACT-1) blocking antibody, 
respectively. Values are means ± SE of number of adherent cells from two representative experiments. 
Student’s t-test and one–way ANOVA analysis revealed statistically significant differences (***P=4.5E-08, 
**$P= 0.004). 
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Figure 7.5 The effects of CCL25, CCL28, CCL21 and CXCL12 chemokines on normal 
lymphocyte adhesion to MAdCAM-1 expressing endothelial cells. PBL from normal individuals 
were perfused over HSEC transduced to express MAdCAM-1 at 0.05Pa. Transfected HSEC that were 
not pre-treated with chemokines were used as control. Where indicated HSEC were pre-incubated with 
recombinant chemokines (10µg/ml for 30min) prior to perfusion of PBL. Adhesion was classified as 
rolling, static adhesion or activation/migration, which were combined to give the total number of 
adherent cells/mm2/106 perfused. Data represent mean ± SEM number of adherent cells in 
representative experiments with n=3 normal donor PBL. (A) Static adhesion is expressed as percentage 
of control adhesion and (B) migration is expressed as percentage of control migration.  
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Figure 7.6 The effects of CCL25, CCL28, CCL21 and CXCL12 (SDF) chemokines on patient 
lymphocyte adhesion to MAdCAM-1 expressing endothelial cells. PBL from patients with IBD 
were perfused over HSEC transduced to express MAdCAM-1 at 0.05Pa. Transfected HSEC that were 
not pre-treated with chemokines were used as control. Where indicated HSEC were pre-incubated with 
recombinant chemokines (10µg/ml for 30min) prior to perfusion of PBL. Adhesion was classified as 
rolling, static adhesion or activation/migration, which were combined to give the total number of 
adherent cells/mm2/106 perfused. Data represent mean ± SEM number of adherent cells in 
representative experiments with n=6 IBD patients’ PBL. (A) Static adhesion is expressed as percentage of 
control adhesion and (B) migration is expressed as percentage of control migration. Statistical analysis 
was performed by Student’s t-test (*P=0.012). 
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Figure 7.7 Effect of pertussis toxin (PTX) treatment on normal lymphocyte adhesion. PBL 
from normal patients were perfused over HSEC transduced to express MAdCAM-1 at 0.05Pa. 
Transfected HSEC that were not pre-treated with chemokines were used as control. Where indicated 
HSEC were pre-incubated with recombinant chemokines (10µg/ml for 30min at 37oC) and PBL with 
pertussis toxin (200ng/ml for 30min at 37oC). Data represent mean ± SEM number of adherent cells 
from n=3 normal PBL. (A) Static adhesion is expressed as percentage of control adhesion and (B) 
migration is expressed as percentage of control migration. 
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Figure 7.8 Effect of pertussis toxin (PTX) treatment on patient lymphocyte adhesion. PBL 
from IBD patients were perfused over HSEC transduced to express MAdCAM-1 at 0.05Pa. Transfected 
HSEC that were not pre-treated with chemokines were used as control. Where indicated HSEC were 
pre-incubated with recombinant CCL25 chemokine (10µg/ml for 30min). Data represent mean ± SEM 
number of adherent cells from n=6 patients PBL. (A) Static adhesion is expressed as percentage of 
control adhesion and (B) migration is expressed as percentage of control migration. (C) Representative 
video images of lymphocyte interacting with MAdCAM-1 expressing HSEC. The panels demonstrate the 
increased numbers of activated shape-changed lymphocytes binding to HSEC with the presence of 
CCL25 and how this is reduced by pre-treatment of PBL with pertussis toxin [(PTX); 200ng/ml, 30min 
at 37oC]. Statistical analysis was performed by one–way ANOVA (**$P=0.007). 
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7.3  DISCUSSION 
In this study, a flow based adhesion system was developed in order to investigate the role of 
gut–expressed chemokines in mediating lymphocyte adhesion to MAdCAM-1 under conditions 
of flow. Using adenoviral constructs for FL–MAdCAM-1 we transfected hepatic endothelial 
cells to constitutively express MAdCAM-1 in vitro. The functional integrity of MAdCAM-1 
protein was validated with the flow based adhesion assay where peripheral blood lymphocytes 
from normal individuals were perfused over the transduced endothelial monolayers at a 
constant shear stress of 0.05Pa, which represents the low shear environment of hepatic 
sinusoids. A significant increase in the total number of adherent cells was observed in cells 
transduced to express MAdCAM-1 (***P=4.5E-08) when compared with the non–transfected 
HSEC, where adhesion was almost undetectable. When HSEC were pre–incubated with a 
blocking antibody directed against MAdCAM-1 (humanised P1 Ab), the total number of 
adherent cells was significantly diminished (**$P=0.04) supporting the functional role of 
MAdCAM-1 in the recruitment of α4β7+ PBL. Of note, when the α4β7 integrin on leukocyte 
surface was blocked (ACT-1 Ab) there was no statistically significant reduction of adherent cells, 
which we suggest is due to the ability of MAdCAM-1 to adhere to α4β1 integrin expressed on 
PBL. 
 
Further studies, where HSEC transduced to express MAdCAM-1 were pre–treated with 
recombinant chemokines CCL21, CCL25, CCL28 and CXCL12, prior to perfusion of PBL 
isolated either from normal individuals or from patients suffering from IBD, were carried out 
to investigate the role of these chemokines in lymphocyte binding to MAdCAM-1. When 
normal PBL were perfused over the transduced endothelial monolayers all the chemokines had 
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a tendency to increase the levels of total adhesion when compared with control transfected 
HSEC that were not pre–treated with chemokines, although these differences were not 
significant. Amongst all chemokines, only CXCL12 activated transendothelial migration. The 
ability of CXCL12 to mediate transendothelial migration, has been previously reported by 
Schreiber et al. who demonstrated that apical presentation CXCL12 could promote locomotion 
on endothelium and diapedesis through endothelial cell junctions, under shear conditions 
(Schreiber et al., 2007). Moreover, our finding was completely in line with previous studies 
from our group (complementary data published by Miles et al., 2008) where CXCL12 and 
CCL21 not only triggered arrest of rolling lymphocytes on MAdCAM-1 but also induced high 
integrin avidity changes via cytoskeletal rearrangements, fluidity in the plasma membrane and 
subsequent clustering. This resulted in stronger adhesive interactions between endothelium and 
leukocytes (Miles et al., 2008), thus leading the latter to adopt a flattened and extended 
morphology, indicative of migratory behaviour (J. R. Chan et al., 2003). Previous studies have 
also reported the ability of CXCL12 and CCL21 to trigger α4β7 mediated binding to 
MAdCAM-1 under shear stress (Pachynski et al., 1998)(Wright et al., 2002).  
 
Of note, when PBL from patients suffering from IBD were perfused over the MAdCAM-1 
transduced endothelial monolayers, the presence of CXCL12 increased the total number of 
adherent cells (by about 48%), and the percentage of migrating cells (*P=0.012). However, it 
should be noted that our chemokine–induced transmigration system was suboptimal, since 
studies have shown that chemokines (with the exception of CXCL12) should be placed below 
the endothelial monolayer in order to induce maximal migration. Therefore, additional flow–
based adhesion assays using luminally and abluminally located chemokines might prove more 
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useful in determining the effects of the different chemokines in inducing migration through 
MAdCAM-1 expressing hepatic endothelial cells. However, using the current system, in the 
presence of CCL28, there was also a trend for increased migration. Previous studies have 
reported the ability of CCL28 to activate α4β7–mediated adhesion to MAdCAM-1 under flow 
(Pachynski et al., 1998). In inflamed colonic tissues from patients with ulcerative colitis elevated 
levels of CCL28 have been detected, which together with similarly increased levels of 
MAdCAM-1 in these tissues, provide further evidence for the role of this chemokine in the 
persistent leukocyte recruitment observed in patients with IBD (Ogawa et al., 2004). Elevated 
CCL28 levels have been also observed on portal vascular endothelium and biliary epithelium in 
livers from patients suffering from chronic inflammatory liver diseases including PSC, PBC and 
ALD, where it could support α4β7– and α4β1– integrin mediated adhesion of liver infiltrating 
lymphocytes to MAdCAM-1 and VCAM-1, respectively. In this study the CCL28 chemokine 
receptor CCR10 was found on almost 17% of liver infiltrating CD3+ T cells in inflamed liver 
but only in 6% of T cells in livers of healthy individuals (Eksteen et al., 2006). These data 
combined with our new evidence showing triggering of α4β7 integrin mediated binding to 
MAdCAM-1 in HSEC by CCL28 strengthens the role of CCL28 in continuous leukocyte 
recruitment to MAdCAM-1 both in IBD and its extra–intestinal complications in the liver 
inflammation.  
 
CXCL12 is expressed in many tissues including lymphoid organs and normal and inflamed 
liver, particularly on bile ducts in portal tracts (Goddard et al., 2001)(Terada et al., 2003). 
Increased levels of CXCL12 are detected in PBC and PSC livers (Terada et al., 2003)(Eksteen et 
al., 2004a) as well as in AIH, CHC (chronic hepatitis C) and liver allograft rejection (Goddard 
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et al., 2001)(Terada et al., 2003)(Wald et al., 2004). We have now confirmed that this 
chemokine can also trigger lymphocyte interactions with MAdCAM-1 expressing hepatic 
endothelium. This observation may be explained by the expression of particularly high levels of 
CXCR4 on the α4β7+ subset and the α4+ population overall. Therefore, we suggest that the 
up–regulation of CXCL12 in the liver under inflammatory conditions, in combination with 
expression of other chemokines might be critical in regulating continuous and un–controlled 
leukocyte recruitment in chronic liver disease.  
 
CCL25 is believed to be the major chemokine responsible for activation of α4β7 in the gut 
(Kunkel et al., 2003a). In our study, CCL25 had a tendency to increase the proportion of 
adherent cells undergoing transendothelial migration in patients with IBD, an effect that was 
abolished when chemokine signalling was blocked by pertussis toxin (**$P=0.007). However, 
the effect was not dissimilar to that induced by CCL28 which may suggest that the hierarchy of 
triggering signals varies from site to site. Moreover, we cannot assume that CCL25 and CCL28 
were immobilised to the same extent on the endothelial monolayers without precise 
quantification and thus it is difficult to define the efficacy of one chemokine over another in 
this system. Nevertheless our CCL25 responses were in line with our previous model, where 
purified MAdCAM-1 protein was immobilised on a glass microslide and the co–immobilization 
of CCL25 also triggered arrest of rolling lymphocytes on MAdCAM-1 under conditions of 
physiological flow (Miles et al, 2008). However, in this system we saw no lymphocyte shape 
change. Therefore, we believe that the presence of an additional signal from the endothelial 
(HSEC) microenvironment might be needed to promote migration through the endothelial 
monolayer and this may come from an additional chemokine. 
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In conclusion, we have shown for the first time that CXCL12, CCL21, CCL28 and CCL25 
chemokines were able to trigger arrest of rolling lymphocytes on HSEC–expressed MAdCAM-1, 
with CXCL12 being the most potent activator of both high affinity and avidity changes in α4β7 
integrin. Overall, we believe that there are distinct functions, which are performed by the 
different chemokines and that cooperative interactions between different chemokines might be 
required for efficient recruitment in MAdCAM-1 expressing hepatic endothelial cells. 
Therefore, further investigation of the chemokine signals important during gut inflammation as 
well as during the extra–intestinal hepatic manifestations of IBD, may identify potential 
therapeutic targets. 
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CHAPTER 8  
 
CONCLUSIONS & FUTURE WORK 
 
 
 
 
 
 
 
 
 
 
 
 238 
 
8.1  OVERVIEW 
The well established role of MAdCAM-1 in chronic inflammation of the gut, particularly in 
inflammatory bowel disease (IBD), and the demonstration of extra–intestinal expression in the 
liver of PSC (primary sclerosing cholangitis) and AIH (autoimmune hepatitis) patients, have 
highlighted the importance of this molecule in inflammatory gut and liver disease. 
Pharmaceutical companies have already begun to develop drugs targeting the specific 
interaction between MAdCAM-1 and its ligand α4β7 integrin [Natalizumab; anti–α4–integrin 
humanised antibody (Stefanelli et al., 2008), MLN02 (Behm and Bickston, 2009); anti–α4β7, 
Vedolizumab (Soler et al., 2009); advanced form of MLN02], which is a key player in sustained 
lymphocyte recruitment to the gut and liver and possibly also in pancreas and brain, where 
MAdCAM-1 is induced during inflammation. Recently, a study regarding the first humanised 
MAdCAM-1 blocking antibody has been published (Pullen et al., 2009); however, although the 
attention of clinicians and drug companies is focused on blocking this crucial interaction, the 
question as to why MAdCAM-1 is ectopically expressed in the liver under particular conditions 
still remains unanswered. The aim of this study was to investigate the presence of MAdCAM-1 
in a variety of liver diseases and examine the role of different factors in its functional expression 
both in vitro and in vivo. 
 
8.2  MADCAM-1 EXPRESSION IN HUMAN LIVER 
In this study, we investigated the presence of MAdCAM-1 in human liver tissues at both 
protein and mRNA level. In accordance with previous studies (Hillan et al., 1999)(Grant et al., 
2001), we detected MAdCAM-1 in a variety of liver diseases associated with IBD (PSC, AIH) as 
well as in non–IBD associated liver diseases (PBC, ALD) at comparable levels on the 
 239 
 
endothelial cell lining of central veins and small vessels. Although, in normal livers MAdCAM-
1 was mainly undetectable by immunostaining, further immunoprecipitation experiments 
revealed the presence of MAdCAM-1 protein even in normal livers. Since this contrasted with 
earlier data from our group, which did not detect any MAdCAM-1 expression in normal liver 
tissues by immunostaining (Grant et al, 2001), the presence of MAdCAM-1 mRNA was further 
investigated and was found to be present in normal samples with significantly elevated levels in 
PSC and AIH diseased livers. In addition, sequencing analysis of message from a normal liver 
revealed complete alignment with the MAdCAM-1 gene sequence, thus validating the presence 
of MAdCAM-1 (see section 3.2). Moreover, in the in vitro studies where primary cultures of 
hepatic endothelial cells were used, MAdCAM-1 was also constitutively expressed even in cells 
isolated from normal livers under basal conditions (see discussion 4.2). Surprisingly, 
constitutive MAdCAM-1 expression was also detected in primary cultures of human umbilical 
vein endothelial cells, at both mRNA and protein level although at much lower levels than in 
HSEC.  
 
Our further experiments regarding the role of the pro–inflammatory cytokine TNFα and the 
amine substrate of SSAO, methylamine, revealed that TNFα either alone or in combination 
with methylamine significantly increased MAdCAM-1 mRNA levels in both HSEC and 
HUVEC. This was in accordance with previous studies that have supported the role of TNFα in 
inducing MAdCAM-1 expression in murine hepatic endothelial cells (Ando et al., 2007), 
human microvascular endothelial cells (Ogawa et al., 2005), and HUVEC (Lindholm et al., 
2004). Surprisingly, despite increased MAdCAM-1 mRNA levels, protein levels under the same 
stimulatory conditions remained unchanged (section 4.2.1), and these data were further verified 
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by the fluorescence–activated cell sorter (FACS) analysis, where MAdCAM-1 was detected not 
only on the surface but also in the cytoplasm in both normal and diseased livers (section 4.2.3). 
Of note, additional western blotting studies revealed that MAdCAM-1 of different molecular 
sizes existed in different cell compartments (see section 4.2.4). The MAdCAM-1 monomer 
(60kDa) was detected only in the cytoplasmic compartment, whereas the dimeric form and a 
putative trimeric form were present in both membrane and cytoplasm cell fractions. Previous 
studies have reported the existence of a dimeric form of MAdCAM-1 (Dando et al., 2002), 
which is suggested to be more functional than the monomeric form, because point mutations 
to the residue (Arg70) responsible for formation and stability of the dimer, inhibit the binding 
of MAdCAM-1 to its integrin ligand (Green et al., 1999)(Dando et al., 2002). In support of this, 
we detected higher levels of the dimeric form at the membrane consistent with a critical role in 
integrin recognition and binding. Since, both the dimeric and trimeric forms of MAdCAM-1 
were also present in the cytoplasm, it seems likely that the cell contains a pool of ready made 
MAdCAM-1 protein, available for transfer to the surface whenever required (Figure 4.19). It is 
not yet known where these molecules are stored; it could be in intracellular granules in the 
endothelial cells similar to those in which VAP-1 is stored (Salmi et al., 2001b) distinct from the 
Weibel–Palade bodies, where P–selectin is stored (Dunlop et al., 1992). Of note, no current 
studies report the presence of MAdCAM-1 trimer, thus further investigation needs to be 
performed in order to verify whether the 180kDa protein being detected is a MAdCAM-1 
oligomer or a complex of MAdCAM-1 with other proteins. Moreover, the investigation of 
whether this trimeric form is functionally active, able to recruit α4β7+ lymphocytes and 
whether this oligomerisation serves to confer mechanical stability upon interaction with the 
ligands, thus leading to stronger adhesion and recruitment, might be of great importance. 
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In addition to the expression of MAdCAM-1 on vascular endothelium, MAdCAM-1 was also 
detected in defined structures inside the hepatocyte cytoplasm and in immune cells with the 
morphology of dendritic cells. More extensive experiments need to be carried out in order to 
verify the presence of MAdCAM-1 in these locations, using double–staining techniques and 
higher number of tissue samples, in order to draw further conclusions regarding the role of 
MAdCAM-1 in those cells. Epithelial expression of MAdCAM-1 has previously been reported 
in the choroid plexus epithelium during experimental autoimmune encephalomyelitis (EAE) 
where supported lymphocyte adhesion (Steffen et al., 1996). Thus our observation of 
hepatocyte MAdCAM-1 might serve a similar role. Alternatively, hepatocytes have the ability to 
take up molecules by pinocytosis and endocytosis and can engulf other cell types, so MAdCAM-
1 within the hepatocyte might reflect uptake and degradation of protein produced in other 
cells. Expression of MAdCAM-1 has been reported on follicular dendritic cells of murine 
normal Peyer’s patches, chronically inflamed spleen (Szabo et al., 1997), dendritic processes 
within human Peyer’s patches (M. Briskin et al., 1997), and on dendritic cells in several liver 
diseases (Grant et al., 2001). Such hepatic expression of MAdCAM-1 could serve as a signal for 
retention of α4β7+ gut derived lymphocytes in the liver. Liver dendritic cells are poor at 
imprinting gut tropism (α4β7+CCR9+) (Eksteen et al., 2009) hence, α4β7+CCR9+ liver 
infiltrating lymphocytes are likely to have been primed in the gut before recruitment to the 
liver. Moreover, isolated follicular dendritic cells have been reported to express VCAM-1 
(Freedman et al., 1990) and ICAM-1 (Koopman et al., 1991) and could present an antigen 
through clustering with α4β1 and LFA-1 expressing B cells, leading to affinity maturation and 
differentiation of B cells into memory cells. Thus, MAdCAM-1 expressed on hepatic DCs might 
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have a similar function. However, further studies would be necessary to validate the presence 
and the role of MAdCAM-1 in such structures. 
 
8.2.1 Secretion of Soluble MAdCAM-1 
Our in vitro experiments with primary cultured cells revealed increased MAdCAM-1 mRNA 
levels upon stimulation but no change in either extracellular or intracellular protein. Based on 
the immunostaining studies in human liver tissues, where a brownish smear within all liver 
tissues was detected (section 3.2), consistent with sMAdCAM-1 in tissue and reports from 
others that have revealed circulating human MAdCAM-1 in the serum and urine (Leung et al., 
2004), we investigated whether MAdCAM-1 is secreted as a soluble form in our in vitro 
experiments. A 60kDa soluble MAdCAM-1 protein was detected in the supernatant of 
stimulated hepatic endothelial cells with statistically significant elevated levels after TNFα and 
methylamine treatment (section 4.2.5). It is not clear yet if this sMAdCAM-1 is a truncated 
form released by shedding of the dimeric or trimeric membrane bound forms, or whether the 
monomeric form stored in the cytoplasm is released through the cell membrane to the 
circulation or if sMAdCAM-1 is an alternatively spliced variant. Since no splice variants have 
been reported that lack the transmembrane domain (Leung et al., 1996), and since the 
sMAdCAM-1 detected was the same as the monomer protein, release from the cytoplasm seems 
more likely. As we discussed in section 4.3 it is not known if the soluble form of MAdCAM-1 is 
biologically active or not, or whether its secretion provides a protective mechanism to reduce 
the number of MAdCAM-1 molecules expressed on the endothelial surface or if sMAdCAM-1 
competes with the membrane bound form for the same receptor, thus leading to decreased 
lymphocyte recruitment to the site. If this is the case, soluble MAdCAM-1 could possibly 
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provide an essential therapy for the treatment of IBD and its extra–intestinal complications. In 
a contrary scenario, the release of sMAdCAM-1 could act as a destructive mechanism 
facilitating the de–adhesion of bound lymphocytes and thus promote their transendothelial 
migration, as has been reported for other soluble adhesion molecules (Gamble et al., 
1990)(Stoddart et al., 1996). It has been reported that VAP-1–dependent signalling induces 
production of soluble E–selectin, which can activate neutrophil β2 integrin, and induction of 
ICAM-1 and VCAM-1, resulting in enhanced lymphocyte adhesion (Lo et al., 1991)(Jalkanen et 
al., 2007)(Lalor et al., 2007). Knowing the already described role of MAdCAM-1 in chronic 
inflammation characterised by destructive leukocyte influx, we believe that the latter 
assumptions are more likely. However, the release of soluble MAdCAM-1 able to bind to its 
counterligand α4β7 integrin on the lymphocyte surface could provide an important therapy for 
the treatment of IBD and its extra–intestinal complications, therefore further studies 
investigating the factors that regulate the shedding or release of MAdCAM-1 protein and its 
role in leukocyte recruitment in normal and diseased livers would be of great importance in 
understanding the role of this molecule in disease. 
 
8.2.2 Structural Characteristics of MAdCAM-1 In Normal Versus Diseased Liver 
The contradictory observations that MAdCAM-1 is only faintly detected in normal liver tissues 
during immunostaining [in accordance with previously published studies from our group 
(Grant et al., 2001)] and the western blotting data where normal MAdCAM-1 levels were 
comparable to those in diseased livers, led us to suggest that MAdCAM-1 may exist in a 
different structural conformation under normal conditions that is not recognised by the 
monoclonal antibody. Indeed, western blotting of the unbound protein in the supernatant 
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from immunoprecipitated tissue samples with the polyclonal anti–MAdCAM-1 Ab, revealed the 
presence of high levels of MAdCAM-1 protein, which were not detected when the same samples 
were probed with the monoclonal Ab. This confirms that MAdCAM-1 protein present in 
normal liver tissues might have a different structural conformation not recognisable by the 
monoclonal antibody (see discussion 3.3). 
 
In support of this, in the flow based adhesion assays no MAdCAM-1–dependent lymphocyte 
binding under basal conditions was observed, whereas under TNFα and TNFα plus 
methylamine treatment significantly increased numbers of adherent lymphocytes were detected 
(section 4.2.6). Therefore, we believe that MAdCAM-1 is present in normal human liver in a 
non–functional folded state that cannot support lymphocyte recruitment, whereas in 
inflammatory conditions the local release of TNFα induces further expression of MAdCAM-1 
and in the presence of another stimulant such as methylamine, the already expressed 
MAdCAM-1 acquires a functional conformation, thus being able to lead to leukocyte–integrin 
recognition and binding. Additional X–ray crystallography and protein nuclear magnetic 
resonance spectroscopy (NMR) experiments will provide useful information regarding the 
topology and folding of the ligand–binding domains of MAdCAM-1 protein in basal and 
inflammatory conditions. 
 
8.3  THE ROLE OF VAP-1/SSAO ACTIVITY IN MADCAM-1 EXPRESSION in vitro AND in vivo. 
In order to investigate whether methylamine had additional effects on MAdCAM-1 expression 
due to VAP-1 enzymatic activity, adenoviral constructs expressing enzymatically active or 
inactive hVAP-1 were used to transduce hepatic endothelial cells, ensuring maximal VAP-1 
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expression. The cells transfected with enzymatically active hVAP-1, when exposed to TNFα or 
methylamine expressed significantly higher levels of MAdCAM-1 protein when compared with 
the non–transfected cells and cells transfected with enzymatically inactive hVAP-1 (section 5.2), 
suggesting that VAP-1/SSAO has an effect on MAdCAM-1 expression by hepatic endothelial 
cells.  
 
This role of VAP-1/SSAO activity was further validated using non–transfected HSEC, which 
were stimulated with the end products released from the methylamine deamination by VAP-1, 
hydrogen peroxide, ammonia and formaldehyde, either when added exogenously or locally 
generated by treatment with enzymatically active sVAP-1 and methylamine. The combination of 
all three end products significantly induced MAdCAM-1 expression. In support of this, 
previously reported studies from our group have also demonstrated that the H2O2 produced 
during VAP-1 mediated amine oxidation could induce expression of other adhesion molecules, 
such as P– and E–selectin, ICAM-1 and VCAM-1 and CXCL8 chemokine on HSEC by 
stimulating the PI3K, MAPK and NF-κB pathways (Lalor et al., 2002a). In addition, studies in 
human umbilical vein endothelial cells, have shown that provision of an amine substrate for 
VAP-1 could also induce expression of P– and E–selectin in vitro (Jalkanen et al., 2007). 
 
In vivo models with wild–type mice, animals deficient for VAP-1, and animals deficient for 
mouse VAP-1 transduced to express enzymatically active or inactive human VAP-1 as a 
transgene, were used in order to test whether VAP-1 enzyme had the ability to induce 
MAdCAM-1 expression in vivo. We supplied exogenous substrate in the form of methylamine 
in drinking water, and we found that VAP-1 enzyme activity significantly induced MAdCAM-1 
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expression in Peyer’s patches and mesenteric lymph nodes, which was confirmed by the 
comparison of MAdCAM-1 expression levels in transgenic mice with enzymatically inactive 
hVAP-1 (section 6.2). These findings were in line with in vivo studies of Jalkanen et al. that also 
demonstrated the ability of VAP-1/SSAO enzymatic activity to induce functionally active P–
selectin expression in small vessels of several organs including heart and intestine of animal 
models stimulated with methylamine (Jalkanen et al., 2007). However, in contrast to the 
human data where MAdCAM-1 was found to be constitutively present in the liver, in all mouse 
models that were used MAdCAM-1 was completely absent from murine livers at both mRNA 
and protein level. Of note, neither methylamine stimulation nor hepatic inflammation induced 
by Concavalin A treatment up–regulated MAdCAM-1 expression, highlighting an important 
difference between the murine and human systems. 
 
8.4  ROLE OF CHEMOKINES IN LYMPHOCYTE ADHESION TO MADCAM-1 
The expression of MAdCAM-1 in the liver, paralleled observations relating to the chemokine 
CCL25 whose expression has also been considered to be restricted to the small intestine and 
thymus (Kunkel et al., 2000)(Kunkel et al., 2003a). The recruitment of lymphocytes to the gut 
requires not only MAdCAM-1/α4β7 integrin interaction but also a chemotactic signal provided 
by CCL25 and its receptor CCR9. CCR9 is co–expressed with α4β7 integrin on gut–homing 
lymphocytes, thus binding of CCL25 to CCR9 leads to adhesion via MAdCAM-1. Previous 
studies from our group have reported the expression of CCL25 in PSC patients, as well as the 
expression of its receptor CCR9 to be strongly associated with co–expression of the gut integrin 
α4β7, in approximately 20% of liver infiltrating lymphocytes (LILs) in PSC. More interestingly, 
in static adhesion assays, the CCR9 on LILs could be triggered by CCL25 to bind to ectopically 
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expressed MAdCAM-1 in PSC via α4β7, supporting the hypothesis that long–lived memory 
cells of mucosal origin activated in the gut are able to circulate between the liver and gut 
providing surveillance against gut derived antigens that have entered the liver via the hepatic 
portal vein (Eksteen et al., 2004a). Although, in this study, CCL25 was undetectable in other 
chronic inflammatory diseases, unpublished data from our group using new and better 
antibodies has revealed the presence of CCL25 in a variety of liver diseased tissues (ALD, PBC, 
PSC, AIH) as well as in normal livers (unpublished data from C. Weston, Centre for Liver 
Research). In the current study, MAdCAM-1 was detected in the same livers as CCL25 had 
been previously detected, supporting the relationship between these two molecules and their 
role in sustained recruitment of α4β7+CCR9+ lymphocytes both in the gut and extra–intestinal 
sites. Although both MAdCAM-1 and CCL25 are both expressed in the liver of patients with 
extra–intestinal complications of IBD, and other liver diseases, their functional role in non–
IBD–related diseases is unknown. Therefore, the study of CCR9 expression in LILs from 
patients with different liver diseases and their ability to adhere to MAdCAM-1 expressed on the 
hepatic endothelium, might prove useful in determining the role of MAdCAM-1/α4β7 and 
CCL25/CCR9 in the pathogenesis of liver diseases. 
 
Using the flow based adhesion assay it was further investigated whether the chemokines 
CCL28, CCL21 and CXCL12, also implicated in lymphocyte recruitment to the gut via α4β7–
mediated adhesion to MAdCAM-1 (Pachynski et al., 1998)(von Andrian and Mackay, 2000), 
are able to mediate lymphocyte arrest in hepatic endothelial cells transduced to express 
MAdCAM-1. Interestingly, CXCL12 chemokine was the most potent activator of α4β7 integrin 
mediated adhesion to HSEC through MAdCAM-1. Although CXCL12 is mainly expressed in 
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secondary lymphoid organs, under normal conditions is also expressed on the bile ducts of 
hepatic portal tracts, with increased levels in diseased livers (PSC, PBC, AIH, CHC and liver 
allograft rejection) (Goddard et al., 2001)(Terada et al., 2003)(Eksteen et al., 2004a)(Wald et al., 
2004). In the flow based adhesion assay system, co–immobilisation of CXCL12 with either 
primary hepatic endothelial cells transduced to express MAdCAM-1 or with purified 
MAdCAM-1 protein immobilised on glass microslides (Miles et al., 2008), led to enhanced 
α4β7–integrin–dependent transendothelial migration. In addition, CCL28 seemed to have a 
tendency to increase the number of migratory cells on hepatic endothelium that expressed 
MAdCAM-1, although the conditions in our system were suboptimal. Notably, increased levels 
of CCL28 have been reported in inflamed colonic tissues from UC patients (Ogawa et al., 
2004), which in line with the elevated levels of MAdCAM-1 enhances the evidence that this 
chemokine is also important for triggering α4β7 integrin activation and lymphocyte arrest on 
MAdCAM-1. Furthermore, elevated levels of CCL28 have been reported in portal vascular and 
biliary epithelium in PSC, PBC and ALD, where it could also support α4β7–and α4β1– 
integrin mediated adhesion of liver infiltrating lymphocytes (LILs) to MAdCAM-1 or VCAM-1. 
Of note, the CCL28 receptor CCR10 was found on almost 17% of LILs in inflamed liver 
(Eksteen et al., 2006), thus suggesting a potential role of this chemokine to mediate lymphocyte 
activation and continuous recruitment through α4β7/MAdCAM-1 both in gut and liver. 
 
Overall, it is apparent that MAdCAM-1 is constitutively expressed in human liver, where it 
becomes functionally active under specific stimulatory conditions. Cooperative interactions 
between the chemokines, which are induced in the same places as MAdCAM-1, might be 
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required for efficient recruitment and retention of lymphocytes and thus establishment of 
chronic liver inflammation.  
 
8.5  ROLE OF MADCAM-1 IN GUT AND LIVER INFLAMMATION 
The first association between colonic ulceration and liver disease was made by Thomas C.H. in 
1874, when he described the case of a young man who died of a “much enlarged, fatty liver in 
the presence of ulceration of the colon” (Saich and Chapman, 2008). Thereafter, the 
association between inflammatory bowel disease and various hepatic complications has been 
well established.  
 
The etiopathogenesis of IBD still remains elusive, however many genetic and environmental 
factors have been associated with IBD and experimental evidence suggests that it develops in 
susceptible individuals as an aberrant immune response to normal gut flora. Despite the 
different clinicopathological features, genetic susceptibility or triggering factors between 
ulcerative colitis and Crohn’s disease, they are both characterised by uncontrolled and 
destructive leukocyte accumulation in the bowel (Eksteen et al., 2008). During gut 
inflammation, the increased release of pro–inflammatory cytokines leads to enhanced 
expression of vascular adhesion molecules, hence sustaining the immuno–inflammatory process 
(S. Nakamura et al., 1993b). Of note, among the up–regulated adhesion molecules in IBD, 
MAdCAM-1 has been recognised as probably the most important receptor in the development 
of chronic inflammation (M. Briskin et al., 1997). Moreover, several reports have demonstrated 
the ability of antibodies directed against either MAdCAM-1 or its ligand α4β7 integrin to 
attenuate inflammation in a variety of animal models as well as in patients with colitis 
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(Guagnozzi and Caprilli, 2008)(Hamann et al., 1994)(Feagan et al., 2005) and Crohn’s disease 
(Feagan et al., 2008)(Guagnozzi and Caprilli, 2008)(Hamann et al., 1994) although with better 
results when combined with antibodies targeting other adhesion molecules, such as VCAM-1 
(Burns et al., 2001), suggesting that a combination of adhesion molecules/integrin ligands 
interactions take part in the destructive inflammatory influx that characterises IBD. 
 
TNFα is probably the most important cytokine in the initiation and progression of IBD, as 
demonstrated by the efficacy of anti–TNFα antibody therapy, which successfully reduces both 
colonic injury and expression of adhesion molecules (Behm and Bickston, 2008). In our 
experiments, we also found that VAP-1/SSAO enzymatic activity could induce MAdCAM-1 
expression in Peyer’s patches and mesenteric lymph nodes in vivo after methylamine 
stimulation, an effect that was significantly diminished in mice expressing enzymatically inactive 
VAP-1. This finding in combination with reports describing the induction of VAP-1 during gut 
inflammation (Salmi et al., 1993), led us to suggest that increased levels of methylamine caused 
either by enhanced absorption (food, wine or cigarette smoke) or by increased de novo synthesis 
(metabolism of adrenaline, sarcosine, creatinine and lecithin) (McEwen and Harrison, 
1965)(Pirisino et al., 2001), acting through VAP-1 could lead to induction of MAdCAM-1 in 
gut mucosa, and thereafter to uncontrolled lymphocyte recruitment. Moreover, since the factors 
that regulate the induction of VAP-1 in gut mucosa are not known, it seems possible that 
production of VAP-1 could act as a protective feedback loop in order to metabolize excessive 
methylamine. Thereafter, increased levels of metabolic products released by the catalytic activity 
of VAP-1 could up–regulate expression of adhesion molecules, including of MAdCAM-1, and 
together with the adhesion–molecule like properties of VAP-1 to promote leukocyte 
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recruitment in the gut during inflammation and the destructive influx during IBD. Thus, we 
believe that increased levels of methylamine might be an early factor predisposing to gut 
inflammation in genetically susceptible individuals and maybe also to further liver 
inflammation.  
 
The fact that liver complications, can occur in a course independent of IBD, led Grant et al. to 
suggest that long–lived memory cells initially activated in the gut during active episodes of IBD 
are able to be recruited in the liver via interactions with MAdCAM-1 or VAP-1 on hepatic 
endothelium upon encountering of an appropriate insult (Grant et al, 2001). Since 
methylamine is present in the portal vein that supplies the liver, it could directly contribute to 
hepatic inflammation. In support of this, increased levels of methylamine have been reported in 
liver diseases according to experimental and clinical studies (Pirisino et al., 2004).  
 
Although hepatic MAdCAM-1 was previously detected mainly in PSC and AIH, the hepatic 
complications of IBD (Hillan et al, 1999) (Grant et al, 2001), we have subsequently detected 
MAdCAM-1 in a variety of liver diseases including PBC and ALD and in normal liver. In 
addition, constitutively expressed MAdCAM-1 under normal conditions seems to exist in a 
non–functional conformation state, with altered antibody–binding epitopes, which may 
possibly explain the low expression levels seen in normal tissue samples in previous studies 
(Grant et al, 2001). However, the presence of methylamine catabolised by VAP-1 was able to 
induce in vitro expression of functionally active MAdCAM-1 on hepatic endothelium. 
Therefore, we believe that circulation of methylamine through the hepatic portal vein and 
catabolism by VAP-1 in the liver may activate constitutive MAdCAM-1 protein in hepatic 
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endothelium in combination with TNFα under inflammatory conditions. Further studies 
investigating the structural conformation of MAdCAM-1 in normal and diseased livers using 
site directed mutagenesis of the residues responsible for integrin recognition and binding might 
help to develop therapies specifically targeting the functionally active MAdCAM-1 thereby 
diminishing side effects caused when widely used pathways are blocked. 
 
It is clear that hepatic MAdCAM-1 is not only associated with the extra–intestinal 
complications of IBD. Up to 70–85% of PSC patients will develop inflammatory bowel disease, 
whereas only 2.4–7.5% of people with ulcerative colitis will develop PSC. Additionally, PSC is 
associated mainly with UC (90% of cases) whilst only 10% of patients with CrD will go on to 
develop PSC (Adams and Eksteen, 2006). This suggests that there is a missing mechanistic link 
relating to the liver microenvironment, which predisposes to bowel inflammation. Notably, 
CrD is suggested to be a Th1–mediated disease, in which Th1 cells are distinguished from other 
effector lineages by the expression of CCR1, CCR5 and CXCR3 whose chemokine ligands, 
CCL3, –4, –5, and CXCL9, –10 and –11, respectively are also found in the liver. In addition, 
MAdCAM-1 is more prominently expressed in CrD rather than in UC (Arihiro et al., 2002). 
Our belief that methylamine is an environmental candidate responsible for the endothelial 
induction of MAdCAM-1 in the gut is further supported by findings which demonstrate that 
cigarette smoking (and hence methylamine exposure) is associated with less frequent 
exacerbations of UC but on the contrary, with enhanced exacerbations in CrD (Baumgart and 
Carding, 2007). The lesser role of MAdCAM-1 in UC might also be due to the non–expression 
of CCL25 and lower levels of CCR9+ T cells (Papadakis et al., 2000)(Kunkel et al., 2003a). 
However, the purpose of the constitutive expression of MAdCAM-1 in hepatic endothelium 
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under normal conditions, as well as its role in the non–IBD associated liver diseases still 
remains to be studied.  
 
Chronic inflammatory liver diseases, including PSC and PBC, are characterised by the 
development of new hepatic tertiary lymphoid tissue, a process named lymphoid neogenesis. 
These inflammatory lymphoid follicles provide a microenvironment for the recruitment and 
retention of lymphocytes at sites of inflammation (Grant et al., 2002a). Of note, CCL21 a 
chemokine particularly expressed in secondary lymphoid organs has also been detected in 
stromal tissues surrounding portal vessels and on the endothelium of CD34+ MAdCAM-1+ 
vessels with the morphology of HEV in lymphoid aggregates in chronic inflammatory liver 
diseases (Grant et al., 2001). In a complementary study, CCL21 was also able to drive α4β7–
mediated migration towards MAdCAM-1 in in vitro flow based adhesion assays (Miles et al., 
2008). Thus, we believe that in these hepatic tertiary lymphoid tissues, as in lymph nodes, in 
the presence of an appropriate antigenic stimulus, antigen presenting cells will activate 
leukocytes and in combination with the cooperative interactions between the different 
chemokines such as CCL21, will result in increased recruitment to highly expressed MAdCAM-
1 in HEV like vessels, retention and final liver chronic inflammation. 
 
8.6  FUTURE WORK 
The well accepted dogma of science is that more questions than answers are generated during 
research. This is certainly true of the current study where additional work would shed light on 
the role of MAdCAM-1 in human liver and may lead to identification of possible therapeutic 
targets. Further studies should involve: 
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Determination of MAdCAM-1 expression sites and of factors that regulate its expression: 
• Extensive investigation of MAdCAM-1 expression in human normal and diseased liver 
tissues, using double staining techniques in order to verify whether it is expressed on 
hepatocytes and liver dendritic cells, and thus understand the role of MAdCAM-1 in 
the liver. 
• A recent report (Kamada et al., 2009) has demonstrated that lamina propria CD14+ 
macrophages in both normal and Crohn’s disease individuals can induce the 
expression of β7 integrin on naïve CD4+ T cells in a retinoic–acid (RA) dependent 
manner. Since hepatic stellate cells serve as storage containers for retinoic acid 
(Friedman et al., 1992), it would be useful to determine whether the α4β7+ cells 
recruited to MAdCAM-1 in the liver can be produced by resident liver macrophages. 
•  The liver is exposed to microbial products synthesized by commensal intestinal flora 
that are transported via the hepatic portal vein to the liver (John and Crispe, 2005). It 
is well accepted that IBD develops due to a non-specific response to commensal 
microorganisms and that it is also associated with extra–intestinal complications in the 
liver. Thus we suggest that TLRs expressed on hepatic sinusoidal endothelial cells, 
which recognise structural motifs on pathogens and commensal microorganisms, might 
also regulate MAdCAM-1 expression in the liver. TLR signaling pathways culminate in 
activation of NF-κB, which is known to activate MAdCAM-1. Further studies 
investigating the possible role of TLRs in MAdCAM-1 expression might prove useful in 
developing therapeutic targets for both gut and liver inflammatory conditions.  
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Determination of the role of MAdCAM-1 in lymphocyte recruitment in the liver: 
• Study the presence of α4β7+ integrin expression in liver infiltrating lymphocytes derived 
from PBC, ALD, AIH and normal patients and their ability to adhere to MAdCAM-1 
under static adhesion assays (in tissues). 
•  Use the adenoviral constructs expressing enzymatically active and inactive hVAP-1 in 
order to determine the functionality of MAdCAM-1 in the presence of methylamine 
under flow based adhesion assays. 
• Study the ability of CCL21, CCL28, CCL25 and CXCL12 chemokines to cause 
recruitment of LILs (isolated from different liver diseases) to liver tissue sections under 
static adhesion assays. 
 
Structural characteristics of MAdCAM-1: 
• Investigate the conformational status of MAdCAM-1 in normal and diseased livers. Use 
adhesion assays to observe the ability of liver– and gut– derived lymphocytes to bind to 
MAdCAM1 under normal or inflammatory conditions. 
• Study the role of methylamine in changing the conformational status of MAdCAM-1 
expressed in normal liver tissues to a functional folding state able to recruit α4β7+ 
lymphocytes. 
• Mutational analysis targeting the residues responsible for the leukocyte integrin 
recognition and binding, treatment with methylamine and thus validation of its role in 
functional unfolding. This would be eventually useful in developing new drugs 
targeting the active sites of MAdCAM-1, thus inhibiting only its ability to recruit 
leukocytes, minimizing any side effects caused after blocking widely used pathways. 
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• Validate the presence of the trimeric form of MAdCAM-1 with spectophotometry and 
further investigate its role in the leukocyte recruitment cascade. 
• Study the mechanisms that cause shedding of MAdCAM-1 and the biological role of the 
soluble form. 
• Investigate the presence and levels of sMAdCAM-1 in the serum of patients with 
different liver inflammatory diseases. 
• Identify the natural cleavage site of MAdCAM-1, for designing sequence specific 
inhibitors in order to determine the biological consequences of interfering with this 
process.  
 
Intracellular pathways responsible for MAdCAM-1 expression: 
• Determine whether TNFα and VAP-1 stimulate induction of MAdCAM-1 through the 
NF-κB transcription factors. 
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